"","...1","Disease","Enrichment.biomarker","Biomarker.relationship","Biomarker.logical.conditions","Marker.type","Drug","Targets","Study.Phase..comparator.","Clinical.State.and.treatment.setting","Primary.End.Point","clinicaltrials.gov.reference","Raw.Text","annotator","STATUS","validator","URL","sheet","drug_drugbank_standard","drug_pubchem","biomarker_ensembl_standard","diseases_EFO_MONDO_standard","biomarker_term","QC"
"1",1,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ABBV-368, ABBV-181","UNK, UNK","I","Advanced, Second Line","Terminal half-life (t1/2) of ABBV-368, Area under the serum concentration-time curve (AUC) of ABBV-368, Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181, Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181, Time to Cmax (Tmax) of ABBV-368, Terminal phase elimination rate constant (β) of ABBV-368, Number of Participants With Adverse Events, Maximum observed serum concentration (Cmax) of ABBV-368","NCT03071757","Participants with advanced or metastatic solid tumors that have exhausted standard treatment for their incurable disease and for whom there is currently no programmed cell death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) approved therapy, with immunogenic type tumors such as, but not limited to triple negative breast cancer (TNBC). Trial includes other cancer types","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03071757",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"2",2,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","BGB-290, TEMOZOLOMIDE","UNK, UNK","I, II","Advanced, First Line, Second Line","Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE,  Incidence, nature and severity of adverse events as assessed by CTCAE","NCT03150810","Trial includes other cancer types, also include patients who have some other deficiency in homologous recombination. a. Previously received at least 1 line of platinum containing chemotherapy and No progression or recurrent disease in 6 months from last platinum containing regimen. Patients with HRD+ or known breast cancer susceptibility gene (BRCA) mutant Triple-Negative Breast Cancer","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03150810",1,"NA,DB00853","135565554, 5394","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"3",3,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, p53","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","LY3143921 HYDRATE","CDC7","I","Advanced, First Line, Second Line","Determination of the maximal dose","NCT03096054","Histological or cytological diagnosis of incurable, advanced/metastatic cancer For Phase Ia (dose escalation): Enriched for patients with tumours associated with p53 mutation or loss of function","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03096054",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000141510","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND P53 MUTATION POSITIVE/NEGATIVE","failed drug"
"4",4,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","MGD013, MARGETUXIMAB","PD1/LAG3, ERBB2","I","Advanced, Second Line","Maximum Tolerated Dose, Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (MGD013 monotherapy)","NCT03219268","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03219268",1,"NA,DB14967","NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"5",5,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CB-103","UNK","I, II","Advanced, First Line, Second Line","Part A: Dose limiting toxicity (DLT), Part B: antitumour efficacy","NCT03422679","Other Cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03422679",1,"DB15279","2735289","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"6",6,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BOS172722, PACLITAXEL","UNK, UNK","I","First Line, Second Line","Incidence of adverse events (AEs), Number of participants with a dose-limiting toxicity (DLT)","NCT03328494","For patients, No standard curative treatment or has declined standard therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03328494",1,"DB15498,DB01229","73386890, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"7",7,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIS793, PDR001","TGFbeta, PD1","I","Advanced, Second Line","Incidence of DLTs, AEs, SAEs and dose reductions / interruptions for NIS793, Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001","NCT02947165","Patients must have resistance to anti-PD-1/PD-L1 therapy is defined as: Documented progressive disease occurring while on/or within 6 months after anti-PD-1 and/or anti-PD-L1 agent (single or combination) received as the last therapy prior to enrollment.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02947165",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"8",8,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","AVELUMAB, TALAZOPARIB","PDL1, PARP","II","Advanced, First Line, Second Line","Dose Limiting Toxicity (DLT), Overall Response (OR)","NCT03330405","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03330405",1,"DB11945,DB11760","NA, 135565082","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"9",9,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","AVELUMAB, TALAZOPARIB","PDL1, PARP","II","Advanced, First Line, Second Line","Dose Limiting Toxicity (DLT), Overall Response (OR)","NCT03330405","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03330405",1,"DB11945,DB11760","NA, 135565082","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"10",10,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","BRCA1, BRCA2, ATM","Positive, Positive, Positive","AND/OR, OR","Mutation, Mutation, Mutation","AVELUMAB, TALAZOPARIB","PDL1, PARP","II","Advanced, First Line, Second Line","Dose Limiting Toxicity (DLT), Overall Response (OR)","NCT03330405","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03330405",1,"DB11945,DB11760","NA, 135565082","ENSG00000012048, ENSG00000139618, ENSG00000149311","MONDO_0007254","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE OR ATM MUTATION POSITIVE","pass"
"11",11,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","MM-310","EPHA2","I","Second Line","Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.","NCT03076372","other cancers included in trial, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03076372",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"12",12,"ADVANCED BREAST CANCER","BRCA1, BRCA2","Positive/Negative, Positive/Negative","AND/OR","Mutation, Mutation","IMP4297","PARP","I","Second Line","The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors, The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297","NCT03507543","Other cancers included in trial. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03507543",1,"NA","NA","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE/NEGATIVE AND/OR BRCA2 MUTATION POSITIVE/NEGATIVE","failed drug"
"13",13,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY3295668","UNK","II","Advanced, Second Line","Objective Response Rate (Phase 2)","NCT03092934","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03092934",1,"NA","121333423","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"14",14,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LY3295668","UNK","II","Advanced, Second Line","Objective Response Rate (Phase 2)","NCT03092934","Other cancers included in trial, must have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03092934",1,"NA","121333423","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"15",15,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","PRS-343","UNK","I","Advanced, Second Line","Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4","NCT03330561","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03330561",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"16",16,"METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","IACS-010759","Oxidative Phosphorylation Inhibitor","I","Advanced, Second Line","Incidence of adverse events, Maximum tolerated dose","NCT03291938","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03291938",1,"NA","86711931","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"17",17,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","RO7198457, ATEZOLIZUMAB","UNK, PDL1","I","Advanced, Second Line","Percentage of Participants with Dose-Limiting Toxicities (DLTs), MTD/Recommended Phase 2 Dose (RP2D) of RO7198457, Percentage of Participants with Adverse Events (AEs), Percentage of Participants with Immune-Mediated Adverse Events (imAEs), Percentage of Participants by Number of Treatment Cycles Received, Dose Intensity of RO7198457, Change from baseline in targeted vital signs, Change from baseline in targeted clinical laboratory test results, Change from baseline in ECGs","NCT03289962","Other cancers included in trial, not previously treated with anti-PD-L1/PD-1 and/or anti-CTLA-4","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03289962",1,"NA,DB11595","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"18",18,"ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT, SY-1365","UNK, UNK","I","Advanced, Second Line","(Part 1) First-cycle dose-limiting toxicities (DLTs), (Part 1) ECG QTc Interval, (Part 1 and 2) Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","NCT03134638","Other cancers included in trial. Patients must have failed prior treatment with a CDK 4/6 inhibitor in combination with a hormonal therapy (i.e. aromatase inhibitors, fulvestrant). Treatment failure is based on development of clinical or documented progression during treatment with a CDK4/6 inhibitor in combination with hormonal therapy after ≥ 6 months of therapy. Progression following discontinuation of CDK4/6 treatment due to safety and/or tolerability is not considered as treatment failure for purposes of inclusion criteria.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03134638",1,"DB00947,NA","104741, 118426108","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"19",19,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TINOSTAMUSTINE","AK-DAC","I, II","Advanced, Second Line","Safety: Number of participants with treatment-related adverse events as assessed by CTCAE V4.03, Objective Response Rate (ORR) and SD that persists for at least 4 months in selected solid tumor cohorts","NCT03345485","Other cancers included in trial, Must have received at least one line of chemotherapy and no other standard therapy with proven clinical benefit is available or recommended based on the investigator's individual risk-benefit assessment for the patient. At least 3 weeks should have elapsed since prior chemotherapy or 5 half-lives, whichever is shorter, as long as the patient recovered from acute toxicity of previous therapies to ≤ grade 1 (or ≤ Grade 2 for any symptomatic neuropathy or endocrinopathies).","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03345485",1,"DB15147","46836227","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"20",20,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PERTUZUMAB, TRASTUZUMAB, ERIBULIN","UNK, UNK, UNK","III","First Line","PFS","NCT03264547","Patients cannot plan to undergo radical surgery if they respond to a treatment, Active comparator is Pertuzumab, Trastuzumab, Docetaxel, Paclitaxel","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03264547",1,"DB06366,DB00072,DB08871","NA, 3001322, 17755248","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"21",21,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CABOZANTINIB, ATEZOLIZUMAB","UNK, UNK","I, II","Advanced, Second Line","Dose Escalation: MTD/Recommended Dose, Dose Expansion: ORR","NCT03170960","Other cancers included in trial, TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03170960",1,"DB08875,DB11595","25102846, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"22",22,"DUCTAL BREAST CARCINOMA","ESR1","Positive","NA","Protein Expression","CONJUGATED ESTROGENS, BAZEDOXIFENE","UNK, UNK","II","First Line, Second Line","Change in Ki-67 protein expression","NCT02694809","Must have surgical therapy. Women presenting after excision with positive margins are eligible. Ki-67, Cox-2, P-16, expression in immediately adjacent tissue is similar to what is found in DCIS","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02694809",1,"DB00286,DB06401","23667301, 154256","ENSG00000091831","EFO_0000186","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"23",23,"RECURRENT OR METASTATIC BREAST CANCER","ESR1, AKT1, AKT2, AKT3","Positive, Postive, Positive, Positive","AND, AND/OR, AND/OR","Protein Expression, Mutation, Mutation, Mutation","AZD5363, FULVESTRANT","UNK, UNK","I","Advanced, Second Line","number of patients with an objective response rate (ORR) of AZD5363","NCT03310541","Patients must be post-menopausal, other cancers are included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03310541",1,"NA,DB00947","25227436, 104741","ENSG00000091831, ENSG00000142208, ENSG00000105221, ENSG00000117020","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND AKT1 MUTATION POSTIVE AND/OR AKT2 MUTATION POSITIVE AND/OR AKT3 MUTATION POSITIVE","pass"
"24",24,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CAN04","IL1RAP","I","Advanced, Second Line","Incidence of Treatment-Emergent Adverse Events","NCT03267316","Other cancers included in trial, TNBC only listed in dose escalation cohort","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03267316",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"25",25,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, EGFR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","AVID100","UNK","I, II","Advanced, Second Line","Phase 1a: Determine safety and tolerability of AVID100, Phase 2a: Evaluation of the preliminary antineoplastic effects of AVID100","NCT03094169","Other cancers included in trial, Patients with triple negative breast cancer who are either EGFR 2+ or EGFR 3+ by validated IHC assay.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03094169",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146648","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND EGFR PROTEIN EXPRESSION POSITIVE","failed drug"
"26",26,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PF-06804103","UNK","I","Second Line","Number of participants with Dose-Limiting Toxicities (DLTs)","NCT03284723","Other cancers included in trial, patients must be resistant to standard therapy or for which no standard therapy is available","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03284723",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"27",27,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DENOSUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN","RANKL, UNK, UNK, UNK, UNK","II","First Line","pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC, pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks","NCT02682693","Patients must have stage cT1c - cT4a-d disease. Testing drugs in different combinations","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02682693",1,"DB06643,NA,DB00445,DB00531,DB00958","NA, 36314, 65348, 2907, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"28",28,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","DENOSUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","RANKL, UNK, UNK, UNK, UNK, UNK, UNK","II","First Line","pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC, pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks","NCT02682693","Patients must have stage cT1c - cT4a-d disease. Testing drugs in different combinations","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02682693",1,"DB06643,NA,DB00445,DB00531,DB00958,DB00072,DB06366","NA, 36314, 65348, 2907, 56840877, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"29",29,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","LXI-15029, EXEMESTANE","UNK, UNK","I","Advanced, Second Line","Number of participants with adverse events","NCT03125746","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03125746",1,"NA,DB00990","NA, 60198","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","failed drug"
"30",30,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY3381916, LY3300054","UNK, PDL1","I","Advanced, First Line, Second Line","Number of Participants with Dose Limiting Toxicities (DLTs)","NCT03343613","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03343613",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"31",31,"DUCTAL CARCINOMA","ESR1","Positive","NA","Protein Expression","AFIMOXIFENE, TAMOXIFEN CITRATE","UNK, UNK","II","First Line, Second Line","Ki67 labeling assessed by standard immunohistochemistry","NCT02993159","Both tested as monotherapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02993159",1,"DB04468,NA","5352135, 2733525","ENSG00000091831","EFO_0006318","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"32",32,"METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB, ONALESPIB","PARP, UNK","I","Advanced, Second Line","Maximum tolerated dose","NCT02898207","Other cancers included in trial, TNBC needs to have metastatic disease and patients with an in breast recurrence are not eligible; up to 4 prior lines in the recurrent setting for patients with triple-negative breast cancer are allowed, or the dose expansion cohort, patients with triple-negative breast cancer may not be BRCA1/2 germline mutation carriers (nothing mentioned about the dose escalation cohort), does not mention somatic mutations, left out of biomarker requirements","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02898207",1,"DB09074,DB06306","23725625, 11955716","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"33",33,"BREAST CANCER","absent","NA","NA","NA","PACLITAXEL","UNK","UNK","First Line","Response to paclitaxel","NCT03096418","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03096418",1,"DB01229","36314","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"34",34,"METASTATIC INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, COBIMETINIB, ERIBULIN","UNK, MEK, UNK","II","Advanced, Second Line","Overall response rate (ORR) calculated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","NCT03202316","Patients with recurrent or metastatic IBC after standard systemic therapy are eligible; patients who have disease progression while receiving standard anthracycline or taxane based neoadjuvant therapy are also eligible. a. patients with HER2-positive disease must have had at least 2 lines of anti-HER2 therapy, including Perjeta and Kadcyla; b. prior eribulin treatment is allowed","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03202316",1,"DB11595,DB05239,DB08871","NA, 71491931, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"35",35,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, PEMBROLIZUMAB","UNK, UNK","II","Advanced, First Line","Progression Free Survival (PFS)","NCT03213041","patients must be positive for circulating tumor cells","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03213041",1,"DB00958,DB09037","56840877, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"36",36,"RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, Fralpha","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","GEMCITABINE, GEMCITABINE HYDROCHLORIDE, MIRVETUXIMAB SORAVTANSINE","UNK, UNK, FOLR1","I","Advanced, Second Line","Recommended phase II dose assessed by Common Terminology Criteria for Adverse Events version 4","NCT02996825","Other cancers included in trial, Cohort A: Patients with TNBC must have received no more than 4 lines of systemic cytotoxic chemotherapy; patients must have received and failed, or have been intolerant to anthracycline, taxanes, capecitabine, eribulin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigator's opinion, patients would benefit from treatment on current protocol","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02996825",1,"DB00441,NA,DB12489","60750, 60749, 91810695","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND FRALPHA PROTEIN EXPRESSION POSITIVE","pass"
"37",37,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, DARATUMUMAB","UNK, UNK","I, II","Advanced, First Line, Second Line","Incidence of adverse events (AE), Incidence of serious adverse events (SAE), Grade of laboratory abnormalities.","NCT03098550","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03098550",1,"DB09035,DB09331","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"38",38,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, CARBOPLATIN, DECITABINE, PEMBROLIZUMAB","UNK, UNK, UNK, UNK, UNK, UNK","II","Advanced, First Line","Increase in percent of tumor and stroma with infiltrating lymphocytes from baseline pre-treatment biopsy to post-immunotherapy biopsy following administration of decitabine followed by pembrolizumab","NCT02957968","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02957968",1,"DB00997,DB00531,DB01229,DB00958,DB01262,DB09037","443939, 2907, 36314, 56840877, 451668, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"39",39,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, DECITABINE, PEMBROLIZUMAB","UNK, UNK, UNK, UNK, UNK","II","Advanced, First Line","Increase in percent of tumor and stroma with infiltrating lymphocytes from baseline pre-treatment biopsy to post-immunotherapy biopsy following administration of decitabine followed by pembrolizumab","NCT02957968","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02957968",1,"DB00997,DB00531,DB01229,DB01262,DB09037","443939, 2907, 36314, 451668, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"40",40,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, CARBOPLATIN, PACLITAXEL","UNK, UNK, UNK","II","First Line","Increase in tumor infiltrating lymphocyte (TIL) percentage","NCT02883062","Active comparator: Carboplatin, Paclitaxel, patients must receive lumpectomy or mastectomy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02883062",1,"DB11595,DB00958,DB01229","NA, 56840877, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"41",41,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","H3B-6545","Eralpha","I, II","Advanced, Second Line","Number of Participants with Dose-limiting Toxicities (DLTs), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","NCT03250676","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03250676",1,"NA","124091040","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","pass"
"42",42,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","ATEZOLIZUMAB, RUCAPARIB","UNK, UNK","I","Advanced, Second Line","Percentage of Participants With Adverse Events, Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1], Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1], Number of Dose Modifications due to Adverse Events [Part 2]","NCT03101280","Other cancers included. TNBC is in part 2 cohort 2, For Part 2 ONLY, have a deleterious germline or somatic breast cancer susceptibility gene 1 (BRCA1) or BRCA2 mutation or tumors that are wild-type BRCA but show high levels of loss of heterozygosity (LOH) (tBRCAwt/LOHhigh) signature","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03101280",1,"DB11595,DB12332","NA, 9931954","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"43",43,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER (III-IV)","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE, PEMBROLIZUMAB","UNK, UNK","II","Advanced, Second Line","Median PFS (median Progression-Free Survival)","NCT03044730","Patients must have histologically-confirmed unresectable, locally advanced or metastatic breast cancer that meets one of the following: Triple negative, defined as estrogen receptor (ER) negative, progesterone receptor (PR) negative, human epidermal growth factor receptor 2 (HER2) negative; HER2 negative defined as immunohistochemistry (IHC) 0 or 1+ or fluorescence in situ hybridization (FISH) negative, Hormone-refractory breast cancer which denotes progression to endocrine therapy (e.g., tamoxifen, aromatase inhibitors, fulvestrant) unless contraindicated","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03044730",1,"DB01101,DB09037","60953, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"44",44,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","UTOMILUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB","41BB, ERBB2, ERBB2","I","Advanced, Second Line","Incidence of Dose-limiting toxicities (DLTs)","NCT03364348","Cohorts seperated by previous treatments, separate cohorts are given different drug combinations","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03364348",1,"DB15113,DB05773,DB00072","NA, NA, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"45",45,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, TREMELIMUMAB","B7H1, CTLA4","I","First Line","Feasibility defined by number of patients willing to enroll, Feasibility defined by number of patients to complete the protocol, Incidence of adverse events","NCT03132467","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03132467",1,"DB11714,DB11771","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"46",46,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ENOBOSARM, PEMBROLIZUMAB","UNK, UNK","II","Advanced, First Line, Second Line","Incidence of adverse events, Response rate (complete response or partial response), Dose limiting toxicities","NCT02971761","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02971761",1,"DB12078,DB09037","11326715, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"47",47,"BREAST CANCER","absent","NA","NA","NA","ORAXOL","UNK","I","First Line, Second Line","Evaluation of PK parameters for oral paclitaxel - Cmax, Evaluation of PK parameters for oral paclitaxel - Cmin, Evaluation of PK parameters for oral paclitaxel - Cavg, Evaluation of PK parameters for oral paclitaxel - AUC0-t, Evaluation of PK parameters for oral paclitaxel - AUC","NCT03165955","Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03165955",1,"NA","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"48",48,"INFLAMMATORY BREAST CANCER (IIIB-IIIC)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","II","Second Line","Disease free survival (DFS)","NCT02971748","Did not achieve pathological complete response (pCR) to any chemotherapy that was given with the intention to induce best response prior surgery. pCR is defined as the current American Joint Committee on Cancer (AJCC) breast cancer staging.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02971748",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"49",49,"INVASIVE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, Fralpha","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","MIRVETUXIMAB SORAVTANSINE","UNK","II","First Line","Response rate","NCT03106077","Two cohorts, Cohort A must be FRalpha positive, cohort B just needs to have analysis.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03106077",1,"DB12489","91810695","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND FRALPHA PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"50",50,"ADVANCED OR METASTATIC BREAST CANCER","BRCA1, BRCA2","Positive, Positive","AND/OR","Mutation, Mutation","TALAZOPARIB","UNK","I","Advanced, Second Line","Number of participants with Dose-limiting toxicities (DLT), Number of Participants With Objective Response","NCT03343054","Other cancers can be included in this trial, Breast cancer is in dose expansion part","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03343054",1,"DB11760","135565082","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"51",51,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER OR INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BEMCENTINIB, PEMBROLIZUMAB","UNK, UNK","II","Advanced, Second Line","Objective Response Rate","NCT03184558","Received one or more prior therapies for TNBC or inflammatory breast cancer in the metastatic setting, and prior treatment (metastatic or (neo) adjuvant) must have included a prior taxane and/or anthracycline-based therapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03184558",1,"NA,DB09037","46215462, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"52",52,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TVB-2640, PACLITAXEL, TRASTUZUMAB","FASN, UNK, HER2","II","Advanced, Second Line","Overall response rate","NCT03179904","Protein Expression, Protein Expression, Protein Expressionone","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03179904",1,"NA,DB01229,DB00072","66548316, 36314, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"53",53,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, ENDOCRINE THERAPY","UNK, UNK","II","Advanced, Second Line","molecular patterns of resistance [with a special focus on retinoblastoma (Rb) status] upon progression to palbociclib plus endocrine therapy in patients who previously achieved clinical benefit with the combination, clinical activity of the combination of palbociclib and endocrine therapy after prior progression to palbociclib in endocrine-sensitive patients","NCT03184090","Endocrine therapy includes physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole, Confirmed disease progression on immediate previous palbociclib plus endocrine therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03184090",1,"DB09073,NA","11478676, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"54",54,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","DECITABINE, PACLITAXEL","UNK, UNK","I","Advanced, Second Line","Maximum Tolerant Dose (MTD) and Dose Limiting Toxicity (DLT) ","NCT03282825","be unable to operate for therapy with HER2 negative breast adenocarcinoma and metastatic breast cancer, one or more chemotherapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03282825",1,"DB01262,DB01229","451668, 36314","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"55",55,"UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEGYLATED LIPOSOMAL DOXORUBICIN","UNK","II","Advanced, Second Line","PFS","NCT03071926","Primary endocrine resistance is defined as: a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03071926",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"56",56,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CB-839, PACLITAXEL","UNK, UNK","II","Advanced, First Line, Second Line","Objective response rate (ORR)","NCT03057600","CB-839 with paclitaxel is denoted in combination as Pac-CB, four separate cohorts based on prior therapies and african ancestry. Patients with prior therapy need two or more lines","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03057600",1,"NA,DB01229","71577426, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"57",57,"INORPERABLE LOCALLY RECURRENT METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, ERIBULIN","UNK, UNK","II","Advanced, Second Line","Efficacy of pembrolizumab in combination with eribulin","NCT03222856","Patients have received at least one, but not more than two, prior chemotherapeutic regimens for locally recurrent and/or metastatic disease. Prior therapy must have included an anthracycline and a taxane in any combination or order and either in the early or metastatic disease setting unless contraindicated for a given patient. Prior anti-hormonal therapy is mandatory.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03222856",1,"DB09037,DB08871","NA, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"58",58,"UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, BICALUTAMIDE","UNK, UNK","II","Advanced, First Line, Second Line","Phase I: Maximum Tolerated Dose, Phase II: Clinical benefit rate (CBR) of treatment combination","NCT03090165","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03090165",1,"DB11730,DB01128","44631912, 56069","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"59",59,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","METFORMIN, SIMVASTATIN, FULVESTRANT","UNK, UNK, UNK","II","Advanced, Second Line","Clinical benefit rate (CBR)","NCT03192293","must be post-menopusal or be on LHRH","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03192293",1,"DB00331,DB00641,DB00947","14219, 54454, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"60",60,"BREAST CANCER","ESR1","Positive","NA","Protein Expression","LENVATINIB","UNK","II","First Line","Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design, Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design, Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design, Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design, Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design, Biological effects of short-course single agent lenvatinib in estrogen receptor positive breast cancer using a window-of-opportunity design","NCT03168074","patients must be Scheduled for upfront definitive breast cancer surgery (breast conserving surgery or mastectomy with or without sentinel lymph node biopsy or axillary lymph node clearance)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03168074",1,"DB09078","11237762","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"61",61,"ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","GSK525762, FULVESTRANT","UNK, UNK","II","Advanced, Second Line","Phase I: Number of subjects with adverse events (AE) and serious adverse events (SAE), for the determination of recommended Phase II dose of GSK525762 [ Time Frame: From Day 1 until end of treatment, Phase I: Number of subjects with dose limiting toxicities (DLT), Phase I: Number of subjects with dose reductions or delays, for the determination of recommended Phase II dose of GSK525762, Phase I: Overall response rate (ORR), Phase I: Plasma concentration of GSK525762, for the determination of recommended Phase II dose of GSK525762, Phase I: Plasma concentration of fulvestrant, for the determination of recommended Phase II dose of GSK525762, Phase II: Progression free survival (PFS)","NCT02964507","prior therapy must be with either Aromatase inhibitor (AI) failures: Disease that relapsed during treatment or within 12 months of completion of adjuvant therapy with an AI, OR disease that progressed during treatment with an AI for advanced/metastatic disease. Prior ovarian suppression and/or tamoxifen are allowed as long as other criteria are met or Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor plus AI failures: Disease that progressed on a CDK4/6 inhibitor plus AI, for advanced/metastatic disease with a minimum duration of treatment of 12 months (>=12 months) with CDK4/6 inhibitor plus AI. Subjects with either measurable disease or bone only disease are allowed. Prior ovarian suppression and/or tamoxifen are allowed as long as other criteria are met.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02964507",1,"NA,DB00947","46943432, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"62",62,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","ANASTROZOLE, PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","I, II","Advanced, First Line","The dose-limiting toxicity (DLT) for palbociclib when administered in combination with anastrozole, trastuzumab and pertuzumab, Maximum Tolerated Dose (MTD), Clinical Benefit Rate (CBR)","NCT03304080","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03304080",1,"DB01217,DB09073,DB00072,DB06366","2187, 11478676, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"63",63,"BREAST CANCER","ERBB2, ESR1, Ki67","Negative, Positive, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TREMELIMUMAB, EXEMESTANE, DURVALUMAB","UNK, UNK, UNK","II","First Line, Second Line","pathological Complete Response","NCT02997995","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02997995",1,"DB11771,DB00990,DB11714","NA, 60198, NA","ENSG00000141736, ENSG00000091831, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE","pass"
"64",64,"BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, GOSERELIN ACETATE, TAMOXIFEN, LETROZOLE","UNK, UNK, UNK, UNK, UNK, UNK","II, III","First Line","Disease-free survival (DFS)","NCT03373708","Seperated into different drug combination groups. randomly assign 200 primary breast cancer patients to receive four cycles of epirubicin and cyclophosphamide (EC) followed by four cycles of docetaxel(T), or four cycles of docetaxel and cyclophosphamide (TC) followed by intensive endocrine therapy (Goserelin acetate+Tamoxifen/Letrozole for young patients)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03373708",1,"DB00445,DB00531,DB01248,NA,DB00675,DB01006","65348, 2907, 148124, 16052011, 2733526, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","pass"
"65",65,"BREAST CANCER","absent","NA","NA","NA","EPIRUBICIN, FLUOROURACIL, CYCLOPHOSPHAMIDE, DOCETAXEL","UNK, UNK, UNK, UNK","II, III","First Line","Percentage of Participants With Pathological Complete Response (pCR)","NCT03349177","Seperated into different drug combination groups, In this trial the investigators will randomly assign 200 primary breast cancer patients to receive six cycles of fluorourcil, epirubicin,and cyclophosphamide(FEC), or four cycles of epirubicin and cyclophosphamide (EC) followed by four cycles of docetaxel(T), or six cycles of docetaxel and cyclophosphamide (TC)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03349177",1,"DB00445,DB00544,DB00531,DB01248","65348, 3385, 2907, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"66",66,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","TESETAXEL, CAPECITABINE","UNK, UNK","III","Second Line","PFS","NCT03326674","active comparator: Capecitabine. must have been previously treated with a taxane in the neoadjuvant or adjuvant setting","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03326674",1,"DB12019,DB01101","6918574, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"67",67,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, CARBOPLATIN","UNK, UNK","II","Advanced, First Line, Second Line","Progression free survival (PFS)","NCT03206203","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03206203",1,"DB11595,DB00958","NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"68",68,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DECITABINE, CARBOPLATIN","UNK, UNK","II","Advanced, First Line, Second Line","Overall response rate","NCT03295552","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03295552",1,"DB01262,DB00958","451668, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"69",69,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB","UNK","I","Advanced, Second Line","Determination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy ","NCT03109080","In combination with radiation therapy. Neoadjuvant chemotherapy (containing anthracyclines or taxanes or the combination of both or containing platinum-based chemotherapy) willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy, and targeted therapies at least two weeks prior to start of Olaparib.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03109080",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"70",70,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","PALBOCICLIB, AROMATASE INHIBITORS, FULVESTRANT","UNK, Aromatase, UNK","III","Advanced, First Line","Co-primary :safety until randomization, Co-primary : efficacy from randomization","NCT03079011","Different drug combinations, palbociclib with aromatase inhibitors (Letrozole, Anastrozole or exemestane) or with the Fulvestrant Injectable Product, patients cannot have Locally advanced breast cancer or loco-regional relapse amenable for any treatment with curative intent","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03079011",1,"DB09073,NA,DB00947","11478676, NA, 104741","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","pass"
"71",71,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND/OR, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","FLUZOPARIB, APATINIB","PARP1/PARP2, VEGFR","I","Advanced, First Line, Second Line","The type and incidence of adverse events [safety and tolerability]","NCT03075462","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03075462",1,"NA,DB14765","56649297, 45139106","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND/OR BRCA1 MUTATION POSITIVE/NEGATIVE AND/OR BRCA2 MUTATION POSITIVE/NEGATIVE","pass"
"72",72,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","EVEROLIMUS, EXEMESTANE","UNK, UNK","II","Advanced, Second Line","Progression-free Survival (PFS)","NCT03312738","Active comparator: Active Comparator: Placebo + Exemestane, must have recurrence or progression on prior NSAI is defined as Recurrence while on, or within one year (12 months) of end of adjuvant treatment with letrozole or anastrozole OR Progression while on or within one month (30 days) of the end of prior treatment with letrozole or anastrozole.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03312738",1,"DB01590,DB00990","6442177, 60198","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","pass"
"73",73,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TRILACICLIB, GEMCITABINE, CARBOPLATIN","CDK4/CDK6, UNK, UNK","II","Advanced, First Line, Second Line","number of Treatment Related Adverse Event, including Abnormal Laboratory Events","NCT02978716","Testing drugs in different combinations","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02978716",1,"DB15442,DB00441,DB00958","68029831, 60750, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"74",74,"LOCALLY RECURRENT UNRESECTABLE INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT, AVELUMAB","CDK4/CDK6, UNK, PD1","II","Advanced, First Line, Second Line","Progression Free Survival","NCT03147287","Testing drugs in different combinations. Participants must have radiological or objective evidence of progression on an endocrine and CDK 4/6 inhibitor regimen in the metastatic setting, and/or relapse/progression during or within 12 months of completion of an endocrine and CDK4/6 inhibitor regimen in the adjuvant setting.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03147287",1,"DB09073,DB00947,DB11945","11478676, 104741, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"75",75,"INVASIVE METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","PD1","II","Advanced, First Line, Second Line","Overall Response Rate","NCT03051672","In combination with palliative radiotherapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03051672",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"76",76,"ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH CHEST WALL DISEASE","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CARBOPLATIN","UNK, UNK, UNK","II","Advanced, First Line, Second Line","Disease control rate, Objective response rate (ORR) defined as complete response (CR)/partial response (PR) assessed by RECIST","NCT03095352","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03095352",1,"DB09037,DB00958","NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"77",77,"ADVANCED BREAST CANCER WITH CHEST WALL DISEASE","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CARBOPLATIN","UNK, UNK","II","Advanced, Second Line","Disease control rate, Objective response rate (ORR) defined as complete response (CR)/partial response (PR) assessed by RECIST","NCT03095352","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03095352",1,"DB09037,DB00958","NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"78",78,"ADVANCED BREAST CANCER WITH CHEST WALL DISEASE","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","PEMBROLIZUMAB, CARBOPLATIN, TRASTUZUMAB","UNK, UNK, UNK","II","Advanced, Second Line","Disease control rate, Objective response rate (ORR) defined as complete response (CR)/partial response (PR) assessed by RECIST","NCT03095352","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03095352",1,"DB09037,DB00958,DB00072","NA, 56840877, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"79",79,"TRIPLE NEGATIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CARBOPLATIN, PACLITAXEL, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First Line, Second Line","Pathological complete response (pCR), defined as absence of invasive cancer in the breast and axillary lymph nodes.","NCT02978495","Different drug combinations depending upon BRCA status, however, BRCA mutation is not required to be enrolled into the trial, not listed in the inclusion critera","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02978495",1,"DB00997,DB00958,DB01229,DB00531","443939, 56840877, 36314, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"80",80,"UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","INTERFERON-GAMMA, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","I","Advanced, First Line, Second Line","Phase 1: Recommended Phase 2 Dose (RP2D)","NCT03112590","Phase 1: Must be candidates to receive paclitaxel chemotherapy in combination with trastuzumab and pertuzumab.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03112590",1,"NA,DB01229,DB00072,DB06366","NA, 36314, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"81",81,"BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","INTERFERON-GAMMA, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","II","First Line, Second Line","Phase 2: Pathologic Complete Response Rate (pCR)","NCT03112590","Phase 2: No prior chemotherapy, radiation, or definitive therapeutic surgery (e.g., mastectomy, lumpectomy or axillary dissection) for this malignancy. Patients who have had a prior sentinel lymph node biopsy for this malignancy are eligible. Patients who received equal to or less than 1 cycle of therapy (up to 4 weeks) will be allowed to enroll in this trial.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03112590",1,"NA,DB01229,DB00072,DB06366","NA, 36314, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"82",82,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, PDR001, FULVESTRANT","CDK, PD1, ESR1","I","Advanced, First Line, Second Line","Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001, Cohort B: MTD/RP2D of the Combination of Ribociclib + PDR001 + Fulvestrant","NCT03294694","Other cancers included in trial.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03294694",1,"DB11730,NA,DB00947","44631912, NA, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"83",83,"BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND/OR, AND/OR","Protein Expression, Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, INDOMETHACIN, OMEPRAZOLE","UNK, UNK, UNK","I","First Line","Surgical Delays","NCT02950259","Patients are also gvien a Dietary Supplement: Multivitamin. Patients will undergo surgical resection with curative intent by partial mastectomy (lumpectomy) or mastectomy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02950259",1,"DB00531,DB00328,DB00338","2907, 3715, 4594","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"84",84,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, INDOMETHACIN, OMEPRAZOLE","UNK, UNK, UNK","I","First Line","Surgical Delays","NCT02950259","Patients are also gvien a Dietary Supplement: Multivitamin. Patients will undergo surgical resection with curative intent by partial mastectomy (lumpectomy) or mastectomy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02950259",1,"DB00531,DB00328,DB00338","2907, 3715, 4594","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"85",85,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","absent","NA","NA","NA","OTS167PO","UNK","I","Advanced, Second Line","MTD","NCT02926690","Relapsed (recurrence or disease progression after achieving a documented clinical response to first- or second-line treatment) or refractory (disease progression while receiving first line or second line treatment).","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02926690",1,"NA","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"86",86,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OTS167PO","UNK","I","Advanced, Second Line","MTD","NCT02926690","Relapsed (recurrence or disease progression after achieving a documented clinical response to first- or second-line treatment) or refractory (disease progression while receiving first line or second line,  treatment).  In the case of TNBC, prior initial therapy with at least one known active regimen for TNBC including, but not limited to, any combination of anthracyclines, taxanes, platinum agents, Ixabepilone, and/or cyclophosphamide is required.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02926690",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"87",87,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","ZW25, PACLITAXEL, CAPECITABINE, VINORELBINE","UNK, UNK, UNK, UNK","I","Advanced, Second Line","The proportion of patients who experience dose-limiting toxicities (DLTs) (Part 1), The proportion patients who experience laboratory abnormalities and/or adverse events as defined by CTCAE v4.03 that are related to treatment (Parts 2 and 3)","NCT02892123","testing different drug combinations, other cancers are included.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02892123",1,"NA,DB01229,DB01101,DB00361","NA, 36314, 60953, 5311497","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"88",88,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CORT125134, NAB-PACLITAXEL","GR, UNK","I, II","Advanced, Second Line","Maximum Tolerated Dose of CORT125134 in Combination with nab-paclitaxe","NCT02762981","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02762981",1,"DB14976,NA","73051463, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"89",89,"UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GSK3326595","PRMT5","I","Advanced, Second Line","Part 1: Number of participants with any adverse events (AEs), Part 1: Number of participants with serious adverse events (SAEs), Part 1: Number of participants withdrawn due to Aes, Part 1: Number of participants with dose interruptions and with dose reductions, Part 3: Number of participants withdrawn due to AEs, Part 3: Number of participants with any adverse events (AEs), Part 3: Number of participants with serious adverse events (SAEs), Part 3: Number of participants with dose interruptions and with dose reductions, Part 1: Number of participants with Dose limiting toxicity (DLT), Part 1: Change from Baseline in Hemoglobin (Hb) (Grams per Liter), Part 3: Change from Baseline in Hemoglobin (Hb) (Grams per Liter), Part 1: Change from Baseline in Hematocrit (Proportion of red blood cells in blood), Part 3: Change from Baseline in Hematocrit (Proportion of red blood cells in blood), Part 1: Change from Baseline Mean Corpuscle Hemoglobin (MCH) (Picograms), Part 3: Change from Baseline Mean Corpuscle Hemoglobin (MCH) (Picograms), Part 1: Change from Baseline in Mean Corpuscle Volume (MCV) (Femtoliters), Part 3: Change from Baseline in Mean Corpuscle Volume (MCV) (Femtoliters), Part 1: Change from Baseline in hematology parameter: red blood cells (RBC) Count (Trillion cells per liter), Part 3: Change from Baseline in hematology parameter: RBC Count (Trillion cells per liter), Part 1: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, platelet count (Giga cells per Liter), Part 3: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, platelet count (Giga cells per Liter), Part 1: Change from Baseline in Blood urea nitrogen (BUN), Creatinine, Glucose (fasting), Sodium, Potassium, Calcium, Total and direct bilirubin (Micromoles per liter), Part 3: Change from Baseline in Blood urea nitrogen (BUN), Creatinine, Glucose (fasting), Sodium, Potassium, Calcium, Total and direct bilirubin (Micromoles per liter), Part 1: Change from Baseline in Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT), Alkaline phosphatase (International units per Liter), Part 3: Change from Baseline in AST, ALT, Alkaline phosphatase (International units per Liter), Part 1: Change from Baseline in total protein and albumin (grams per day), Part 3: Change from Baseline in total protein and albumin (grams per day), Part 1: Change from Baseline in Serum Lipase, Serum Amylase (Units per liter), Part 3: Change from Baseline in Serum Lipase, Serum Amylase (Units per liter), Part 1: Change from Baseline in temperature (Degrees Celsius), Part 3: Change from Baseline in temperature (Degrees Celsius), Part 1: Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio), Part 3: Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio), Part 1: Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH), Part 3: Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH), Part 1: Change from Baseline in urinalysis parameter: Glucose (Millimole per liter), Part 3: Change from Baseline in urinalysis parameter: Glucose (Millimole per liter), Part 1: Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter), Part 3: Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter), Part 1: Change from Baseline in urinalysis parameter: Occult blood (10^9 cells per liter), Part 3: Change from Baseline in urinalysis parameter: Occult blood (10^9 cells per liter), Part 1: Change from Baseline in urinalysis parameter: Protein, Part 3: Change from Baseline in urinalysis parameter: Protein, Part 1: Change from Baseline in Pulse rate (Beats per minute), Part 3: Change from Baseline in Pulse rate (Beats per minute), Part 1: Change from Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval, Corrected QT interval using the Fridericia formula (QTcF) (Milliseconds), Part 3: Change from Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval, Corrected QT interval using the Fridericia formula (QTcF) (Milliseconds), Part 1: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeter of mercury), Part 3: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeter of mercury), Part 1: Number of participants with clinically significant change in respiratory rate, Part 3: Number of participants with clinically significant change in respiratory rate, Part 1: Number of participants with clinically significant change in organ-specific parameters, Part 2: Solid tumor cohorts (non-GBM): Overall response rate (ORR) of participants, Part 2: Non-Hodgkin's lymphoma (NHL) cohort(s): Overall response rate (ORR) of participants, Part 2: GMB cohort: Progression free survival (PFS) rate of participants, Part 3: Number of participants with clinically significant change in organ-specific parameters, Part 1: Number of participants with abnormality in physical examinations, Part 3: Number of participants with abnormality in physical examinations","NCT02783300","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02783300",1,"NA","90241742","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"90",90,"UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","GSK3326595","PRMT5","I","Advanced, Second Line","Part 1: Number of participants with any adverse events (AEs), Part 1: Number of participants with serious adverse events (SAEs), Part 1: Number of participants withdrawn due to Aes, Part 1: Number of participants with dose interruptions and with dose reductions, Part 3: Number of participants withdrawn due to AEs, Part 3: Number of participants with any adverse events (AEs), Part 3: Number of participants with serious adverse events (SAEs), Part 3: Number of participants with dose interruptions and with dose reductions, Part 1: Number of participants with Dose limiting toxicity (DLT), Part 1: Change from Baseline in Hemoglobin (Hb) (Grams per Liter), Part 3: Change from Baseline in Hemoglobin (Hb) (Grams per Liter), Part 1: Change from Baseline in Hematocrit (Proportion of red blood cells in blood), Part 3: Change from Baseline in Hematocrit (Proportion of red blood cells in blood), Part 1: Change from Baseline Mean Corpuscle Hemoglobin (MCH) (Picograms), Part 3: Change from Baseline Mean Corpuscle Hemoglobin (MCH) (Picograms), Part 1: Change from Baseline in Mean Corpuscle Volume (MCV) (Femtoliters), Part 3: Change from Baseline in Mean Corpuscle Volume (MCV) (Femtoliters), Part 1: Change from Baseline in hematology parameter: red blood cells (RBC) Count (Trillion cells per liter), Part 3: Change from Baseline in hematology parameter: RBC Count (Trillion cells per liter), Part 1: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, platelet count (Giga cells per Liter), Part 3: Change from Baseline in Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, platelet count (Giga cells per Liter), Part 1: Change from Baseline in Blood urea nitrogen (BUN), Creatinine, Glucose (fasting), Sodium, Potassium, Calcium, Total and direct bilirubin (Micromoles per liter), Part 3: Change from Baseline in Blood urea nitrogen (BUN), Creatinine, Glucose (fasting), Sodium, Potassium, Calcium, Total and direct bilirubin (Micromoles per liter), Part 1: Change from Baseline in Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT), Alkaline phosphatase (International units per Liter), Part 3: Change from Baseline in AST, ALT, Alkaline phosphatase (International units per Liter), Part 1: Change from Baseline in total protein and albumin (grams per day), Part 3: Change from Baseline in total protein and albumin (grams per day), Part 1: Change from Baseline in Serum Lipase, Serum Amylase (Units per liter), Part 3: Change from Baseline in Serum Lipase, Serum Amylase (Units per liter), Part 1: Change from Baseline in temperature (Degrees Celsius), Part 3: Change from Baseline in temperature (Degrees Celsius), Part 1: Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio), Part 3: Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio), Part 1: Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH), Part 3: Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH), Part 1: Change from Baseline in urinalysis parameter: Glucose (Millimole per liter), Part 3: Change from Baseline in urinalysis parameter: Glucose (Millimole per liter), Part 1: Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter), Part 3: Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter), Part 1: Change from Baseline in urinalysis parameter: Occult blood (10^9 cells per liter), Part 3: Change from Baseline in urinalysis parameter: Occult blood (10^9 cells per liter), Part 1: Change from Baseline in urinalysis parameter: Protein, Part 3: Change from Baseline in urinalysis parameter: Protein, Part 1: Change from Baseline in Pulse rate (Beats per minute), Part 3: Change from Baseline in Pulse rate (Beats per minute), Part 1: Change from Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval, Corrected QT interval using the Fridericia formula (QTcF) (Milliseconds), Part 3: Change from Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval, Corrected QT interval using the Fridericia formula (QTcF) (Milliseconds), Part 1: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeter of mercury), Part 3: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeter of mercury), Part 1: Number of participants with clinically significant change in respiratory rate, Part 3: Number of participants with clinically significant change in respiratory rate, Part 1: Number of participants with clinically significant change in organ-specific parameters, Part 2: Solid tumor cohorts (non-GBM): Overall response rate (ORR) of participants, Part 2: Non-Hodgkin's lymphoma (NHL) cohort(s): Overall response rate (ORR) of participants, Part 2: GMB cohort: Progression free survival (PFS) rate of participants, Part 3: Number of participants with clinically significant change in organ-specific parameters, Part 1: Number of participants with abnormality in physical examinations, Part 3: Number of participants with abnormality in physical examinations","NCT02783300","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02783300",1,"NA","90241742","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"91",91,"DUCTAL CARCINOMA (II-III)","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND/OR, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","I","First Line, Second Line","Maximum tolerated dose (MTD), Dose-limiting toxicities (DLTs), Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells (treated vs. untreated participants) as measured using multiplex immunofluorescence on FFPE tissue sections","NCT02872025","Must plan on having surgical treatment to remove the lesion. Have at least 2 of the following high risk features associated with her DCIS - high-grade (grade II-III), palpable mass, hormone receptor negative (less than 1%), Her2 positive, young age (less than 45 years old), and large size (greater than 5 cm)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02872025",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0000186","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"92",92,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, ITACITINIB, INCB050465","UNK, UNK, UNK","I","Advanced, Second Line","Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events","NCT02646748","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02646748",1,"DB09037,DB12154,DB14867","NA, 53380437, 86677874","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"93",93,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","LY3300054, ABEMACICLIB","PDL1, UNK","I","Advanced, Second Line","Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs)","NCT02791334","Other cancers included in trial, must have previously received prior treatment with at least 1 but no more than 3 chemotherapy regimens in the metastatic setting","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02791334",1,"NA,DB12001","NA, 46220502","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"94",94,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY3039478, GEMCITABINE, CARBOPLATIN","UNK, UNK, UNK","I","Advanced, Second Line","Maximum Tolerated Dose (MTD) of LY3039478","NCT02784795","Other cancers included in trial, All participants must have histological evidence of locally advanced or metastatic triple negative breast cancer (TNBC) and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received >2 lines of systemic treatment for advanced or metastatic TNBC.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02784795",1,"NA,DB00441,DB00958","71236992, 60750, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"95",95,"BREAST CANCER (II-III)","absent","NA","NA","NA","PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE, TAXOTERE","UNK, UNK, UNK","II","First Line","improvement of pathological complete response（PCR)","NCT02953184","Active comparator: Cyclophosphamide, Taxotere, Dexrazoxane (DZR), Doxorubicin. Patients will also undergo procedures","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02953184",1,"NA,DB00531,NA","NA, 2907, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"96",96,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, DURVALUMAB, TREMELIMUMAB, CARBOPLATIN, GEMCITABINE","UNK, UNK, UNK, UNK, UNK","I","Advanced, First Line","Laboratory findings (including: clinical chemistry, hematology, and urinalysis), Incidence of Adverse Events","NCT02658214","Other cancers included in trial, drugs tested in different combinations for TNBC, must be chemotherapy-naïve","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02658214",1,"NA,DB11714,DB11771,DB00958,DB00441","36314, NA, NA, 56840877, 60750","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"97",97,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","PDL1","II","Advanced, Second Line","Changes in genomic and immune biomarkers that will be measured in blood and tumor pre-treatment, on-treatment and at progression (progression biopsies only done for those who have complete or partial responses, or stable disease for more than 4 months)","NCT02644369","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02644369",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"98",98,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIR178, PDR001","A2AR, UNK","II","Advanced, Second Line","Determine the overall response rate, Determine the overall response rate, Determine the overall response rate","NCT03207867","other cancers included in trial, Patients with triple negative breast cancer must have received a prior taxane-containing regimen","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03207867",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"99",99,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY2880070, GEMCITABINE","UNK, UNK","I, II","Advanced, Second Line","Maximum Tolerated Dose(s)","NCT02632448","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02632448",1,"NA,DB00441","NA, 60750","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"100",100,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Mutation, Mutation","OLAPARIB, MEDI4736","UNK, UNK","II","Advanced, First Line, Second Line","Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of the number and grade of adverse events, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of physical examination, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of vital signs, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of blood samples, ORR (CR + PR) based on RECIST 1.1, and as determined by investigator, Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, DCR (CR+PR+SD) based on RECIST 1.1","NCT02734004","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02734004",1,"DB09074,NA","23725625, NA","ENSG00000141736, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"101",101,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L","Negative, Negative, Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","OLAPARIB, MEDI4736","UNK, UNK","II","Advanced, First Line, Second Line","Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of the number and grade of adverse events, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of physical examination, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of vital signs, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of blood samples, ORR (CR + PR) based on RECIST 1.1, and as determined by investigator, Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, DCR (CR+PR+SD) based on RECIST 1.1","NCT02734004","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02734004",1,"DB09074,NA","23725625, NA","ENSG00000141736, ENSG00000012048, ENSG00000139618, ENSG00000149311, ENSG00000138376, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000115392, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE","pass"
"102",102,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L","Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative, Negative,","AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","OLAPARIB, MEDI4736, BEVACIZUMAB","UNK, UNK, UNK","II","Advanced, First Line, Second Line","Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of the number and grade of adverse events, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of physical examination, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of vital signs, The safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) by assessment of blood samples, ORR (CR + PR) based on RECIST 1.1, and as determined by investigator, Disease control rate (DCR) [Complete response + Partial response + Stable disease (CR+PR+SD)] based on RECIST 1.1, DCR (CR+PR+SD) based on RECIST 1.1","NCT02734004","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02734004",1,"DB09074,NA,DB00112","23725625, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618, ENSG00000149311, ENSG00000138376, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000115392, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ATM MUTATION NEGATIVE AND BARD1 MUTATION NEGATIVE AND BRIP1 MUTATION NEGATIVE AND CDK12 MUTATION NEGATIVE AND CHEK1 MUTATION NEGATIVE AND CHEK2 MUTATION NEGATIVE AND FANCL MUTATION NEGATIVE AND PALB2 MUTATION NEGATIVE AND PPP2R2A MUTATION NEGATIVE AND RAD51B MUTATION NEGATIVE AND RAD51C MUTATION NEGATIVE AND RAD51D MUTATION NEGATIVE AND RAD54L MUTATION NEGATIVE","pass"
"103",103,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Postitive","AND","Protein Expression, Protein Expression","AZACITIDINE, DURVALUMAB","UNK, UNK","II","Advanced, Second Line","Overall response rate (ORR)","NCT02811497","other cancers included","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02811497",1,"DB00928,DB11714","9444, NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE","pass"
"104",104,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","MCS110, PDR001","UNK, UNK","I, II","Advanced, Second Line","(phase 1) Number of patients with adverse events, as a measure of safety, (phase 2) : Overall Response rate (ORR)","NCT02807844","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02807844",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"105",105,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","BTP-114","UNK","I","Advanced, Second Line","Part 1 - Maximum tolerated dose (MTD) of BTP-114 determined during the dose escalation phase of study based on number of patients experiencing a dose-limiting toxicity, Part 1 - Recommended Phase 2 Dose (RP2D) of BTP-114 based on the MTD, review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study, Part 1 - Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.3 during the study, Part 2 - Proportion of patients with an objective response (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 or the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, Part 2 - Proportion of patients whose disease is controlled (DCR) using RECIST, Version 1.1 or PCWG2 criteria, Part 2 - Duration of response (DOR) measured from the date of first CR or PR until the first date of progressive disease or death from any cause, Part 2 - Progression-free survival (PFS) measured as the time from the date of initiation of BTP-114 treatment to the documented disease progression (PD) or death from any cause","NCT02950064","other cancers included. Other biomarkers included, however, is not clear on requirements","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02950064",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","failed drug"
"106",106,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PDR001, ACZ885, CJM112, TMT212, EGF816","UNK, UNK, UNK, UNK, UNK","I","Advanced, Second Line","Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety, Changes between baseline and post-baseline laboratory parameters and vital signs, Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only), Frequency of dose interruptions, Dose intensities, Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety, Frequency of dose reductions","NCT02900664","other cancers included, different drug combinations and monotherapies are tested with TNBC","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02900664",1,"NA,NA,NA,NA,NA","NA, NA, NA, 11707110, 72703790","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"107",107,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PDR001, LCL161, EVEROLIMUS, PANOBINOSTAT, QBM076","PD1, UNK, UNK, UNK, UNK","I","Advanced, Second Line","Phase 1: Incidence of dose limiting toxicities (DLTs), Frequency of dose interruptions and reductions, Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs), Changes between baseline and post-baseline laboratory parameters and vital signs, Dose intensities","NCT02890069","Other cancers included in trial, drugs tested in different combinations for TNBC, must be chemotherapy-naïve","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02890069",1,"NA,NA,DB01590,DB06603,NA","NA, 24737642, 6442177, 6918837, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"108",108,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, PACLITAXEL, PANITUMUMAB","UNK,  UNK, EGFR","II","Second Line","Pathologic compete response (pCR) (residual cancer burden [RCB]-0) or RCB-I response rates of patients with localized triple-negative breast cancer (TNBC) treated with panitumumab, carboplatin and paclitaxel (PaCT)","NCT02593175","Patients must have received at least one dose of an anthracycline based neoadjuvant regimen; patients are eligible if therapy was discontinued due to disease progression or therapy intolerance","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02593175",1,"DB00958,DB01229,DB01269","56840877, 36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"109",109,"DUCTAL BREAST CARCINOMA","ESR1","Positive","NA","Protein Expression","FULVESTRANT","UNK","II","First Line, Second Line","Safety and Tolerability of Two Delivery methods, Compare the pathological effects between the 2 routes of administration","NCT02540330","Patients must be Scheduled to undergo non-nipple sparing mastectomy for Invasive Breast Cancer or DCIS within 1 month, not have inflammatory breast carcinoma, have Pathological diagnosis of Invasive Ductal Breast Cancer or Ductal Carcinoma in Situ requiring mastectomy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02540330",1,"DB00947","104741","ENSG00000091831","EFO_0000186","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"110",110,"INVASIVE ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BEVACIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE","VEGF, UNK","II","Advanced, Second Line","Proportion of patients with pathologic complete response (residual cancer burden-0) or minimal residual disease (residual cancer burden-I) as the response rate","NCT02456857","Undergone molecular testing for integral biomarkers including immunohistochemical staining; the tumor must have evidence of mesenchymal differentiation defined as metaplastic breast cancer, or vimentin >= 50% by IHC. Received at least one dose of an anthracycline-based NACT; patients are eligible if therapy was discontinued due to disease progression or therapy intolerance","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02456857",1,"DB00112,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"111",111,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIRAPARIB, PEMBROLIZUMAB","UNK, UNK","I, II","Advanced, First Line, Second Line","Phase 1: Number of Subjects Reporting Dose-Limiting Toxicities (DLTs), Phase 2: Objective Response Rate (ORR)","NCT02657889","Other cancers included in trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02657889",1,"DB11793,DB09037","24958200, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"112",112,"INVASIVE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, PACLITAXEL, PANITUMUMAB","UNK, UNK, EGF","II","First Line, Second Line","Complete pathologic response","NCT02876107","Tested drugs with different combinations. Patients cannot have Stage IV disease, if the metastatic sites are not amendable for local therapy (i.e. radiation and/or surgery), and are not candidates for breast surgery will not be eligible","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02876107",1,"DB00958,DB01229,DB01269","56840877, 36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"113",113,"INVASIVE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, NAB-PACLITAXEL","UNK, UNK","II","First Line, Second Line","Pathologic complete response (pCR)/residual cancer burden (RCB)-0 + RCB-I responses in patients with triple-negative breast cancer","NCT02530489","Cannot have metastatic disease. No prior treatment for primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy or surgery other than the anthracycline and cyclophosphamide chemotherapy with or without 5-fluorouracil; treatment for ductal carcinoma in situ is allowed, such as surgery, hormonal therapy and radiotherapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02530489",1,"DB11595,NA","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"114",114,"ADVANCED BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","ARX788","UNK","I","Advanced, Second Line","Maximum tolerated dose of ARX788","NCT02512237","Other cancers included in trial, seperated into cohorts based on HER2 expression, Tumor tissue local laboratory HER2 testing results (clinical pathology report) based on FDA or other regulatory agency approved, validated or commercially available IHC or ISH HER2 assay. Pre-screening for HER2 is allowed only for subjects with breast and gastric cancer, where applicable. Subjects with other types of cancer must have previously tested for HER2 status by HER2 IHC or ISH assay. 1) Phase 1a: ISH positive or IHC 2+ or 3+. 2) Phase 1b: Cohort 1: advanced breast cancer, ISH positive or IHC 3+; Cohort 2: advanced breast cancer, ISH negative with IHC 2+; and Cohort 3: advanced gastric cancer, ISH positive or IHC 3+.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02512237",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"115",115,"INVASIVE BREAST CANCER (IIA-IIIC)","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","LETROZOLE, CTX, ANTHRACYCLINES, DOCETAXEL","Aromatase, UNK, UNK, UNK","III","First Line","effective rate","NCT02769104","Active Comparator is  CTX, Anthracyclines, Docetaxel (denoted as AC*4-T*4). Cannot have metastatic disease, patients must be postmenopausal","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02769104",1,"DB01006,NA,NA,DB01248","3902, 6442245, NA, 148124","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"116",116,"METASTATIC BREAST CANCER","WNT5A","Positive","NA","Protein Expression","FOXY-5","UNK","I","Advanced, Second Line","Presence of Dose Limiting Toxicities (DLTs)","NCT02655952","Positive would be loss or reduced expression of WNT5A","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02655952",1,"DB13034","44628955","ENSG00000114251","EFO_1000984","WNT5A PROTEIN EXPRESSION POSITIVE","pass"
"117",117,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Mutation, Mutation","OLAPARIB, ATEZOLIZUMAB","PARP, UNK","II","Advanced, First Line, Second Line","Progression-free survival (PFS)","NCT02849496","Testing olaparib in cominbation and as a monotherapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02849496",1,"DB09074,DB11595","23725625, NA","ENSG00000141736, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"118",118,"TRIPLE NEGATIVE BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN HYDROCHLORIDE, PEMBROLIZUMAB","UNK, UNK","II","Advanced, First Line, Second Line","Incidence of toxicities, assessed by Common Terminology Criteria for Adverse Events, version 4.0 criteria, Overall response rate in PD-L1 not enriched stage IV breast cancer when combining a previously untested combination of pembrolizumab and aromatase inhibitor (exemestane preferred), Overall response rate in PD-L1 not enriched stage IV breast cancer when combining a previously untested combination of pembrolizumab and doxorubicin hydrochloride (Cohort 1)","NCT02648477","Cohort 1: Has triple negative breast cancer, is considered for cohort 1 participation, and received prior anthracycline therapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02648477",1,"NA,DB09037","443939, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"119",119,"BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","ANASTROZOLE, LETROZOLE, PEMBROLIZUMAB","UNK, UNK, UNK","II","Advanced, First Line, Second Line","Incidence of toxicities, assessed by Common Terminology Criteria for Adverse Events, version 4.0 criteria, Overall response rate in PD-L1 not enriched stage IV breast cancer when combining a previously untested combination of pembrolizumab and aromatase inhibitor (exemestane preferred)","NCT02648477","Cohort 2: Has received prior aromatase inhibitor therapy and is deemed to be resistant to all three (anastrozole, letrozole, exemestane) approved AIs; resistance is defined as progression within 12 months or while on an AI","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02648477",1,"DB01217,DB01006,DB09037","2187, 3902, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"120",120,"INVASIVE TRIPLE NEGATIVE BREAST CANCER (IV)","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","GALUNISERTIB, PACLITAXEL","TGFβR1, UNK","I","Advanced, First Line, Second Line","Incidence of adverse events, Maximum Tolerated Dose (MTD) of paclitaxel + LY2157299","NCT02672475","Patient cannot have androgen receptor (AR) positive breast cancer (AR staining > 10% by immunohistochemistry is considered positive). If the AR status is unknown, the patient can go on study","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02672475",1,"DB11911,DB01229","10090485, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION NEGATIVE","pass"
"121",121,"BREAST CANCER (0-IIB)","ESR1","Positive","NA","Protein Expression","EXEMESTANE","UNK","II","First Line","Percentage change of serum estradiol concentration","NCT02598557","Changing dosing before surgery, in post-menopausal women, women with larger tumors who refuse chemotherapy (chemo) and/or endocrine neoadjuvant therapy can be eligible","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02598557",1,"DB00990","60198","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"122",122,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PAMIPARIB","UNK","I","Advanced, Second Line","Phase I:Number of participants with treatment-related adverse events assessed by NCI-CTCAE v4.03","NCT03333915","Other cancers included, TNBC is only in first phase of trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03333915",1,"DB14769","135565554","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"123",123,"INVASIVE BREAST CANCER (IA-IIIC)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT, PALBOCICLIB, AROMATASE INHIBITORS","UNK, CDK, Aromatase","II","First Line, Second Line","Treatment failure-free survival (TFFS)","NCT02760030","Aromatase inhibitors not listed. Patients must be vulnerable or frail by Balducci Criteria or the patient is refusing breast surgery; vulnerable patients are defined as those with dependence in some instrumental activities of daily living, well controlled co-morbidities, and early symptoms of geriatric syndrome; frail patients are defined as those with three or more co-morbidities, dependence in one or more activities of daily living, or a clinically significant geriatric syndrome; geriatric syndromes include: dementia, delirium, incontinence (fecal and/or urinary), osteoporosis or spontaneous fractures, polypharmacy, visual/hearing impairment, sarcopenia and neglect or abuse","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02760030",1,"DB00947,DB09073,NA","104741, 11478676, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"124",124,"ADVANCED BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","GB221, CAPECITABINE","UNK, UNK","III","Advanced, Second Line","Progression-free survival, PFS","NCT04164615","Placebo Comparator: Placebo control + capecitabine tablets. The relapsed or metastatic patients who failed respond to the previous taxanes and/or anthracyclines, previous first-line chemotherapy for the metastatic lesion is acceptable. Cannot have received the standard anti-HER2 treatment. excluded if subjects who previously received no taxanes; or subjects who respond to taxanes (no disease progression or intolerable toxic reactions)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04164615",1,"NA,DB01101","NA, 60953","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"125",125,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, EXEMESTANE, LEUPROLIDE ACETATE","UNK, UNK, GNRH","II","Advanced, Second Line","Progression free survival (PFS) in patients with metastatic breast cancer who received palbociclib plus exemestane with goserelin versus capecitabine","NCT02592746","patient must be premenopausal,  Patient who have stage IV breast cancer at diagnosis, allow disease that progressed after 1st line chemotherapy. B. Patient who have stage IV breast cancer at diagnosis, allow disease that progressed after tamoxifen or goserelin. C. In case of recur/metastatic breast cancer, allow disease that progressed after 12 month of completion of neo/adjuvant chemotherapy .","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02592746",1,"DB09073,DB00990,NA","11478676, 60198, 657180","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"126",126,"METASTATIC TRIPLE NEGATIVE BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","IMPRIME PGG, PEMBROLIZUMAB","UNK, PD1","II","Advanced, Second Line","Overall Response Rate (ORR) to Imprime PGG + pembrolizumab using RECIST v1.1 criteria","NCT02981303","Have documented objective radiographic or clinical disease progression after PD-1/PD-L1 +/- anti-CTLA-4 inhibitor therapy (melanoma) or after at least 1 line of chemotherapy for metastatic disease (TNBC)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02981303",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"127",127,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","REBASTINIB, PACLITAXEL, ERIBULIN MESYLATE","TIE2, UNK, UNK","I","Advanced, Second Line","Recommended Phase 2 dose(RP2D","NCT02824575","Drugs tested in different combinations. Arm A: Rebastinib plus paclitaxel: Up to two prior non-taxane chemotherapy regimens for metastatic or incurable locally advanced disease permitted (no prior paclitaxel, docetaxel, or eribulin for metastatic disease)..Prior therapy with paclitaxel or docetaxel in the neo/adjuvant setting is allowable if there is at least a 6 month interval between the last adjuvant/neoadjuvant paclitaxel or docetaxel dose and recurrence, Arm B: Rebastinib plus Eribulin: Patients must have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease (no prior eribulin, but prior paclitaxel, nab-paclitaxel, or docetaxel allowed). Prior therapy should have included a taxane in either the adjuvant or metastatic setting, Arms A and B: Patients with hormone receptor positive disease must have had progressive disease and at least 2 lines of endocrine therapy, including one endocrine regimen used in combination with an approved CDK 4/6 (cyclin-dependent kinase ) inhibitor (eg, palbociclib). Relapse while receiving or within 6 months of completing adjuvant endocrine therapy may be considered failure of one prior endocrine regimen","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02824575",1,"DB13005,DB01229,NA","25066467, 36314, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"128",128,"METASTATIC BREAST CANCER (IIIB-IV)","absent","NA","NA","NA","VERTEPORFIN","UNK","II","Advanced, First Line, Second Line","Objective Response Rate","NCT02939274","Study uses Continuous Low-Irradiance Photodynamic Therapy (CLIPT), must have cutaneous metastases","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02939274",1,"DB00460","5362420","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"129",129,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, TAMOXIFEN","UNK, UNK","II","Advanced, First Line","Response Rates in Subjects with HR(+)/HER2(-) Advanced Breast Cancer who have not Received Prior Systemic Anti-Cancer Therapies for their Advanced/Metastatic Disease Treated with Palbociclib in Combination with Tamoxifen","NCT02668666","No prior systemic anti-cancer therapy for advanced HR+ disease. NOTE: Subjects receiving adjuvant treatment with aromatase inhibitors at time of recurrence are allowed to participate. There is no AI washout period required.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02668666",1,"DB09073,DB00675","11478676, 2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"130",130,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","RC48-ADC","UNK","I, II","Advanced, Second Line","Progression Free Survival (PFS)","NCT03052634","Active Comparator: Lapatinib plus capecitabine","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03052634",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"131",131,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, LETROZOLE, GOSERELIN, LEUPROLIDE","UNK, UNK, UNK, UNK","III","Advanced, First Line, Second Line","The number of participants with adverse events as a measure of safety and tolerability","NCT02941926","Patient who received any prior systemic hormonal therapy for advanced breast cancer; no more than one prior regimen of chemotherapy for the treatment of metastatic disease is permitted.  Goserelin and Leuprolide are given for men and premenopausal women.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02941926",1,"DB11730,DB01006,DB00014,DB00007","44631912, 3902, 5311128, 657181","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"132",132,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CISPLATIN, VELIPARIB","UNK, PARP1","II","Advanced, First Line, Second Line","Progression-free survival (PFS)","NCT02595905","Active comparator is cisplatin alone","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02595905",1,"DB00515,DB07232","135804801, 11960529","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"133",133,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","BRCA1, BRCA2","Positive, Positive","OR","Mutation, Mutation","CISPLATIN, VELIPARIB","UNK, PARP1","II","Advanced, First Line, Second Line","Progression-free survival (PFS)","NCT02595905","Active comparator is cisplatin alone","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02595905",1,"DB00515,DB07232","135804801, 11960529","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","pass"
"134",134,"BREAST CANCER (I-II)","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","EXEMESTANE, LETROZOLE, ANASTROZOLE, LEUPROLIDE ACETATE, PERTUZUMAB, TRASTUZUMAB","Aromatase, Aromatase, Aromatase, LHRH, ERBB2, ERBB2","II","First Line","Evidence of Pathological Response","NCT02689921","LHRH, Luteinizing Hormone-Releasing Hormone agonist","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02689921",1,"DB00990,DB01006,DB01217,NA,DB06366,DB00072","60198, 3902, 2187, 657180, NA, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"135",135,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","XMT-1522","UNK","I","Advanced, First Line, Second Line","Maximum tolerated dose or recommended Phase 2 dose","NCT02952729","other cancers included, Advanced breast cancer, HER2 IHC 1+, or HER2 IHC 2+ without HER2 gene amplification","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02952729",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"136",136,"BREAST CANCER","ESR1","Positive","NA","Protein Expression","GOSERELIN, AROMATASE INHIBITORS","UNK, Aromatase","III","Second Line","Disease-Free Survival (DFS)","NCT02914158","Active Comparator: Goserelin and tamoxifen, aromatase inhibitors not defined, must be in Premenopausal patients with age ≤35 years (at least menstruate once for prior 3 months, assess menstruation situation before chemotherapy if have), no distant metastasis allowed","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02914158",1,"DB00014,NA","5311128, NA","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"137",137,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, PEMBROLIZUMAB","UNK, UNK","I","Advanced, Second Line","Number of Participants with One or More Serious Adverse Event(s) (SAEs), Number of Participants with Non-Serious Adverse Event(s)","NCT02779751","Other cancers included in trial, tested different drug combinations, must have previously received prior treatment with at least 1 but no more than 2 chemotherapy regimens in the metastatic setting","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02779751",1,"DB12001,DB09037","46220502, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"138",138,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, PEMBROLIZUMAB, ANASTROZOLE","UNK, UNK, UNK","I","Advanced, First Line","Number of Participants with One or More Serious Adverse Event(s) (SAEs), Number of Participants with Non-Serious Adverse Event(s)","NCT02779751","Other cancers included in trial, tested different drug combinations, cannot have received endocrine therapy or chemotherapy as treatment in the locoregionally recurrent or metastatic breast cancer disease setting. Note: Participants may be enrolled if they received prior (neo)adjuvant chemotherapy or endocrine therapy for localized disease","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02779751",1,"DB12001,DB09037,DB01217","46220502, NA, 2187","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"139",139,"INVASIVE ADVANCED TRIPLE NEGATIVE BREAST CANCER (I-III)","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ENZALUTAMIDE","UNK","II","First Line, Second Line","The treatment discontinuation rate of enzalutamide in the adherent population","NCT02750358","cannot have evidence of metastatic/Stage 4 breast cance","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02750358",1,"DB08899","15951529","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"140",140,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, EVEROLIMUS, EXEMESTANE","UNK, UNK, UNK","I, II","Advanced, Second Line","Number of participants with Dose-Limiting Toxicities (DLT), Clinical Benefit Rate","NCT02871791","Participants must have radiological or objective evidence of progression to a CDK4/6 inhibitor regimen in the metastatic setting AND relapse/progression on an NSAI (defined as either relapsed ≤ 12 months after completing adjuvant NSAI or progressed through an NSAI for metastatic or locally advanced breast cancer)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02871791",1,"DB09073,DB01590,DB00990","11478676, 6442177, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"141",141,"TRIPLE NEGATIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","II","Advanced, Second Line","Overall Response Rate in Unirradiated Lesions","NCT02730130","study Pembrolizumab in combination with radiotherapy, some tissue will not receive radiation therapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02730130",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"142",142,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ANASTROZOLE, PALBOCICLIB","UNK, UNK","II","Advanced, First Line, Second Line","Response rate","NCT02942355","separate cohorts. For Cohort A: previous treatment with endocrine therapy in the adjuvant or neoadjuvant setting is allowed, For Cohort B: only first-line chemotherapy (can be single-agent or a combination regimen) for metastatic disease with response (defined as a complete response or partial response by RECIST version 1.1, or stable disease for six months or more from this regimen) and chemotherapy discontinued for 21 days is allowed; patients may have received prior systemic therapy in the adjuvant or neoadjuvant setting.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02942355",1,"DB01217,DB09073","2187, 11478676","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"143",143,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression & Amplification","TRASTUZUMAB EMTANSINE","UNK","IV","Advanced, Second Line","Severity of Adverse Events, Percentage of Participants With Adverse Events","NCT02658734","Who Have Received Prior Treatment With Trastuzumab and a Taxane","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02658734",1,"DB05773","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"144",144,"BREAST CANCER (I-III)","ERBB2","Negative","NA","Protein Expression","ME-344, BEVACIZUMAB","Mitochondria, VEGFA","I","First Line","Reduction of FDG uptake, SDH (succinate dehydrogenase) levels staining","NCT02806817","must be breast cancer patients that are not candidates for neoadjuvant therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02806817",1,"DB13062,DB00112","68026984, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"145",145,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, TRASTUZUMAB, FULVESTRANT","UNK, UNK, UNK","II","Advanced, Second Line","Progression Free Survival (PFS)","NCT02675231","drugs given in combination, Active Comparator: Trastuzumab + Standard of Care Chemotherapy (physician's choice), at least 2 HER2-directed therapies for advanced disease, participant must have received trastuzumab emtansine (T-DM1) in any disease setting","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02675231",1,"DB12001,DB00072,DB00947","46220502, 3001322, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"146",146,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Postitive, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","CR1447","UNK","II","Advanced, First Line, Second Line","Disease control at 24 weeks (DC24)","NCT02067741","Patients had 1 line of prior endocrine treatment for advanced disease with a treatment duration of ≥6 months and no evidence of progression at 6 months. No previous chemotherapy for advanced disease is allowed.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02067741",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"147",147,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","CR1447","UNK","II","Advanced, First Line, Second Line","Disease control at 24 weeks (DC24)","NCT02067741","TN-ARpos BC patients had ≤2 lines of prior chemotherapy treatment for advanced disease","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02067741",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","failed drug"
"148",148,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, FULVESTRANT","UNK, UNK, UNK","II, III","Advanced, First Line, Second Line","Proportion of patients who complete planned oncologic therapy without the development of a hematological event","NCT02692755","Given Letrozole or Fulvestrant, studying Hematological safety","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02692755",1,"DB09073,DB01006,DB00947","11478676, 3902, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"149",149,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, NAB-PACLITAXEL, PACLITAXEL, GEMCITABINE, CARBOPLATIN","UNK, UNK, UNK, UNK, UNK","III","Advanced, First Line","Part 1: Percentage of Participants Who Experience an Adverse Event (AE) - All Participants, Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE - All Participants, Part 2: Progression-Free Survival (PFS) - All Participants, Part 2: PFS - Participants with Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Tumors, Part 2: PFS - Participants with PD-L1 CPS ≥10 Tumors, Part 2: Overall Survival (OS) - All Participants, Part 2: OS - Participants with PD-L1 CPS ≥1 Tumors, Part 2: OS - Participants with PD-L1 CPS ≥10 Tumors","NCT02819518","Drugs are tested in different combinations. Active comparator for part 2: Nab-paclitaxel, Paclitaxel, Gemcitabine, Carboplatin. Has been treated with (neo)adjuvant anthracycline, if they received systemic treatment in the (neo)adjuvant setting, unless anthracycline was contraindicated or not considered the best treatment option for the participant in the opinion of the treating physician.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02819518",1,"DB09037,NA,DB01229,DB00441,DB00958","NA, 36314, 36314, 60750, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"150",150,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","COPANLISIB, TRASTUZUMAB","UNK, UNK","I","Advanced, Second Line","Maximum Tolerated Dose of copanlisib in combination with trastuzumab measured by the incidence of dose limiting toxicity (DLT) of copanlisib in combination with trastuzumab within the 1st cycle at each dose level, Clinical Benefit Rate, defined as complete response (CR) or partial response (PR) at any time-point on the study; or stable disease (SD) lasting at least 24 weeks based on radiological assessment","NCT02705859","must not be considered curable, Patient has received at least one trastuzumab based or TDM1-based treatment regimen in the setting of metastatic disease or incurable locoregional recurrence. A trastuzumab based or TDM1-based treatment regimen is considered as any treatment regimen that includes trastuzumab or TDM1.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02705859",1,"DB12483,DB00072","135565785, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"151",151,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","MSB0010718C","PDL1","III","First Line, Second Line","Disease free survival, Disease free survival in PD-L1-positive patients","NCT02926196","Adequately excised: patients must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy. The margins of the resected specimen should be free of invasive tumor and ductal carcinoma in situ (no ink on tumor). In the case of breast-conserving surgery patients with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection. For patients who undergo mastectomy, patients with a microscopic positive deep margin are eligible, provided they will receive radiotherapy on chest wall. Seperate cohorts depending upon if treatment is in the adjuvant or neoadjuvant setting","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02926196",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"152",152,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ENDOTAG-1, PACLITAXEL, GEMCITABINE HYDROCHLORIDE","UNK, UNK, UNK","III","Advanced, First Line","PFS","NCT03002103","Active comparator is Paclitaxel, Gemcitabine Hydrochloride, Patients must have had prior adjuvant treatment with either sequential or concurrent anthracycline- and/or taxane-based chemotherapy. Patients may have received neoadjuvant treatment prior to the adjuvant anthracycline- and/or taxane-based chemotherapy as well.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03002103",1,"NA,DB01229,NA","36314, 36314, 60749","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"153",153,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","BICALUTAMIDE","UNK","III","Advanced, First Line","Clinical benefit rate for 16 weeks","NCT03055312","Active comparator is chemo of physicans choice, docetaxel, paclitaxel, or gemcitabine","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03055312",1,"DB01128","56069","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"154",154,"ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","DURVALUMAB, BEVACIZUMAB","PDL1, VEGFA","I","Advanced, Second Line","Changes Immunodynamics factors: kynurenine, prostaglandin, tryptophan levels","NCT02802098","Patients previously treated with any regimen containing chemotherapy plus bevacizumab as first line of treatment, switched to maintenance treatment with bevacizumab alone and disease progression during this treatment. At least 6 weeks (two doses) must have passed since the last chemotherapy administration, while in treatment with bevacizumab alone, in order to consider bevacizumab monotherapy as maintenance therapy. Any disease progression according to RECIST 1.1 criteria after this timeframe will be considered progression during bevacizumab maintenance.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02802098",1,"DB11714,DB00112","NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"155",155,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","ERIBULIN MESYLATE, PEGYLATED RECOMBINANT HUMAN HYALURONIDASE","UNK, UNK","I, II","Advanced, First Line, Second Line","Recommended Phase 2 dose (RP2D) of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase (PEGPH20) - Phase 1b, Objective response rate (ORR) - Phase 2","NCT02753595","Drugs tested in different combinations.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02753595",1,"NA,NA","17755248, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"156",156,"EARLY AND LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SELUMETINIB, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL","MEK1/MEK2, UNK, UNK, UNK","II","Non-Advanced/Advanced, First Line","Pathological complete response rate","NCT02685657","Active comparator: Doxorubicin, Cyclophosphamide, Docetaxel","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02685657",1,"DB11689,DB00997,DB00531,DB01248","10127622, 443939, 2907, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"157",157,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification","ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","UNK, UNK","II","Advanced, Second Line","Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1), Percentage of Participants With Adverse Events","NCT02924883","Active Comparator: Trastuzumab Emtansine + Placebo, Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02924883",1,"DB11595,DB05773","NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"158",158,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DINACICLIB, PEMBROLIZUMAB","UNK, UNK","I","Advanced, First Line, Second Line","Maximum tolerated dose (MTD), Define dose-limiting toxicities (DLTs)","NCT01676753","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT01676753",1,"DB12021,DB09037","46926350, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"159",159,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","TAMOXIFEN, RIBOCICLIB, GOSERELIN","UNK, CDK, UNK","I","Advanced, First Line, Second Line","Recommended Phase II Dose (RP2D)","NCT02586675","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02586675",1,"DB00675,DB11730,DB00014","2733526, 44631912, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE","pass"
"160",160,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","NTRK1, NTRK2, NTRK3","Positive, Positive, Positive","AND/OR, AND/OR","gene fusion, gene fusion, gene fusion","LAROTRECTINIB, VITRAKVI","UNK, UNK, UNK","II","Advanced, Second Line","Best overall response rate by IRC","NCT02576431","Trial includes other cancer types, Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02576431",1,"DB14723,NA","67330085, 46188928","ENSG00000198400, ENSG00000148053, ENSG00000140538","MONDO_0007254","NTRK1 GENE FUSION POSITIVE AND/OR NTRK2 GENE FUSION POSITIVE AND/OR NTRK3 GENE FUSION POSITIVE","pass"
"161",161,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BAY1217389, PACLITAXEL","MPS1, UNK","I","Advanced, Second Line","Maximum tolerated dose (MTD), Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability, Plasma concentration of BAY 1217389 characterized by Cmax","NCT02366949","Trial includes other cancer types","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02366949",1,"NA,DB01229","78320750, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"162",162,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","AZD1775","UNK","I","Advanced, Second Line","Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability.","NCT02482311","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/show/NCT02482311",1,"NA","24856436","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"163",163,"TRIPLE NEGATIVE INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, IPI-549","UNK, UNK","I","Second Line","Duration of Response (DoR) ","NCT02637531","Has a TNBC cohort in a trial that includes multiple cancer","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02637531",1,"DB09035,NA","NA, 91933883","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"164",164,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","MEDI4276","UNK","I","Second Line","Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs)","NCT02576548","Has a specific cohort for BC. Prior treatment with trastuzumab, pertuzumab, and T-DM1, either alone or in combination, is required.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02576548",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"165",165,"BREAST CANCER (STAGE III-IV)","ERBB2, ESR1, PGR","Positive/Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, IBRUTINIB","PDL1, BTK","I, II","Advanced, Second Line","Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose., Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1.","NCT02403271","Trial had multiple cancers, but had specific conditions for BC. Must have failed two separate treatments","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02403271",1,"DB11714,DB09053","NA, 24821094","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"166",166,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","SEVITERONEL","CYP17","I, II","First&Second line","Estimate efficacy of seviteronel as measured by clinical benefit rate at 16 weeks (CBR16) for female subjects with TNBC, Estimate efficacy of seviteronel as measured by clinical benefit rate at 24 weeks (CBR24) for female subjects with ER+ BC, Estimate efficacy of seviteronel as measured by CBR16 for all male BC subjects.","NCT02580448","only requires having no therapeutic treatments for breast cancer","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02580448",1,"DB12275","78357816","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"167",167,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SEVITERONEL","CYP18","I, II","First&Second line","Estimate efficacy of seviteronel as measured by clinical benefit rate at 16 weeks (CBR16) for female subjects with TNBC, Estimate efficacy of seviteronel as measured by clinical benefit rate at 24 weeks (CBR24) for female subjects with ER+ BC, Estimate efficacy of seviteronel as measured by CBR16 for all male BC subjects.","NCT02580449","only requires having no therapeutic treatments for breast cancer","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02580448",1,"DB12275","78357816","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"168",168,"METASTATIC BREAST CANCER","absent","NA","NA","NA","SEVITERONEL","CYP19","I, II","Advanced, First Line, Second Line","Estimate efficacy of seviteronel as measured by clinical benefit rate at 16 weeks (CBR16) for female subjects with TNBC, Estimate efficacy of seviteronel as measured by clinical benefit rate at 24 weeks (CBR24) for female subjects with ER+ BC, Estimate efficacy of seviteronel as measured by CBR16 for all male BC subjects.","NCT02580450","only requires having no therapeutic treatments for breast cancer. this was a male only cohort","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02580448",1,"DB12275","78357816","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"169",169,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/Protein Expression & Amplification/Mutation","PYROTINIB","UNK","I","Advanced, Second Line","Part 1 Maximum Tolerated Dose (MTD), Part 2 Overall Response Rate (ORR)","NCT02500199","Part 1: Patients with HER2 positive (defined as documented overexpression or amplification or mutation) metastatic breast cancer who have experienced disease progression following at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required, Part 2: Patients with HER2 positive metastatic breast cancer who have experienced disease progression after at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required;","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02500199",1,"DB14993","51039030","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION/MUTATION POSITIVE","pass"
"170",170,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","RO6874281, TRASTUZUMAB","UNK, UNK","I","Advanced, Second Line","Percentage of Participants With Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) of RO6874281, Optimal Biological Dose (OBD) of RO6874281, Recommended Dose for Further Development of RO6874281, Systemic Clearance (CL) of RO6874281, Volume of Distribution at Steady State (Vss) of RO6874281, Area Under the Concentration-Time Curve (AUC) of RO6874281, Maximum Observed Serum Concentration (Cmax) of RO6874281","NCT02627274","must have progressed on at least two lines of HER2-directed therapies in the metastatic setting and the last therapy prior to going on study has to contain a HER2-directed antibody, other cancers included","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02627274",1,"NA,DB00072","NA, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"171",171,"ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PDR001","PD1","II","Advanced, First Line, Second Line","Part ll: Overall response Rate (ORR)","NCT02404441","other cancers included in trial, breast cancer only in phase II","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02404441",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"172",172,"ADVANCED BREAST CANCER","ESR1","Positive","NA","Protein Expression","GS-5829, EXEMESTANE, FULVESTRANT","UNK, UNK, UNK","I","Advanced, First Line, Second Line","Incidence of dose limiting toxicities","NCT02392611","other cancers are included, must be post-menopausal","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02392611",1,"NA,DB00990,DB00947","86281210, 60198, 104741","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"173",173,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT, LKB1, EGFR, FGFR, ERBB2, MET, RET, KIT, NF1","Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","AZD2014, AZD6244","mTORC1/mTORC2, MEK1/MEK2","I","Advanced, Second Line","Establish feasible dose levels and regimens of AZD2014 and selumetinib when given in combination by close observation of any dose limiting toxicities","NCT02583542","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02583542",1,"NA,NA","25262792, 10127622","ENSG00000133703, ENSG00000213281, ENSG00000157764, ENSG00000121879, ENSG00000171862, ENSG00000166971, ENSG00000118046, ENSG00000146648, ENSG00000068078, ENSG00000141736, ENSG00000105976, ENSG00000165731, ENSG00000157404, ENSG00000196712","MONDO_0007254","KRAS MUTATION POSITIVE AND/OR NRAS MUTATION POSITIVE AND/OR BRAF MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE AND/OR PTEN MUTATION POSITIVE AND/OR AKT MUTATION POSITIVE AND/OR LKB1 MUTATION POSITIVE AND/OR EGFR MUTATION POSITIVE AND/OR FGFR MUTATION POSITIVE AND/OR ERBB2 MUTATION POSITIVE AND/OR MET MUTATION POSITIVE AND/OR RET MUTATION POSITIVE AND/OR KIT MUTATION POSITIVE AND/OR NF1 MUTATION POSITIVE","pass"
"174",174,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","AZD2014, AZD6244","mTORC1/mTORC2, MEK1/MEK2","II","Advanced, Second Line","Establish feasible dose levels and regimens of AZD2014 and selumetinib when given in combination by close observation of any dose limiting toxicities","NCT02583542","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02583542",1,"NA,NA","25262792, 10127622","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"175",175,"LOCALLY ADVANCED URESECTABLE OR METASTATIC BREAST CANCER (III-IV)","ERBB2","Negative","NA","Protein Expression","ENTINOSTAT, IPILIMUMAB, NIVOLUMAB","HDAC, CTLA4","I","Advanced, Second Line","Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab","NCT02453620","must have had at least 1 prior chemotherapy regimen in the metastatic setting, and two lines of hormonal therapy (administered in the adjuvant or metastatic setting) for patients with hormone receptor-positive disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02453620",1,"DB11841,DB06186,DB09035","4261, NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"176",176,"LOCALLY ADVANCED URESECTABLE OR METASTATIC BREAST CANCER (III-IV)","Absent","NA","NA","NA","ENTINOSTAT, IPILIMUMAB, NIVOLUMAB","HDAC, CTLA4","I","Advanced, Second Line","Incidence of adverse events of entinostat and nivolumab in combination with ipilimumab","NCT02453620","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02453620",1,"DB11841,DB06186,DB09035","4261, NA, NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","pass"
"177",177,"METASTATIC BREAST CANCER (IV)","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","IMP321, PACLITAXEL","UNK, UNK","II","Advanced, First Line","Stage 1 to determine the recommended phase two dose for the randomised phase, Assessment of Progression-Free Survival (PFS)","NCT02614833","Active Comparator: Comparator: Paclitaxel + Placebo","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02614833",1,"NA,DB01229","NA, 36314","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"178",178,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PCAD","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PCA062","UNK","I","Advanced, Second Line","Incidence rate of dose limiting toxicities","NCT02375958","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02375958",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000062038","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PCAD PROTEIN EXPRESSION POSITIVE","failed drug"
"179",179,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TREMELIMUMAB, MEDI4736","UNK, UNK","II","Advanced, Second Line","Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase","NCT02527434","drug combinations tested, both tested as monotherapies, other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02527434",1,"DB11771,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"180",180,"INVASIVE TRIPLE NEGATIVE BREAST CANCER (IB-IIIC)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, CARBOPLATIN","UNK, UNK, UNK, UNK, UNK","III","Second Line","IDFS","NCT02488967","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02488967",1,"DB00531,NA,DB01229,DB00958","2907, 443939, 36314, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"181",181,"INVASIVE TRIPLE NEGATIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, CISPLATIN, CAPECITABINE","UNK, UNK, UNK","III","Second Line","Invasive disease-free survival (IDFS) of patients with basal-like triple-negative breast cancer (TNBC)","NCT02445391","Active comparator is just observation, must have completed definitive resection of the primary tumor, Patients must have completed neoadjuvant taxane +/- anthracycline; patients must NOT have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen. Requirement for the randomization step: residual disease in the breast or axilla resected at the time of definitive surgery completed. Drugs tested in different combinations","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02445391",1,"DB00958,DB00515,DB01101","56840877, 135804801, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"182",182,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, LETROZOLE","UNK, UNK","UNK","Advanced, Second Line","Progression free survival(PFS) of the subjects","NCT02583828","trial studied in elderly patients, drugs given in different combinations based on patient critera","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02583828",1,"DB00531,DB01006","2907, 3902","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"183",183,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","FULVESTRANT, VANDETANIB","ESR1, VEGFR","II","Advanced, Second Line","Progression-Free Survival (PFS)","NCT02530411","Placebo Comparator: Fulvestrant, must be post-menopausal, must have Progressive disease whilst receiving third generation aromatase inhibitor for locally advanced or metastatic BC or relapsed with metastatic disease whilst receiving third generation AI in adjuvant setting","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02530411",1,"DB00947,DB05294","104741, 3081361","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"184",184,"METASTATIC BREAST CANCER","absent","NA","NA","NA","CYCLOPHOSPHAMIDE","UNK","I","Advanced, Second Line","Identification of the immunological effects, in peripheral blood and tumor biopsies, of the combined treatment with radiation and cyclophosphamide","NCT02441270","In combination with Stereotactic body radiotherapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02441270",1,"DB00531","2907","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"185",185,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PM01183, OLAPARIB","UNK, UNK","II","Advanced, Second Line","Dose limiting toxicity, Maximum tolerated dose, Efficacy in terms of Tumor Response Rate according to RECIST 1.1 criteria","NCT02684318","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02684318",1,"NA,DB09074","57327016, 23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"186",186,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, B7H3","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","MGD009","UNK","I","Advanced, Second Line","Number of participants with adverse events","NCT02628535","other cancers included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02628535",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000103855","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND B7H3 PROTEIN EXPRESSION POSITIVE","failed drug"
"187",187,"ADVANCED BREAST CANCER","FGF, FGFR","Positive, Positive","AND/OR","gene others, gene others","PEMIGATINIB, GEMCITABINE, CISPLATIN, PEMBROLIZUMAB, DOCETAXEL, TRASTUZUMAB, INCMGA00012","UNK, UNK, UNK, UNK, UNK, UNK, UNK","I, II","Advanced, Second Line","Determination of the maximum tolerated dose of Pemigatinib as a monotherapy and in combination as measured by the number of participants with adverse events, Assess the pharmacodynamics of pemigatinib as a monotherapy and in combination as indicated by serum phosphorus level","NCT02393248","other cancers are included, drugs tested in different combination in part 3 of the trial. Must be a ""genetic alteration"" in FGF, FGFR","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02393248",1,"DB15102,DB00441,DB00515,DB09037,DB01248,DB00072,NA","86705695, 60750, 135804801, NA, 148124, 3001322, NA","ENSG00000162344, ENSG00000068078","MONDO_0007254","FGF GENE OTHERS POSITIVE AND/OR FGFR GENE OTHERS POSITIVE","pass"
"188",188,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","AVELUMAB, UTOMILUMAB","PDL1, 41BB","II","Advanced, First Line, Second Line","Number of participants with Dose-Limiting Toxicities (DLT) , Objective Response - Number of Participants With Objective Response","NCT02554812","Other cancers included in trial","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02554812",1,"DB11945,DB15113","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"189",189,"BREAST CANCER (I-II)","ERBB2","Positive","NA","Protein Expression","CYCLOPHOSPHAMIDE, PACLITAXEL, TRASTUZUMAB","UNK, UNK, ERBB2","II","First Line","Incidence of neutropenia, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03, Incidence of paclitaxel-related neuropathy, graded according to the NCI CTCAE v4.03, Incidence of grade 3/4 cardiotoxicity, graded according to the NCI CTCAE v4.03, Incidence of grade 3/4 nausea/vomiting, graded according to the NCI CTCAE v4.03, Recurrence free survival (RFS), Incidence of inability to complete treatment, defined as a patient that requires a lower dose of therapy (defined as dose lowered by 50%), or a postponement of scheduled treatment of longer than 28 days, or discontinuation of treatment for any reason","NCT02654119","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02654119",1,"DB00531,DB01229,DB00072","2907, 36314, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"190",190,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ESR1","Positive","NA","Protein Expression","FULVESTRANT","UNK","IV","Advanced, Second Line","Safety","NCT02447328","must have Post menopausal status","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02447328",1,"DB00947","104741","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"191",191,"INVASIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, ENDOCRINE THERAPY","UNK, UNK","III","First Line, Second Line","Invasive Disease Free Survival (iDFS)","NCT02513394","Endocrine therapy not defined","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02513394",1,"DB09073,NA","11478676, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"192",192,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","MARGETUXIMAB, CAPECITABINE, ERIBULIN, GEMCITABINE, VINORELBINE","UNK, UNK, UNK, UNK, UNK","III","Advanced, Second Line","Progression-free survival (PFS) as determined by independent radiological review, Overall survival (OS) defined as the number of days from randomization to the date of death (from any cause), Infusion rate sub-study Grade 3 plus safety","NCT02492711","Active comparator is Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02492711",1,"DB14967,DB01101,DB08871,DB00441,DB00361","NA, 60953, 17755248, 60750, 5311497","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"193",193,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT, TAMOXIFEN","UNK, UNK, UNK","II","Advanced, Second Line","Tumor Progression as measured by RECIST 1.1","NCT02384239","Must have received prior treatment with an mTOR or PI3K inhibitor, patients receive either fulvestrant or tamoxifen","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02384239",1,"DB09073,DB00947,DB00675","11478676, 104741, 2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"194",194,"LOCALLY ADVANCED OR EARLY BREAST CANCER","ERBB2","Positive","NA","Protein Expression","ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK, UNK, UNK, UNK","I","First Line, Second Line","Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F, Percentage of Participants With DLT - Cohort 1E, Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)","NCT02605915","Drugs tested in different combinations","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02605915",1,"DB11595,DB06366,DB00072,DB05773,DB01248,DB00958","NA, NA, 3001322, NA, 148124, 56840877","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"195",195,"LOCALLY ADVANCED OR EARLY BREAST CANCER","ERBB2","Negative","NA","Protein Expression","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","I","Non-Advanced, Advanced, First Line, Second Line","Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F, Percentage of Participants With DLT - Cohort 1E, Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)","NCT02605915","ERBB2 negative disease is only in cohort E","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02605915",1,"DB11595,DB00997,DB00531","NA, 443939, 2907","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"196",196,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ICOTINIB","UNK","II","Advanced, Second Line","Progression Free Survival","NCT02362230","must received at least two prior treatments","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02362230",1,"DB11737","44609731","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"197",197,"LOCALLY ADVANCED BREAST CANCER (IIB-IIIC)","ESR1","Positive","NA","Protein Expression","METFORMIN, TOREMIFENE, MELATONIN","UNK, UNK, UNK","II","Advanced, First Line","Response rate, Pathomorphological response","NCT02506790","studied looking at also reducing side effects, active comparator is Toremifene, drugs tested in different combinations","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02506790",1,"DB00331,DB00539,DB01065","14219, 3005573, 896","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"198",198,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL","Negative, Negative, Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND, AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation, Mutation","TALAZOPARIB TOSYLATE","PARP","II","Advanced, Second Line","Objective response rate (ORR)","NCT02401347","other biomarkers in the of HR related genes","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02401347",1,"NA","135565654","ENSG00000141736, ENSG00000012048, ENSG00000139618, ENSG00000171862, ENSG00000083093, ENSG00000183765, ENSG00000149311, ENSG00000104320, ENSG00000138376, ENSG00000136492, ENSG00000113522, ENSG00000108384, ENSG00000185379, ENSG00000020922, ENSG00000175054, ENSG00000187741, ENSG00000158169, ENSG00000144554, ENSG00000112039, ENSG00000183161, ENSG00000221829, ENSG00000115392","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE AND PTEN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR RAD50 MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR MRE11 MUTATION POSITIVE AND/OR ATR MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FANCC MUTATION POSITIVE AND/OR FANCD2 MUTATION POSITIVE AND/OR FANCE MUTATION POSITIVE AND/OR FANCF MUTATION POSITIVE AND/OR FANCG MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE","pass"
"199",199,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PIK3CA","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Mutation","TASELISIB, FULVESTRANT","UNK, UNK","III","Advanced, Second Line","Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)","NCT02340221","Placebo Comparator: Placebo + Fulvestrant, must be post-menopausal","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02340221",1,"DB12108,DB00947","51001932, 104741","ENSG00000141736, ENSG00000091831, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"200",200,"INVASIVE BREAST CANCER (II-IIIA)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LETROZOLE, PALBOCICLIB","UNK, UNK","II","First Line","Evaluation of the number of patients with a Residual Cancer Burden (RCB) 0-I index as a measure of efficacy","NCT02400567","active comparator is Fluorouracile, Epirubicin, Cyclophosphamide, Either Luminal A AND proven nodal involvement (cytology or histology), or Luminal B through PAM50 ROR (Prosigna™) centralized evaluation, cannot have metastatic disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02400567",1,"DB01006,DB09073","3902, 11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"201",201,"TRIPLE NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, CARBOPLATIN","Gp60/Bcl2, DNA/Protein","III","First Line, Second Line","Pathologic complete response (PCR)","NCT04137653","Removed active comparator: Active Comparator: paclitaxel group","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04137653",1,"NA,DB00958","NA, 56840877","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"202",202,"TRIPLE NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein Expression","NIVOLUMAB, IPILIMUMAB","PD1, CTLA4","II","Second Line","Disease Free Survival (DFS)","NCT03818685","Excludes metastatic TN Breast Cancer, Removed active comparator: Active Comparator: Capecitabine","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03818685",1,"DB09035,DB06186","NA, NA","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"203",203,"TRIPLE NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein Expression & amplification","IMIPRAMINE","FoxM1","I","First Line","Decrease in the proliferation rate of triple negative breast cancer","NCT03122444","Pre-surgical treatment, must be surgical candidate, reference for FoxM1: https://clincancerres.aacrjournals.org/content/22/14/3524","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03122444",1,"DB00458","8228","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","pass"
"204",204,"BREAST CANCER (STAGE II-III)","ERBB2, PGR, ESR1","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE","Gp60/Bcl2, DNA, DNA","IV","First Line","RCB","NCT04182568","Did not include active comparator: Docetaxel","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04182568",1,"NA,NA,DB00531","NA, NA, 2907","ENSG00000141736, ENSG00000082175, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"205",205,"BREAST CANCER","ERBB2, PGR, ESR1","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","PALBOCICLIB, LETROZOLE","CDK4/CDK6, aromatase","III","Advanced","Progression-Free survival","NCT04047758","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04047758",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, ENSG00000082175, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"206",206,"TRIPLE NEGATIVE BREAST CANCER (II-III)","ESR1, PGR, ERBB2","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, CARBOPLATIN","Gp60/Bcl2, DNA/Protein","IV","First Line","Pathologic complete remission rate","NCT04136782","Removed active comparator:Drug: Epirubicin combined with docetaxel","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04136782",1,"NA,DB00958","NA, 56840877","ENSG00000091831, ENSG00000082175, ENSG00000141736","EFO_0005537","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"207",207,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression & Amplification","PYROTINIB, ETOPOSIDE","ERBB2, Topoisomerase II/DNA","II","Advanced, Second Line","Objective Response Rate (ORR)","NCT03923179","Must be locally advanced/metastatic(Advanced, Second Line)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03923179",1,"DB14993,DB00773","51039030, 36462","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"208",208,"RECURRENT BREAST CANCER","ERBB2","Negative","NA","Protein Expression","DOCETAXEL, RITONAVIR","Microtubles, UNK","II","Advanced, Second Line","The objective response rate (ORR)","NCT03890744","Drug combination (oral docetaxel and ritonavir is called ModraDoc006/r)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03890744",1,"DB01248,DB00503","148124, 392622","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"209",209,"BREAST CANCER (I-II)","ERBB2, PGR, ESR1","Positive, Negative, Negative","AND, AND","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, TRASTUZUMAB, PERTUZUMAB","PDL1, ERBB2, ERBB2","II","Advanced, First Line, Second Line","Pathologic complete response (pCR) rate in the breast cancer patients with ERBB2-enriched and ERBB2-amplified breast cancer","NCT03820141","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03820141",1,"DB11714,DB00072,DB06366","NA, 3001322, NA","ENSG00000141736, ENSG00000082175, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","pass"
"210",210,"BREAST CANCER (STAGE II-III)","ERBB2, PGR, ESR1","Positive, Negative, Negative","AND, AND","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, TRASTUZUMAB, CARBOPLATIN, PERTUZUMAB","Bcl2, ERBB2, DNA/Protein, ERBB2","II","First Line","Event free survival at three years","NCT03820063","Drug combination (PTC-Ptz)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03820063",1,"DB01229,DB00072,DB00958,DB06366","36314, 3001322, 56840877, NA","ENSG00000141736, ENSG00000082175, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","pass"
"211",211,"BREAST CANCER (I-II)","ESR1, PGR, ERBB2, Ki67","Positive, Positive, Negative, Positive","AND, AND, AND","Protein Expression, Protein expression, Protein Expression, Protein expression","ONAPRISTONE","progesterone receptor","I","First Line, Second Line","Complete Cell Cycle Arrest","NCT04142892","Women must be post-menopausal","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04142892",1,"DB12637","5311505","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000148773","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"212",212,"METASTATIC BREAST CANCER (III-IV)","ESR1, ERBB2","Positive, Negative","AND","Protein Expression, Protein Expression","PEMBROLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN","PD1, Topoisomerase II/DNA","I, II","Advanced, Second Line","To establish safe dose of PLD when delivered in combination with pembrolizumab, To evaluate the Tumor Response Rate according to Response Evaluation Criteria in Solid Tumors (RECIST) after 9 weeks (3 Cycles) of treatment in patients with measurable disease","NCT03591276","Endocrine-resistant breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03591276",1,"DB09037,NA","NA, NA","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"213",213,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression & Amplification","PYROTINIB, CAPECITABINE","ERBB2, DNA/RNA/Protein Synthesis","II","Advanced, Second Line","Objective Response Rate(ORR)","NCT03923166","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03923166",1,"DB14993,DB01101","51039030, 60953","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"214",214,"LOCALLY ADVANCED OR METASTATIC LUMINAL B BREAST CANCER","ESR1, ERBB2, Ki67","Positive, Negative, Positive","AND, AND","Protein Expression, Protein expression, Protein Expression","PEMBROLIZUMAB, PACLITAXEL","PDL, Bcl2","II","Advanced, First Line","Progression-free survival, Overall Survival","NCT03841747","in patients with locally advanced or metastatic ER-positive, ERBB2-negative, Luminal B breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03841747",1,"DB09037,DB01229","NA, 36314","ENSG00000091831, ENSG00000141736, ENSG00000148773","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"215",215,"BREAST CANCER (I-III)","ERBB2","Positive","NA","Protein Expression &Amplification/Protein Expression","PYROTINIB, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB, EPRIRUBICIN, CYCLOPHOSPHAMIDE","ERBB2, GP60/Bcl2, ERBB2, Topoisomerase II/DNA, DNA","II","First Line","Percentage of Participants With Total Pathologic Complete Response (tpCR)","NCT04066790","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04066790",1,"DB14993,NA,DB00072,NA,DB00531","51039030, NA, 3001322, NA, 2907","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION &AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"216",216,"BREAST CANCER (II-III)","ERBB2","Positive","NA","Protein Expression & Amplification/Protein Expression","PEGYLATED LIPOSOMAL DOXORUBICIN, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB","Topoisomerase II/DNA, GP60/Bcl2, ERBB2","I, II","First Line","Pathological complete response(pCR) rate","NCT03994107","the first phase aims to determine the maximum tolerated dose (MTD) of PLD, and the second phase will explore the efficacy and safety of the regimen.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03994107",1,"NA,NA,DB00072","NA, NA, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"217",217,"BREAST CANCER (I-III)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GDC-9545","ESR1","I","First Line","Change from Baseline in Tumor Cell Proliferation Measured by Ki67 Expression Between Pre- and Post-Treatment Tumor Biopsy Samples","NCT03916744","must be operable, postmenopausal, found GDC-9545 target at https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792379, hormone receptor status needs to be known","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03916744",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"218",218,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PYROTINIB","ERBB2","III","First Line, Second Line","Invasive Disease-free Survival (iDFS)","NCT03980054","Early stage high-risk breast cancer, first line for those who have lymph node mestastases, requires treatment with adjuvant trastuzumab","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03980054",1,"DB14993","51039030","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"219",219,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRACA1, BRACA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein expression, Protein Expression, Mutation, Mutation","ZEN003694, TALAZOPARIB","Bromodomain, PARP","II","Advanced, Second Line","Part 1 and Part 2: Incidence of of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE), Part 1: Incidence of dose-limiting toxicities (DLT), Part 2: Objective response rate (ORR) defined as a complete response (CR), partial response (PR) or stable disease (SD ≥ 4 cycles) by RECIST 1.1","NCT03901469","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03901469",1,"NA,DB11760","NA, 135565082","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRACA1 MUTATION NEGATIVE AND BRACA2 MUTATION NEGATIVE","failed drug"
"220",220,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","LETROZOLE, PYROTINIB, SHR6390","Aromatase, ERBB2, CDK4/CDK6","I, II","Advanced, First Line, Second Line","The number of patients in the Phase 1b part of the study with any adverse events (AE), The number of patients with progression-free survival (PFS)","NCT03772353","SHR6390 found on NCI Drug Dictionary, The study will enroll natural postmenopausal women, or women who have undergone bilateral oophorectomy.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03772353",1,"DB01006,DB14993,NA","3902, 51039030, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"221",221,"NON-METASTATIC INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","CAPECITABINE","DNA/RNA/Protein Synthesis","I","Second Line","Percentage of patients who complete concurrent capecitabine-radiotherapy","NCT03958721","capecitabine-radiotherapy regimen, must complete radiation therapy, First line cannot be capecitabine or 5-FU containing or Hormone receptor therapies","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03958721",1,"DB01101","60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"222",222,"BREAST NEOPLASMS","ERBB2","Positive","NA","Protein Expression","DOCETAXEL, CYCLOPHOSPHAMIDE, TRASTUZUMAB","microtubles/VEGF, DNA, ERBB2","III","First Line","Feasibility of performing a pragmatic clinical trial with an Integrated Consent Model.","NCT03705429","early stage, low risk ERBB2+ Breast Cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03705429",1,"DB01248,DB00531,DB00072","148124, 2907, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"223",223,"BREAST CANCER (IIA-III)","ERBB2","Positive","NA","Protein Expression","PYROTINIB","ERBB2","II","First Line","pCR","NCT04126525","invasive ERBB2 positive breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04126525",1,"DB14993","51039030","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"224",224,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","439859","ESR1","I","Advanced, Second Line","Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)","NCT03816839","found SAR439859 on NCI Drug Dictionary, women must be postmenopausal. Locally advanced and unable to perform radiation or surgery and/or metastatic","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03816839",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"225",225,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","CAPECITABINE","DNA/RNA/Protein Synthesis","II","Advanced, Second Line","2-year DFS (Disease Free Survival rate in two years)","NCT03638648","Neoadjuvant chemotherapy regimen should include anthracyclines and taxane, Clinical stage cT1-4cN0-3M0 (AJCC 8th)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03638648",1,"DB01101","60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"226",226,"LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","IPATASERTIB, PALBOCICLIB, FULVESTRANT","Akt, CDK4/CDK6, ER","I, III","Advanced, Second Line","Progression-Free Survival (PFS) in Intent-to-Treat (ITT), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Progression-Free Survival (PFS) in Patients with PIK3CA/AKT1/PTEN Altered Tumors, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)","NCT04060862","Locally Advanced Unresectable or Metastatic Breast Cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04060862",1,"DB11743,DB09073,DB00947","24788740, 11478676, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"227",227,"LOCALLY RECURRENT OR METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","ERIBULIN, BALIXAFORTIDE","UNK, UNK","III","Advanced, Second Line","Progression Free Survival as assessed by Independent Review Committee","NCT03786094","Metastatic Breast Cancer currently of stage IV disease or unresectable locoregionally recurrent breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03786094",1,"DB08871,DB15370","17755248, 138752609","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"228",228,"METASTATIC BREAST CANCER","CD205, ERBB2","Positive, Negative","AND","Protein Expression, Protein Expression","OBT076","CD205","I","Advanced, Second Line","Incidence of Adverse Events (AEs) as assessed by NCI CTCAE (Version 5)","NCT04064359","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04064359",1,"NA","NA","ENSG00000054219, ENSG00000141736","EFO_1000984","CD205 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"229",229,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ESR1, Bcl2, ERBB2","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein Expression","VENETOCLAX, PALBOCICLIB, LETROZOLE","UNK, CDK4/CDK6, aromatase","I","Advanced, Second Line","Determination of the Maximum Tolerated Dose (MTD), dose-limiting toxicities (DLTs) and recommended phase 2 dose of drug combination of palbociclib, letrozole and venetoclax.","NCT03900884","Must be post menopausal or If pre or peri menopausal, patients must be willing to receive ovarian suppression/ablation, ERBB2 non-amplified (per ASCO/CAP guidelines); can have protein expression, just not amplification","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03900884",1,"DB11581,DB09073,DB01006","49846579, 11478676, 3902","ENSG00000091831, ENSG00000171791, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND BCL2 PROTEIN EXPRESSION POSITIVE AND/OR ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"230",230,"METASTATIC BREAST CANCER (IV)","NA","NA","NA","NA","METFORMIN","UNK","I","Advanced, Second Line","disease progression through tumor size","NCT04143282","Must be a non-diabetic","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04143282",1,"DB00331","14219","ENSG00000183023","MONDO_0007254","NA NA NA","pass"
"231",231,"BREAST CANCER (I-III)","ERBB2, ESR1, PGR, PDL1","Positive, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND/OR, AND/OR","Protein Expression, Protein expression, Protein Expression, Protein expression","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB EMTANSINE","UNK, UNK, UNK, UNK, UNK, UNK","III","First Line","Percentage of Participants with Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3), pCR in the ITT Population","NCT03726879","early ERBB2-positive breast cancer (T2-4, N1-3, M0).","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03726879",1,"DB11595,DB00997,DB00531,DB01229,DB06366,DB05773","NA, 443939, 2907, 36314, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"232",232,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression & Amplification/Protein Expression","FS-1502","ERBB2","I","Advanced, Second Line","Dose limiting toxicity (DLT) within 28 days of first single dose of FS-1502, Overall response rate (ORR) by measurement of target lesions","NCT03944499","Patients with ERBB2 expressed advanced malignant solid tumor had failed to standard therapy (including surgery, chemotherapy, radiation therapy or biotherapy), or no standard therapy is available","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03944499",1,"NA","2760428","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"233",233,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein expression, Protein Expression, Protein Expression","IPI-549, ATEZOLIZUMAB, NAB-PACLITAXEL","PI3Kgamma, PDL1, microtubles","II","Advanced, Second Line","Complete Response (CR) rate (change in target lesion size)","NCT03961698","Trial also includes renal cell carcinoma","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03961698",1,"NA,DB11595,NA","91933883, NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"234",234,"BREAST NEOPLASM","ESR1, ERBB2, Ki67","Positive, Negative, Positive","AND, AND","Protein Expression, Protein expression, Protein Expression","ALL-TRANS RETINOIC ACID, ANASTROZOLE","RARα, UNK","II","First Line","Evaluate the proportion of responder patients in the 2 arm (Aa vs. a) according to the Ki67 assessment, measured at baseline and after treatment, must be post menopausal","NCT04113863","NA","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04113863",1,"NA,DB01217","444795, 2187","ENSG00000091831, ENSG00000141736, ENSG00000148773","EFO_0003869","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"235",235,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression & Amplification, Protein Expression, Protein Expression","PYROTINIB, CAPECITABINE","EGFR/ERBB2/HER4, UNK","II","Advanced, Second Line","Progression Free Survival (PFS)","NCT04001621","Patients must have trastuzumab resistance: Progression during or within 12 months after treatment in neoadjuvant or adjuvant setting (at least 9 weeks of trastuzumab treatment); Or Progression during or within 6 months after treatment for locally advanced or metastatic disease in the first-line setting (at least 6 weeks of trastuzumab treatment).","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04001621",1,"DB14993,DB01101","51039030, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"236",236,"ADVANCED OR METASTATIC BREAST CANCER","ESR1, ERBB2","Positive, Negative","AND","Protein Expression, Protein Expression","LY3484356, ABEMACICLIB","UNK, UNK","I","Advanced, Second Line","Number of Participants with Dose Limiting Toxicities (DLTs)","NCT04188548","Must have had a first line of standard therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04188548",1,"NA,DB12001","NA, 46220502","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"237",237,"METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, IPILIMUMAB, BICALUTAMIDE","PD1, CTLA4, AR","II","Advanced, Second Line","iRECIST Clinical Benefit Rate","NCT03650894","Previous systemic chemotherapy: no greater than one line of previous chemotherapy in non-curative setting; subjects with metastatic progression within 1 year following completion of curative-intent chemotherapy are eligible if they have not received any additional lines of systemic therapy in the non-curative setting.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03650894",1,"DB09035,DB06186,DB01128","NA, NA, 56069","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"238",238,"ADVANCED TRIPLE-NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, CARBOPLATIN, CAPECITABINE","UNK, UNK, UNK","II","Advanced, Second Line","Progression free survival (PFS)","NCT04159142","Only up to one line of previous therapy; two separate experimental lines using Nab-paclitaxel + Carboplatin and Nab-paclitaxel + Capecitabine","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04159142",1,"NA,DB00958,DB01101","36314, 56840877, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"239",239,"POSTMENOPAUSAL ADVANCED METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression and Amplification, Protein Expression, Protein Expression","RIBOCICLIB, TRASTUZUMAB, LETROZOLE","CDK4/CDK6, UNK, UNK","I, II","Advanced, First Line","Progression free survival","NCT03913234","Women with advanced (loco-regionally recurrent or metastatic) breast cancer not amenable for curative therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03913234",1,"DB11730,DB00072,DB01006","44631912, 3001322, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION AND AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"240",240,"BREAST CANCER (II-IIIB)","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","LETROZOLE, PALBOCICLIB","UNK, UNK","II","First Line","Difference on Recurrence Score between pre and post-treatment (molecular results) ","NCT03819010","No Metastatic Disease, Patients seperated into two different experimental groups based on Pre Treatment recurrence score 18-25 group and 26-100 group","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03819010",1,"DB01006,DB09073","3902, 11478676","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"241",241,"EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK, UNK","III","First Line","pCR","NCT03756064","Cannot have Metastatic disease (Stage IV) or inflammatory breast cancer, The target population is women with early breast cancer (stage of T1-4N0-3M0)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03756064",1,"DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"242",242,"UNRESECTABLE LOCALLY ADVANCED OR METASTATIC  BREAST CANCER","ERBB2","Positive","NA","Protein Expression & Amplification/Protein Expression","COPANLISIB, TRASTUZUMAB EMTANSINE","UNK, UNK","I","Advanced, First Line","To determine the incidence of dose limiting toxicity (DLT) of copanlisib in combination with trastuzumab emtansine within the 1st cycle at each dose level.","NCT04042051","Patients must have unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. first line treatment for advanced disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04042051",1,"DB12483,DB05773","135565785, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"243",243,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, CAPECITABINE","PDL1, UNK","II","Second Line","5-yr invasive disease-free survival (IDFS) rate","NCT03756298","Patients must have had neoadjuvant chemotherapy followed by surgery; the recommended neoadjuvant treatment should include 16-24 weeks of a third generation chemotherapy regimen as recommended by National Comprehensive Cancer Network (NCCN) guidelines for triple negative breast cancer. Patients who cannot complete all planned treatment cycles for any reason are considered high risk and therefore are eligible for the study if they have residual disease, Patients cannot have metastatic disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03756298",1,"DB11595,DB01101","NA, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"244",244,"RELAPSED REFRACTORY METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ORIN1001, PACLITAXEL","UNK, UNK","I","Advanced, Second Line","To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors, To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer, To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study, To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in the dose escalation and expansion stages of the study","NCT03950570","must have progressed through at least 2 lines of therapy and for whom there are no available therapies that confer a clinical benefit","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03950570",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"245",245,"RELAPSED REFRACTORY METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","ORIN1001, PACLITAXEL","UNK, UNK","I","Advanced, Second Line","To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors, To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer, To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study, To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in the dose escalation and expansion stages of the study","NCT03950570","must have progressed through at least 2 lines of therapy and for whom there are no available therapies that confer a clinical benefit","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03950570",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"246",246,"RELAPSED REFRACTORY METASTATIC BREAST CANCER","MYC","Positive","NA","Mutation","ORIN1001, PACLITAXEL","UNK, UNK","I","Advanced, Second Line","To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors, To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer, To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study, To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in the dose escalation and expansion stages of the study","NCT03950570","must have progressed through at least 2 lines of therapy and for whom there are no available therapies that confer a clinical benefit","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03950570",1,"NA,DB01229","NA, 36314","ENSG00000136997","MONDO_0007254","MYC MUTATION POSITIVE","failed drug"
"247",247,"METASTATIC OR LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FAND2, FANCL, MRE11A, NBN, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, AKT1, FGFR1, FGFR2, FGFR3, PIK3CA","Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","Protein Expression, Protein Expression/mutation, mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation, mutation, mutation, mutation","DURVALUMAB, OLAPARIB, FULVESTRANT","UNK, UNK, UNK","II","Advanced, Second Line","Progression-free survival rate (PFSR)","NCT04053322","Patients could have received 1 line of endocrine therapy (including CDK4/6 inhibitor, but excluding fulvestrant or mTOR inhibitor) and/or 1 line of chemotherapy in the metastatic setting, Documented personal germline alteration in BRCA1 or BRCA2 that is predicted to be deleterious. Testing may be performed at any time prior to inclusion. Documented personal germline alteration in BRCA1 or BRCA2 that is predicted to be deleterious. Testing may be performed at any time prior to inclusion.OR Deleterious germline or somatic alterations implicated in the HRR pathway (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FAND2, FANCL, MRE11A, NBN, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D and RAD54L) or in MSI status or other actionable genes (AKT1, ESR1, FGFR1, FGFR2, FGFR3, and PIK3CA) all based on central tumor next generation DNA sequencing performed at screening visit.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04053322",1,"DB11714,DB09074,DB00947","NA, 23725625, 104741","ENSG00000141736, ENSG00000091831, ENSG00000149311, ENSG00000138376, ENSG00000012048, ENSG00000139618, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000187741, NA, ENSG00000115392, ENSG00000020922, ENSG00000104320, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224, ENSG00000142208, ENSG00000077782, ENSG00000066468, ENSG00000068078, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION/MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FAND2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR MRE11A MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE AND/OR AKT1 MUTATION POSITIVE AND/OR FGFR1 MUTATION POSITIVE AND/OR FGFR2 MUTATION POSITIVE AND/OR FGFR3 MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE","pass"
"248",248,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PYROTINIB MALEATE, DOCETAXEL","UNK, UNK","II","Advanced, First Line","Objective Response Rate","NCT03876587","Local recurrent or metastatic breast cancer suitable for chemotherapy, HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03876587",1,"NA,DB01248","138115215, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"249",249,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","TESETAXEL, CAPECITABINE","UNK, UNK, UNK","II","Advanced, Second Line","ORR Objective Response Rate","NCT03858972","locally advanced breast cancer that is not considered curable by surgery and/or radiation; or (b) metastatic breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03858972",1,"DB12019,DB01101","6918574, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"250",250,"EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB","EGFR/ERBB2, UNK, UNK","I, II","First Line","pathologic Complete Response(pCR)","NCT04152057","No patients can have inflammatory breast cancer or metastatic stage IV breast cancer, patients who are hormone receptor positive can have concurrent endocrine treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04152057",1,"NA,NA,DB00072","138115215, NA, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"251",251,"METASTATIC MALIGNANT NEOPLASM IN THE CHEST WALL","ERBB2, ESR1, PGR, BRCA1, BRCA2","Positive/Negative, Positive/Negative, Positive/Negative, Negative, Negative","AND/OR, AND/OR, AND, AND","Protein Expression, Protein Expression, Protein Expression, mutation, mutation","OLAPARIB","PARP","I","Advanced, Second Line","Incidence of adverse events","NCT03955640","Patients are also treated using hypothermia","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03955640",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_1000051","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"252",252,"BREAST CANCER STAGE IV","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE","CDK4/CDK6, UNK","UNK","Advanced, First Line","Overall survival rate in patients receiving the letrozole plus palbociclib combination plus locoregional treatment","NCT03870919","Prior therapy for metastatic breast cancer (systemic or local) excludes patients from the trial, After 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy, patients who are non-menopausal will be giving a Monthly Luteinizing hormone-releasing hormone (LHRH) analogue, Surgical bilateral oophorectomy is an acceptable option","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03870919",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"253",253,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PYROTINIB, TRASTUZUMAB, DOCETAXEL","UNK, UNK, UNK","III","Advanced, First Line","PFS Progression Free Survival","NCT03863223","Patients are excluded if they have a history of anti-cancer therapy for MBC（with the exception of one prior hormonal regimen for MBC)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03863223",1,"DB14993,DB00072,DB01248","51039030, 3001322, 148124","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"254",254,"METASTATIC OR LOCALLY RECURRENT INOPERABLE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","SACITUZUMAB GOVITECAN","Trop2/SN38/CL2A","III","Advanved, Second Line","Progression-free survival (PFS), Objective (overall) response rate (ORR)","NCT03901339","Active Comparator: Eribulin; Capecitabine; Gemcitabine; Vinorelbine. Patients can start clincial trial after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03901339",1,"DB12893","91668186","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"255",255,"EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NERATINIB, PACLITAXEL, CARBOPLATIN","UNK, UNK, UNK","II","First Line","The percentage of patients experiencing ≥ 20% response to neratinib only therapy, rate of pathologic complete response (pCR)","NCT03812393","T3 or T4 tumors including inflammatory breast cancer are excluded, only patients with  abnormal HER2-driven signaling pathways will be enrolled, determined by Celcuity CELx HSF assay","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03812393",1,"DB11828,DB01229,DB00958","9915743, 36314, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"256",256,"LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, BOSUTINIB, FULVESTRANT","UNK, UNK, UNK","I","Advanced, Second Line","Toxicity of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors, Incidence of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors, Grade of adverse events of bosutinib when used in combination with palbociclib and fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors, Maximum Tolerated Doses (MTD) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors, Recommended Phase II Dose (RP2D) of palbociclib and bosutinib when used in combination with fulvestrant in patients with advanced HR+MBC who are refractory to AI and CDK4/6 inhibitors","NCT03854903","patients must be progressive on at least one aromatase inhibitor and one CDK 4/6 inhibitor","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03854903",1,"DB09073,DB06616,DB00947","11478676, 5328940, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"257",257,"ADVANCED BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","TQB3616","CDK","I","Advanced, Second Line","DLT , MTD","NCT03850873","Patients must have failed standard endocrine therapy, excludes patients with malignant tumors, except for Cured cutaneous basal cell carcinoma and cervical carcinoma in situ","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03850873",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"258",258,"LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ERBB2, CCR5, ESR1, PGR","Negative, Positive, Negative, Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","LERONLIMAB, CARBOPLATIN","CCR5, UNK","I, II","Advanced, First Line","Phase Ib: Maximum Tolerated Dose (MTD) of leronlimab (PRO 140) when combined with carboplatin AUC5, Phase II: Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first.","NCT03838367","who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03838367",1,"DB05941,DB00958","NA, 56840877","ENSG00000141736, ENSG00000160791, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND CCR5 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"259",259,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY3023414, PREXASERTIB","non-homologous end joining, UNK","II","Advanced, Second Line","Efficacy (objective response rate)","NCT04032080","Patients must have a diagnosis of metastatic TNBC previously treated with standard anthracycline, cyclophosphamide, and taxane chemotherapy, unless there was a contraindication to doxorubicin, in which case prior treatment with this agent is not required.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04032080",1,"NA,DB12008","57519748, 46700756","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"260",260,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, CARBOPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","UNK","First Line","pathologic complete response（pCR)","NCT04067102","Active Comparator: nab-paclitaxel, carboplatin, epirubicin, cyclophosphamide","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04067102",1,"NA,DB00958,DB00445,DB00531","36314, 56840877, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"261",261,"RECURRENT AND METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SHR-1210, APATINIB, FLUZOPARIB","PD1, UNK, UNK","I","Advanced, Second Line","Dose Limiting Toxicity (DLT)","NCT03945604","At least 1-line chemotherapy failed at the stage of recurrence and metastasis","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03945604",1,"NA,DB14765,NA","NA, 45139106, 56649297","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"262",262,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, COPANLISIB, COPANLISIB HYDROCHLORIDE, FULVESTRANT","UNK, PI3K, UNK, UNK","I, II","Advanced, First Line, Second Line","Dose-limiting toxicity (DLT) (Phase I), Progression-free survival (PFS) (Phase II)","NCT03939897","No more than 1 prior chemotherapy in the metastatic setting. There is no limit on prior lines of endocrine therapy. (For patients enrolling to the phase 1 portion of the study, prior fulvestrant, CDK4/6 inhibitor, and everolimus is allowed)","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03939897",1,"DB12001,DB12483,NA,DB00947","46220502, 135565785, 135565785, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"263",263,"EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB, EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE","EGFR/ERBB2, UNK, UNK","I, II","First Line","pathologic Complete Response(pCR)","NCT04152057","No patients can have inflammatory breast cancer or metastatic stage IV breast cancer, patients who are hormone receptor positive can have concurrent endocrine treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04152057",1,"NA,NA,DB00072,NA,DB00531","138115215, NA, 3001322, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"264",264,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GB1275, PEMBROLIZUMAB","UNK, PD1","I","Advanced, First Line, Second Line","Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs), Regimens A, B,and C: Incidence of adverse events (AEs), Regimens A and B: Cmax of GB1275, Regimens A and B: Ctrough of GB1275, Regimens A and B: Tmax of GB1275, Regimens A and B: t1/2 of GB1275, Regimens A and B: AUC of GB1275,  Regimens A and B: CL/F of GB1275,  Expansion Cohorts 1, 2 and 3: Objective Response Rate (ORR)","NCT04060342","Trial studies multiple cancers. TNBC is only included in the first phase of this trial and can only take Regimen A and B (GB1275, pembrolizumab), Not regimen C (nab-paclitaxel and gemcitabine).","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04060342",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"265",265,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, LDH","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, LENVATINIB","UNK, UNK","II","Advanced, Second Line","Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Glioblastoma (GBM) by Investigator Assessment in Initial Cohorts, ORR per RECIST 1.1 or RANO (GBM) by Blinded Independent Central Review (BICR) in Expanded Cohorts (Combined with Initial Cohorts), Percentage of Participants who Experience an Adverse Event (AE), Percentage of Participants who Discontinue Study Treatment Due to an Adverse Event (AE)","NCT03797326","Trial studies multiple cancers.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03797326",1,"DB09037,DB09078","NA, 11237762","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000134333","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND LDH PROTEIN EXPRESSION POSITIVE","pass"
"266",266,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ABBV-927, ABBV-368","UNK, UNK","I","Advanced, Second Line","Dose Expansion: Objective Response Rate (ORR), Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368, Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181","NCT03893955","Breast cancer is in arm 1 of the dose expansion phase of this trial. Patients must have disease progression during or after at least 1 systemic therapy that included a taxane in the metastatic or recurrent setting and who are treatment-naïve to immunotherapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03893955",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"267",267,"METASTATIC OR UNRESECTABLE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SGN-CD228A","UNK","I","Advanced, Second Line","Number of patients with adverse events, Number of patients with laboratory abnormalities, Number of patients with dose limiting toxicities","NCT04042480","Trial Includes multiple cancers. Participants must have received 1 or more prior lines of therapy for locally advanced or metastatic disease. Prior therapies must include taxane. Hormone-receptor-positive subjects should have received CDK4/6 inhibitor therapy and have received at least 1 prior hormonally-directed therapy, unless contraindicated.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04042480",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"268",268,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TPST-1120, NIVOLUMAB, DOCETAXEL, CETUXIMAB","PPARα, PD1, UNK, EGFR","I","Advanced, First Line, Second Line","Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab, in combination with docetaxel and in combination with cetuximab, Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab, in combination with docetaxel and in combination with cetuximab, Identify the maximum tolerated dose","NCT03829436","Progressive disease or previously untreated tumors for which no standard therapy exists or treatment naïve at the time of study entry are eligible. Multiple treatment arms with TPST-1120 as a monotherapy and in combination with Nivolumab, Docetaxel or Cetuximab.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03829436",1,"NA,DB09035,DB01248,DB00002","NA, NA, 148124, 136170999","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"269",269,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ZN-C3, TALAZOPARIB","UNK, UNK","I, II","Advanced, Second Line","Safety and tolerability of single agent ZN c3, including identification of the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), Objective response rate (ORR) of ZN c3 as a single agent and in combination with a PARP inhibitor and with a PD-1 inhibitor, respectively, Safety of ZN-c3 in combination with a PARP inhibitor and with a PD-1 inhibitor, respectively, including the determination of a RP2D for the combinations","NCT04158336","Multiple Experimental arms with various cancer types. Breast cancer listed in phase two only with ZN-c3 and talazoparib. Pembrolizumab is also listed in trial, but not for breast cancer patients.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04158336",1,"NA,DB11760","NA, 135565082","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"270",270,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SO-C101, PEMBROLIZUMAB","UNK, UNK","I","Advanced, Second Line","Part A;Number of Participants With Dose-Limiting Toxicities (DLT), Part A;Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Part A;Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs), Part A;Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0, Part A;Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0: Biochemistry and Hematology, Part A;Number of Participants With Laboratory Test Abnormalities: Urinalysis, Part A;Number of Participants With Clinically Significant Change From Screening in Vital Signs, Part A; Number of Participants With Eastern Cooperative Oncology Group [ECOG] Performance Status Score, Part B: Number of Participants With Dose-Limiting Toxicities (DLT): Dose Finding Phase, Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events, Part B: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events, Part B: Number of Participants With Adverse Events (AEs) According to Severity of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0, Part B: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 5.0: Biochemistry and Hematology, Part B: Number of Participants With Laboratory Test Abnormalities: Urinalysis, Part B: Number of Participants With Clinically Significant Change From Screening in Vital Signs, Part B: Number of Participants With Eastern Cooperative Oncology Group [ECOG]","NCT04234113","Patients with selected histologically or cytologically confirmed advanced and/or metastatic solid tumors who are refractory to or intolerant of existing therapies known to provide clinical benefit for their condition. Multiple cancers included in this trial. Part A is SO-C101 monotherapy, Part B is SO-C101 in combination with pembrolizumab","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04234113",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"271",271,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","XMAB22841, PEMBROLIZUMAB","UNK, UNK","I","Advanced, Second Line","Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.","NCT03849469","Trial with multiple cancers. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03849469",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"272",272,"METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GEN1046","UNK","I, II","Advanced, Second Line","Dose limiting toxicity (DLT), Adverse events, Safety laboratory parameters (hematology, biochemistry, coagulation, endocrines)","NCT03917381","Must be patients that are longer candidates for standard therapy. Multiple cancers included in this trial","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03917381",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"273",273,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","9-ING-41, GEMCITABINE, DOXORUBICIN, LOMUSTINE, CARBOPLATIN, NAB PACLITAXEL, PACLITAXEL, IRINOTECAN","GSK-3β, UNK, UNK, UNK, UNK, UNK, UNK, UNK","I, II","Advanced, Second Line","Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","NCT03678883","Multiple cancers. 9-ING-41 is tested as a monotherapy and in combination with other drugs. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition, Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit, alignancy has relapsed after standard therapy, Malignancy for which there is no standard therapy that improves survival by at least 3 months","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03678883",1,"NA,DB00441,DB00997,DB01206,DB00958,NA,DB01229,DB00762","44582816, 60750, 443939, 3950, 56840877, 36314, 36314, 60838","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"274",274,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","KY1044, ATEZOLIZUMAB","ICOS, PDL1","I, II","Advanced, Second Line","Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Number of dose interruptions, reductions and dose intensity, Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (phase 2)","NCT03829501"," there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03829501",1,"NA,DB11595","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"275",275,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","XMAB23104","UNK","I","Advanced, Second Line","Treatment-related adverse events as assessed by CTCAE v4.03","NCT03752398","All subjects' cancer must have progressed after treatment with standard/approved therapies or have no appropriate available therapies. Multiple cancer types included in study","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03752398",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"276",276,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LY3435151, PEMBROLIZUMAB","UNK, UNK","I","Advanced, Second Line","Number of Participants with LY3435151 Dose-Limiting Toxicities (DLTs)","NCT04099277","Multiple cancers included in trial. Participant must have progressed through or are intolerant to therapies with known clinical benefit, which your study doctor will discuss with you","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04099277",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"277",277,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, 5T4","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","UNK, UNK","I","Advanced, Second Line","The incidence and characteristics of adverse events, associated with ascending doses of Nap in combination with a set dose of durvalumab, Establish MTD, Establish Recommended Phase 2 Dose (RP2D)","NCT03983954","Trial includes multiple cancer. Breast cancer tissue has a high (>80%) probability of 5T4 expression. Histologically and/or cytologically confirmed solid tumor that is metastatic/advanced, for which no curative therapy exists","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03983954",1,"DB12807,DB11714","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146242","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"278",278,"ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, 5T4","Negative, Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","UNK, UNK","I","Advanced, Second Line","The incidence and characteristics of adverse events, associated with ascending doses of Nap in combination with a set dose of durvalumab, Establish MTD, Establish Recommended Phase 2 Dose (RP2D)","NCT03983954","Trial includes multiple cancer. Breast cancer tissue has a high (>80%) probability of 5T4 expression. Histologically and/or cytologically confirmed solid tumor that is metastatic/advanced, for which no curative therapy exists.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03983954",1,"DB12807,DB11714","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000146242","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"279",279,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AID","Negative, Negative, Negative, Positive/Negative","AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Protein Expression","CYT-0851","RAD51","I, II","Advanced, Second Line","Dose limiting Toxicity, Overall Response Rate","NCT03997968","Trial includes multiple cancers. Triple negative breast cancer was the only breast cancer listed with specific biomarkers. Metastatic breast cancer was also included in phase one, however, this lacked mention of specific biomarkers other than the multi-cancer marker AID (activation-induced cytidine deaminase","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03997968",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000111732","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND/OR AID PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"280",280,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","REBASTINIB, CARBOPLATIN","UNK, UNK","I, II","Advanced, Second Line","Adverse Events (Part 1 and Part 2), objective response rate (ORR)","NCT03717415","Trial studies multiple cancers.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03717415",1,"DB13005,DB00958","25066467, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"281",281,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","DF1001, PEMBROLIZUMAB","NK Cells, PD1","I, II","Advanced, Second Line","Assessment of number of dose limiting toxicities experienced on study as defined per criteria in the study protocol, Assess Overall Response Rate","NCT04143711","Trial Studies multiple cancers. Patients must have received a taxane and an anthracycline unless anthracycline is contraindicated, progressed after their last line of therapy","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04143711",1,"NA,DB09037","NA, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"282",282,"METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2, ESR1, PGR","Negative, Positive, Positive, Positive/Negative, Positive/Negative","AND, AND/OR, AND/OR, AND/OR","Protein Expression, Mutation, Mutation, Protein Expression, Protein Expression","NMS-03305293","PARP","I","Advanced, Second Line","Number of Participants with first-cycle dose limiting toxicity","NCT04182516","Trial Studies multiple cancers. HER2 negative breast cancer: no more than 3 prior chemotherapy regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies). At least 1 line of taxane or anthracycline based chemotherapy, if not contraindicated, in adjuvant/neoadjuvant or metastatic setting, If HR (Hormone Receptor) positive, at least 1 line of prior endocrine therapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04182516",1,"NA","NA","ENSG00000141736, ENSG00000012048, ENSG00000139618, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"283",283,"ADVANCED BREAST CANCER","ERBB2, ERBB3, EGFR","Positive, Positive, Positive","AND/OR, AND/OR","Protein Expression/ Protein Amplification/Mutation, Mutation, Mutation","BDTX-189","UNK","I, II","Advanced, Second Line","Incidence of dose limiting toxicities as a determinant of the Recommended Phase 2 Dose (RP2D), Phase 2: Objective response rate as a measure of antitumor activity","NCT04209465","Trial studies multiple cancers. Phase 1 Only: olid tumor patients with alterations that may be associated with antitumor activity based on preclinical data for BDTX-189 such as: Allosteric HER2 or HER3 mutation(s), EGFR or HER2 exon 20 insertion mutation(s), HER2 amplified or overexpressing tumors, EGFR exon 19 deletion or L858R mutation. Phase 2 only: Patients with a solid tumor harboring an: Allosteric HER2 mutation (including but not limited to S310F/Y, R678Q, L755S/P, V777L, V842I), EGFR or HER2 exon 20 insertion mutation","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04209465",1,"NA","NA","ENSG00000141736, ENSG00000065361, ENSG00000146648","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN AMPLIFICATION/MUTATION POSITIVE AND/OR ERBB3 MUTATION POSITIVE AND/OR EGFR MUTATION POSITIVE","failed drug"
"284",284,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ABBV-151, ABBV-181","UNK, UNK","I","Advanced, Second Line","Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy, Dose Escalation: RP2D ABBV-151 + ABBV-181 Combination Therapy, Dose Expansion: Objective Response Rate (ORR)","NCT03821935","Trial studies multiple cancers. who must have disease progression during or after at least 1 systemic therapy that included a taxane in the metastatic or recurrent setting. Study with ABBV-151 as a monotherapy and in combination with ABBV-181","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03821935",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"285",285,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","ACTR T CELL PRODUCT, TRASTUZUMAB","Unk, ERBB2","I","Advanced, Second Line","Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values, Determination of recommended phase 2 dose (RP2D) regimen","NCT03680560","Trial Studies multiple cancers. ACTR T Cell Productz: Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087). For those with metastatic breast cancer, must have received HER2-directed therapy including trastuzumab, pertuzumab and ado-trastuzumab in any breast cancer disease setting","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03680560",1,"NA,DB00072","NA, 3001322","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"286",286,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","KN026, DOCETAXOL","UNK, UNK","II","Advanced, First Line, Second Line","The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria","NCT04165993","The HER2 positive mBC subjects without systemic treatment will be enrolled in cohort 1 and received 30 mg/kg KN026 and docetaxol. The HER2 expressing mBC subjects failed standard therapy will be enrolled in cohort 2 and received KN026 monotherapy.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04165993",1,"NA,NA","NA, 148124","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"287",287,"METASTATIC  BREAST CANCER","NA","NA","NA","NA","VINORELBINE, CARBOPLATIN, GEMCITABINE","UNK, UNK, UNK","II","Advanced, Second Line","Progression Free Survival ","NCT04143906","Patients need to have received a previous treatment with anthracyclines and taxanes. Separate study arms: Arm A: Vinorelbine 25 mg/m2 d1,8; Carboplatin AUC=6 d1 q 3 weeks; Arm B: Gemcitabine 1000 mg/m2 d1,8; Carboplatin AUC=6 d1 q 3 weeks","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04143906",1,"DB00361,DB00958,DB00441","5311497, 56840877, 60750","ENSG00000183023","EFO_1000984","NA NA NA","pass"
"288",288,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","PYROTINIB, SHR6390, LETROZOLE","UNK, UNK, UNK","II","Advanced, Second Line","Objective Overall Response Rate (ORR)","NCT04095390","Prior treatment with trastuzumab required. Patients cannot have had Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04095390",1,"DB14993,NA,DB01006","51039030, NA, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"289",289,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression/Protein expression & Amplification, Protein Expression, Protein Expression","PYROTINIB, SHR6390, CAPECITABINE","UNK, UNK, UNK","II","Advanced, Second Line","Objective Overall Response Rate (ORR)","NCT04095390","Prior treatment with trastuzumab required. Patients cannot have had Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past. Two separate drug combinations, Pyrotinib, SHR6390, Capecitabine and Pyrotinib, SHR6390","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04095390",1,"DB14993,NA,DB01101","51039030, NA, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"290",290,"METASTATIC  BREAST CANCER","NA","NA","NA","NA","PMD-026","RSK1/RSK2/RSK3/RSK4","I","Advanced, Second Line","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Maximum tolerated dose (MTD) of PMD-026, Recommended Phase 2 Dose (RP2D) of PMD-026, Efficacy in Patients","NCT04115306","Metastatic breast cancer that has progressed on or after the standard of care therapy and for which no standard of care therapy is available","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04115306",1,"NA","NA","ENSG00000183023","EFO_1000984","NA NA NA","failed drug"
"291",291,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PMD-026","RSK1/RSK2/RSK3/RSK4","I","Advanced, Second Line","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Maximum tolerated dose (MTD) of PMD-026, Recommended Phase 2 Dose (RP2D) of PMD-026, Efficacy in Patients","NCT04115306","Metastatic breast cancer that has progressed on or after the standard of care therapy and for which no standard of care therapy is available","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04115306",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"292",292,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1, BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","ATEZOLIZUMAB, IPATASERTIB, PACLITAXEL","UNK, UNK, UNK","III","Advanced, First Line","Investigator-assessed Progression Free Survival (PFS), Overall Survival (OS)","NCT04177108","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04177108",1,"DB11595,DB11743,DB01229","NA, 24788740, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"293",293,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Negative, Negative","AND, AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","ATEZOLIZUMAB, IPATASERTIB, PACLITAXEL","UNK, UNK, UNK","III","Advanced, First Line","Investigator-assessed Progression Free Survival (PFS), Overall Survival (OS)","NCT04177108","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04177108",1,"DB11595,DB11743,DB01229","NA, 24788740, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"294",294,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","NIVOLUMAB, ABEMACICLIB, ANASTROZOLE, PALBOCICLIB","UNK, UNK, UNK, UNK, UNK","II","First Line","Dose Limiting Toxicity, Residual Cancer Burden RCB","NCT04075604","Trial has numerous drug combination experimental arms","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04075604",1,"DB09035,DB12001,DB01217,DB09073","NA, 46220502, 2187, 11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"295",295,"RESECTABLE PRIMARY TRIPLE NEGATIVE BREAST CANCER (STAGE I-III)","ERBB2, ESR1, PGR, Ki67","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, DOXORUBICIN","UNK, UNK","II","First Line","Immune activation after pre-operative nivolumab","NCT03815890","Testing Nivolumab as a monotherapy and in combination with doxorubicin","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03815890",1,"DB09035,DB00997","NA, 443939","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"296",296,"RESECTABLE PRIMARY BREAST CANCER (STAGE I-III)","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Negative, Positve","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, DOXORUBICIN","UNK, UNK","II","First Line","Immune activation after pre-operative nivolumab","NCT03815890","Testing Nivolumab as a monotherapy and in combination with doxorubicin","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03815890",1,"DB09035,DB00997","NA, 443939","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITVE","pass"
"297",297,"INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First Line","Change in pathological complete response (pCR)","NCT03742986","Must have Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03742986",1,"DB09035,DB01229,DB00997,DB00531","NA, 36314, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"298",298,"INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK, UNK, UNK","II","First Line","Change in pathological complete response (pCR)","NCT03742986","Must have Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03742986",1,"DB09035,DB01229,DB00997,DB00531,DB00072,DB06366","NA, 36314, 443939, 2907, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"299",299,"INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First Line","Change in pathological complete response (pCR)","NCT03742986","Must have Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03742986",1,"DB09035,DB01229,DB00997,DB00531","NA, 36314, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"300",300,"LOCALLY ADVANCED BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, DURVALUMAB, AROMATASE INHIBITOR","UNK, UNK, aromatase","I","Advanced, First Line","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","NCT04088032","one of three aromatase inhibitors: exemestane, anastrozole, or letrozole","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT04088032",1,"DB12001,DB11714,NA","46220502, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"301",301,"TRIPLE NEGATIVE INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, CARBOPLATIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","I","Advanced, First Line","Toxicity and receipt of planned therapy (feasibility)","NCT03858322","Testing different drug combinations with Paclitaxel. Patients must be aged 70 years and older.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03858322",1,"DB01229,DB00958,DB00531","36314, 56840877, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"302",302,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, CARBOPLATIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","I","Advanced, First Line","Toxicity and receipt of planned therapy (feasibility)","NCT03858322","Testing different drug combinations with Paclitaxel. Patients must be aged 70 years and older.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03858322",1,"DB01229,DB00958,DB00531","36314, 56840877, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"303",303,"VISCERAL METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","RIBOCICLIB, ENDOCRINE THERAPY","UNK, UNK","III","Advanced First Line","Quality of life-adjusted early disease control , Quality of life-adjusted early disease control","NCT03905343","Specific endocrine therapy is decided upon by the investigator. Active comparator is mono-chemotherapy and endocrine therapy following. Measurable visceral disease according to RECIST v1.1. Visceral disease in liver and/or lung. Peritoneal and/or pleural metastases only are accepted, with the condition to be measurable","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03905343",1,"DB11730,NA","44631912, NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"304",304,"METASTATIC BREAST CANCER, BREAST CANCER","ESR1, PGR, ERBB2","Positve/negative, positive/negative, negative","OR, AND","protein expression, protein expression, protein expression","ENTINOSTAT, CAPECITABINE","HDAC, DNA/RNA/Protein Synthesis","I","Advanced, Second line","Identification of a maximum tolerated dose, Frequency of adverse events, Severity","NCT03473639","Stage IV UNK, I-III second line, http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20140378420.PGNR.&OS=DN/20140378420&RS=DN/20140378420 (Etinostat breast cancer target source) found the other drugs use on pubchem capecitabine is a pro-drug","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03473639",1,"DB11841,DB01101","4261, 60953","ENSG00000091831, ENSG00000082175, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITVE/NEGATIVE OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"305",305,"METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ESR1, PGR, ERBB2","Negative, negative, negative","AND, AND","protein expression, protein expression, protein expression","TALAZOPARIB, SACITUZUMAB GOVITECAN","PARP, Topoisomerase I-DNA covalent complexes","I, II","Advanced, Second line","Dose Limiting Toxicity","NCT04039230","Sacituzumab Govitecan target was found on pubchem","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04039230",1,"DB11760,DB12893","135565082, 91668186","ENSG00000091831, ENSG00000082175, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"306",306,"ERBB2-POSITIVE BREAST CANCER BRAIN METASTASES","ERBB2","Positve","NA","protein expression & amplification","TRASTUZUMAB, GDC-0084","ERBB2, PI3-Kinase","II","Advanced, First line&Second line","Overall Response Rate in the CNS, To evaluate the correlation between inhibition of p-4EBP1 in resected brain tumor tissue and intracranial response in the corresponding patient-derived xenograft (PDX) models of BCBM","NCT03765983","All about CNS metastasis, could be first or second line, it did not specifiy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03765983",1,"DB00072,DB15186","3001322, 57384863","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","pass"
"307",307,"BREAST CANCER (STAGE I-III)","ESR1, ERBB2","Positve, negative","AND","protein expression, protein expression","ASPIRIN, TAMOXIFEN, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","COX, Estrogen Receptors, DNA/DNA-topoisomerase II complex, DNA, Bcl2","II","Non-advanced and advanced, First line","Pathologic complete response (pCR) rate, Adverse Events","NCT04038489","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04038489",1,"DB00945,DB00675,DB00997,DB00531,DB01229","2244, 2733526, 443939, 2907, 36314","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"308",308,"PRIMARY INVASIVE BREAST CANCER AND CLINICAL STAGE I - III, FIRST OPTION Ⅳ","ERBB2, ESR1, PGR","Positive/Negative, Negative, Negative","AND, AND","protein expression, protein expression, protein expression","NAB-PACLITAXEL","Bcl2/GP60","II","Advanced, First line&Second line","the Pathological complete remission(pCR), Disease-free survival (DFS)","NCT03959397","Seems to be first line, but only excludes those whom have had ""Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03959397",1,"NA","36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"309",309,"METASTATIC BREAST CANCER","ERBB2, ER, PGR","Negative, negative/positive, negative/positive","AND/OR, AND/OR","protein expression, protein expression, protein expression","NIVOLUMAB, IPILIMUMAB","PD1, CTLA4","II","Advanced, Second Line","Overall Response Rate of nivolumab in combination with ipilimumab","NCT03789110","ER/PR positive paitents must have had progression after HR treatment","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03789110",1,"DB09035,DB06186","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR ER PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"310",310,"BREAST CANCER STAGE (STAGE IV)","ERBB2","Positive","NA","protein expression & amplification","SIMVASTATIN","UNK","II","Advanced, Second line","Objective Response","NCT03324425","Simvastatin is a drug that is approved by the Food and Drug Administration (FDA) to treat high cholesterol. Laboratory research has shown that simvastatin together with dual ERBB2-targeted therapy slows the growth of breast cancer tumors that had been growing on dual ERBB2-targeting therapy alone.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03324425",1,"DB00641","54454","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"311",311,"BREAST CANCER FEMALE","ESR1, ERBB2, PGR","Positve, negative, positive","AND, AND/OR","mutation, protein expression, protein expression","PEMBROLIZUMAB, TAMOXIFEN","PD1, Estrogen Receptors","II","Advanced, Second line","Progression Free Survival, Overall Response Rate (ORR)","NCT03879174","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03879174",1,"DB09037,DB00675","NA, 2733526","ENSG00000091831, ENSG00000141736, ENSG00000082175","MONDO_0007254","ESR1 MUTATION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"312",312,"BREAST CANCER","ERBB2","Negative","NA","protein expression","APATINIB, PACLITAXEL, CISPLATIN","VEGFR2, Bcl2, Replication and transcription of DNA","II","Advanced First line, First line","Pathologic Complete Response (pCR) of the Primary Tumor in the Breast","NCT03982485","Must include surgery","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03982485",1,"DB14765,DB01229,DB00515","45139106, 36314, 135804801","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"313",313,"BREAST CANCER STAGE (STAGE II-III)","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","PALBOCICLIB","CDK4/CDK6","II","Advanced first line, First line","distant recurrence-free interval (D-RFI) rate","NCT03609047","has comparator with different treatments","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03609047",1,"DB09073","11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"314",314,"BREAST CANCER FEMALE, MALIGNANT NEOPLASM OF BREAST","ERBB2, ESR1, PGR","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","ENDOCRINE THERAPY","Hormone Receptors","III","First line","Pre-operative Endocrine Prognostic Index (PEPI Score) , EndoPredict™ EPclin Score","NCT03969121","has comparator with different treatments","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03969121",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"315",315,"EARLY-STAGE BREAST CANCER","ERBB2, ESR1, PGR, PDl1","Positive, positive, positive, positve","AND, AND, AND","protein expression & amplification, protein expression, protein expression, protein expression","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB, EPIRUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","VEGF/microtubule, DNA/Protein, ERBB2, ERBB2,  DNA/DNA-topoisomerase II complex, DNA, CD274, microtubules","II","First line","Rate of pathological objective response to primary medical treatment","NCT03894007","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03894007",1,"DB01248,DB00958,DB00072,DB06366,DB00445,DB00531,DB11595,DB05773","148124, 56840877, 3001322, NA, 65348, 2907, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION POSITVE","pass"
"316",316,"BREAST CANCER METASTATIC, BREAST CANCER","ERBB2","Negative","NA","protein expression","OLAPARIB, VORINOSTAT","PARP, HDAC","I","Advanced, Second line","MTD ","NCT03742245","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03742245",1,"DB09074,DB02546","23725625, 5311","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"317",317,"BREAST NEOPLASMS","ERBB2, ESR1, PR","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","ENDOCRINE THERAPY","Hormone receptors","II","First line","Percentage Change From Pre-treatment to Post-treatment in Ki-67 Labelling Index","NCT04023292","must have operable breast cancer, drugs used depended upon policy for specific tumor","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04023292",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000134551","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","failed drug"
"318",318,"METASTATIC BREAST CANCER, ERBB2 POSITIVE BREAST CARCINOMA","ERBB2, ESR1, PR","Positive, negativie/positive, negative/positive","AND/OR, AND/OR","protein expression & amplification, protein expression, protein expression","NIRAPARIB, TRASTUZUMAB","PARP1/PARP2, ERBB2","I/II","Advanced, Second line","Phase 1: Dose-limiting toxicity (DLT), Phase 2: Objective Response Rate","NCT03368729","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03368729",1,"DB11793,DB00072","24958200, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000134551","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVIE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"319",319,"INVASIVE BREAST CARCINOMA","ERBB2","Positve","NA","protein expression & amplification","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","VEGF/microtuble, DNA/Protein, ERBB2, ERBB2","II","First line","pathologic complete response","NCT04094896","has comparator with different treatments","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04094896",1,"DB01248,DB00958,DB00072,DB06366","148124, 56840877, 3001322, NA","ENSG00000141736","EFO_1000307","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","pass"
"320",320,"ADVANCED BREAST CANCER","NA","NA","NA","NA","TALAZOPARIB, AVELUMAB","PARP, PDL1","I/II","Advanced, Second line","The number of participants with treatment-related adverse events","NCT03964532","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03964532",1,"DB11760,DB11945","135565082, NA","ENSG00000183023","MONDO_0007254","NA NA NA","pass"
"321",321,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","ARV-471","ESR1 ligand","I","Advanced, Second line","Incidence of Dose Limiting Toxicities, Number of Patients with Adverse Events as a measure of safety and tolerability , ncidence of laboratory abnormalities as a measure of safety and tolerability","NCT04072952","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04072952",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"322",322,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, positive, negative/positive","AND, AND","protein expression, protein expression, protein expression","NIVOLUMAB, PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","PD1, Bcl2, DNA/DNA-topoisomerase II complex, DNA,  hormone receptors","III","Advanced, First line","Pathological Complete response (pCR) Pathological Complete response (pCR), Event-Free Survival (EFS)","NCT04109066","has comparator with different treatments","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04109066",1,"DB09035,DB01229,NA,DB00531,NA","NA, 36314, NA, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"323",323,"BREAST CANCER","ERBB2","Positive","NA","protein expression","KN035, TRASTUZUMAB, DOCETAXEL","PDL1,ERBB2, VEGF/microtuble","II","First line","To estimate the overall response rate (CR + PR) of KN035 in combination with trastuzumab and docetaxel in patients with recurrent or metastatic ERBB2-positive breast cancer.","NCT04034823","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04034823",1,"NA,DB00072,DB01248","NA, 3001322, 148124","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"324",324,"TNBC BREAST CANCER  (STAGE I-III)","ERBB2, ESR1, PGR","negative, negative, negative","AND, AND","protein expression, protein expression, protein expression","RUCAPARIB","PDL1","I","Non-advanced and advanced, First line","Measurement of expression of PD-L1 by IHC via core biopsy","NCT03911453","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03911453",1,"DB12332","9931954","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"325",325,"BREAST CANCER METASTATIC, BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","protein expression, protein expression","GMI-1359","CXCR4/E-selectin/sialyl-Lewis x antigen","I","Non-advanced and advanced, First line","Occurrences of dose-limiting toxicities (DLT) including protocol-defined adverse events (AEs)/serious adverse events (SAEs), and/or laboratory abnormalities will be assessed in order to determine recommended phase II dose (Safety and Tolerability)","NCT04197999","Target found: https://www.ncbi.nlm.nih.gov/pubmed/31877673. However, it is a paper related to prostate cancer. Full paper includes sources that related to hormone dependent breast cancer, that denote the sialyl-lewis x antigen as a target of the drug, however, doesnt mention GMI-1359 directly.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04197999",1,"NA","NA","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"326",326,"BREAST CANCER","ESR1, ERBB2","Positive, Positive","AND","protein expression, protein expression/protein expression & amplification","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, PERTUZUMAB","CDK4/CDK6, aromatase, ERBB2, ERBB2","II","First line","Pathological complete response (pCR)","NCT03644186","has comparator with different treatments","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03644186",1,"DB09073,DB01006,DB00072,DB06366","11478676, 3902, 3001322, NA","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"327",327,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, negative, negative","AND, AND","protein expression, protein expression, protein expression","VRP-ERBB2, PEMBROLIZUMAB","ERBB2 RNA, PD1","II","First line","Number of Tumor infiltrating Lymphocytes and ERBB2 specific antibodies","NCT03632941","in combination with first line treatment","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03632941",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"328",328,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative/positive, negative/positive","AND, AND/OR","protein expression, protein expression, protein expression","ERIBULIN","Tubulin","II","Advanced, Second line","Efficacy of eribulin for treatment of ERBB2-negative BCBM","NCT03637868","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03637868",1,"DB08871","17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"329",329,"ADVANCED BREAST CANCER","ERBB2, PGR,ESR1","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","CDK4/CDK6, aromatase OR aromatase, GnRH receptors","II","Advanced, Second line","Overall Response Rate (ORR)","NCT03822468","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03822468",1,"DB11730,NA,DB00014","44631912, NA, 5311128","ENSG00000141736, ENSG00000082175, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"330",330,"TNBC BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","protein expression, protein expression, protein expression","IPILIMUMAB, NIVOLUMAB","CTLA4, PD1","II","First line","Event-Free Survival","NCT03546686","Expermential group requires surgery, cyroablation.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03546686",1,"DB06186,DB09035","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"331",331,"BREAST CANCER","NA","NA","NA","NA","METFORMIN HYDROCHLORIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","NADPH:ubiquinone oxidoreductase, DNA/DNA-topoisomerase II complex, DNA, Bcl2","II","First line","Evaluation of the effect on tumor proliferation as measured by Ki-67 immunohistochemical (IHC) assessment , Evaluation of the effect on tumor apoptosis as measured by Caspase-3, Chemotherapy toxicities","NCT04170465","They list their biomarkers as: i. Ki-67 ii. Caspase-3 iii. TNF-α","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04170465",1,"NA,DB00997,DB00531,DB01229","14219, 443939, 2907, 36314","ENSG00000183023","MONDO_0007254","NA NA NA","pass"
"332",332,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","PALBOCICLIB, EXEMESTANE, GOSERELIN","CDK4/CDK6, aromatase, GnRH receptors","II","Advanced, First Line","Progression free survival","NCT02917005","has comparator with different treatments","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02917005",1,"DB09073,DB00990,DB00014","11478676, 60198, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"333",333,"LOCALLY-RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","ERIBULIN","Tubulin","II","Advanced, Second line","The overall response rate (ORR)","NCT03795012","has comparator with different treatments, States: ""no prior line of chemotherapy in the metastatic setting"", but requires hormone therapy in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03795012",1,"DB08871","17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"334",334,"NON-METASTATIC PRIMARY LUMINAL BREAST CANCER (STAGE II-III)","ERBB2, ESR1, PGR","Negative, Positive, negative/positive","AND, AND","protein expression, protein expression, protein expression","RIBOCICLIB, LETROZOLE","UNK","II","Non-advanced and advanced, First line","Difference in complete cell cycle arrest","NCT03283384","has comparator with different treatments, States: ""no prior line of chemotherapy in the metastatic setting"", but requires hormone therapy in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03283384",1,"DB11730,DB01006","44631912, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"335",335,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, negative/positive","AND","protein expression, protein expression","ERIBULIN, NIVOLUMAB","UNK","I/II","Advanced, Second line","6 months progression-free survival (PFS) rate","NCT04061863","different experiments, but they use the same drugs. Dependent upon ERBB2 status","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04061863",1,"DB08871,DB09035","17755248, NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"336",336,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, negative/positive, negative/positive","AND/OR, AND/OR","protein expression & amplification, protein expression, protein expression","PEMBROLIZUMAB, TRASTUZUMAB BIOSIMILAR ABP 980, PERTUZUMAB","UNK","II","First line","Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-ERBB2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with ERBB2-enriched early breast cancer assessed by PAM50 testing","NCT03988036","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03988036",1,"DB09037,NA,DB06366","NA, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"337",337,"TNBC BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","protein expression, protein expression, protein expression","CFI-400945, DURVALUMAB","PLK4, PDl1","II","Advanced, Second line","Objective Response Rate of CFI-400945 given with durvalumab using RECIST","NCT04176848","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04176848",1,"NA,DB11714","58486178, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"338",338,"PREMENOPAUSAL OR PERIMENOPAUSAL LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, positive, positive","AND, AND/OR","protein expression, protein expression, protein expression","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","UNK","II","Advanced, First line","Progression Free Survival","NCT03839823","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03839823",1,"DB11730,NA,DB00014","44631912, NA, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"339",339,"RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","NAB-PACLITAXEL","UNK","II","Advanced, First line","Objective Response Rate (ORR)","NCT04194684","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04194684",1,"NA","36314","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"340",340,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","CHIDAMIDE, CISPLATIN","UNK","II","Advanced, Second line","Overall response rate (ORR","NCT04192903","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04192903",1,"DB06334,DB00515","9800555, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"341",341,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein expression&amplification, protein expression, protein expression","PYROTINIB, FULVESTRANT","TK, UNK","II","Advanced, Second line","Progression Free Surviva","NCT04034589","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04034589",1,"DB14993,DB00947","51039030, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"342",342,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","LASOFOXIFENE","ER Receptor","II","Advanced, Second line","Progression-Free Survival (PFS)","NCT03781063","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03781063",1,"DB06202","216416","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"343",343,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","439859","UNK","II","Advanced, Second line","Progression free survival (PFS)","NCT04059484","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04059484",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"344",344,"RECURRENT OR METASTATIC BREAST CANCER","BRCA1,BRCA2, ERBB2","Positive, Positive, Positive","AND/OR, AND","mutation, mutation, protein expression&amplification","OLAPARIB, TRASTUZUMAB","UNK","II","Advanced, Second line","Overall response rate (ORR), Progression-free survival","NCT03931551","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03931551",1,"DB09074,DB00072","23725625, 3001322","ENSG00000012048, ENSG00000139618, ENSG00000141736","MONDO_0007254","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"345",345,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","protein expression&amplification","PYROTINIB COMBINE, SHR6390","TK,CDK4/CDK6","II","Advanced, First&Second line","Objective Response Rate","NCT03993964","only requirement is 4 weeks of of last chemo treatmen. First line or second line","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03993964",1,"NA,NA","NA, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","failed drug"
"346",346,"OCALLY RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein expression, protein expression, protein expression","SHR6390, FULVESTRANT","UNK, UNK","III","Advanced, Second line","Investigator-assessed PFS","NCT03927456","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03927456",1,"NA,DB00947","NA, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"347",347,"RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","protein expression, protein expression, protein expression","SHR6390, ENDROCRINE THERAPY","UNK, UNK","III","Advanced, First line","Investigator-assessed PFS","NCT03966898","Endocrine therapy can be either Letrozole or Anastrozole Tablets","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03966898",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"348",348,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein expression, protein expression, protein expression","ABEMACICLIB, FULVESTRANT","UNK, UNK","IV","Advanced, Second line","Objective Response Rate","NCT04031885","post-menopausal status","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04031885",1,"DB12001,DB00947","46220502, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"349",349,"ADVANCED BREAST CANCER","ERBB2","Positive","NA","protein expression","KN026","UNK","I","Advanced, First&Second line","The proportion of patients experiencing dose limiting toxicities","NCT03847168","also includes gastric cancer, but doesn’t require it","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03847168",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"350",350,"STAGE IV METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","protein expression, protein expression","PEMBROLIZUMAB","UNK","II","Advanced, Second line","Change of objective response rate(ORR)","NCT03492918","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03492918",1,"DB09037","NA","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"351",351,"METASTATIC BREAST CANCER","NA","NA","NA","NA","GOSERELIN","UNK","III","Advanced, Second line","To evaluate and compare the pharmacodynamics","NCT03936933","premenopausal ","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03936933",1,"DB00014","5311128","ENSG00000183023","EFO_1000984","NA NA NA","pass"
"352",352,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein expression","PYROTINIB, VINORELBINE","UNK","II","Advanced, Second line","maximum-tolerated dose","NCT03997539","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03997539",1,"DB14993,DB00361","51039030, 5311497","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"353",353,"RECURRENT BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein expression, protein expression, protein expression","PALBOCICLIB, ENDOCRINE THERAPY","CDK4/CDK6, Hormone receptors","III","Advanced, First line","Duration of invasive disease free survival of all randomized participants","NCT03820830"," receive a drug called an LHRH (luteinizing hormone-releasing hormone) agonist by injection.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03820830",1,"DB09073,NA","11478676, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"354",354,"BREAST CANCER","ERBB2, ESR1","negative, positive","AND","Protein expression, protein expression","DURVALUMAB, ENDOCRINE THERAPY","UNK, aromatase inhibitor","II","First Line","Rate of Modified Preoperative Endocrine Prognostic Index ","NCT03874325","Endocrine therapy can be either Anastrozole or Letrozole or Exemestane (aromatase inhibitor)","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03874325",1,"DB11714,NA","NA, NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"355",355,"TRIPLE NEGATIVE BREAST CANCER","BRCA1,BRCA2, ERBB2, ESR1, PGR","Positive, positive, negative, negative, negative","AND/OR, AND, AND, AND","Mutation, mutation, protein expression, protein expression, protein expression","LYNPARZA","PARP","I","First Line","Measure DNA damage response to PARP inhibition, Characterize changes in ADP ribosylation to PARP inhibition, Correlate DNA damage response to ADP ribosylated proteome","NCT04041128","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04041128",1,"NA","23725625","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"356",356,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVEBREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","KN046, NAB-PACLITAXEL","UNK, UNK","I/II","Advanced, Second line","IRC assessed objective response, IRC assessed duration of response","NCT03872791","Had two different arms","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03872791",1,"NA,NA","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"357",357,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","TTAC-000, PEMBROLIZUMAB","UNK, UNK","I","Advanced, First&Second line","Dose limiting toxicities, Adverse events, Immunogenicity","NCT03720431","only requirement is 2 weeks from having received systemic chemo, or 4 weeks from other investigational drugs","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03720431",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"358",358,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","VINORELBINE, APATINIB","UNK, VEGF2","II","Advanced, Second line","Progress-Free Survival(PFS) ","NCT03932526","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03932526",1,"DB00361,DB14765","5311497, 45139106","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"359",359,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein expression, protein expression","ABEMACICLIB, ANASTROZOLE, FULVESTRANT, LETROZOLE, PALBOCICLIB, RIBOCICLIB","CDK4/CDK6, UNK, UNK, UNK, CDK4/CDK6, CDK4/CDK6","II","Advanced, Second line","To assess progression free survival (PFS) with transition to fulvestrant compared with continuing aromatase inhibitor (AI) therapy in patients with emergence of estrogen receptor 1 (ESR1) mutations in plasma.","NCT04256941","Has different treatment arms, each require the same biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04256941",1,"DB12001,DB01217,DB00947,DB01006,DB09073,DB11730","46220502, 2187, 104741, 3902, 11478676, 44631912","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"360",360,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, negative, negative, positive","AND, AND, AND","Protein expression, protein expression, protein expression, protein expression","PACLITAXEL, NAB-PACLITAXEL, ATEZOLIZUMAB","UNK, UNK, UNK","III","Advanced, First line","Percentage of Participants with treatment-emergent Grade≥3 Aes, Percentage of Participants with treatment-emergent Grade≥2 imAEs","NCT04148911","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04148911",1,"DB01229,NA,DB11595","36314, 36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"361",361,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","TT-00420","UNK","I","Advanced, second line","Maximum Tolerated Dose (MTD) and/or Dose Limiting Toxicity (DLT)","NCT03654547","Included solid tumors in this study. However, TNBC was seperated into a different cohort of the trial.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03654547",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"362",362,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First Line","Pathological complete response (pCR) rate","NCT04083963","must be operable","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04083963",1,"DB00958,DB01229,DB00997,DB00531","56840877, 36314, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"363",363,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","NIRAPARIB","PARP","I","First line","Maximum Tolerated Dose","NCT03945721","Experimental treatment includes radiation therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03945721",1,"DB11793","24958200","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"364",364,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","JS001, GP","UNK, UNK","II","Advanced, First line","Maximum Tolerated Dose (MTD) of JS001 when combined with GP","NCT03251313","the author never directly states what ""GP"" stands for","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03251313",1,"NA,NA","NA, 66793","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"365",365,"EARLY STAGE (I, IIA, IIB, IIIA) BREAST CANCER","ESR1, PGR","Positive, Positive","And/OR","Protein expression, protein expression","","UNK","II","First Line","(Z-)endoxifen plasma concentration ","NCT03931928","This is given with conjuction of tamoxifen, which is the drug acting upon the cancer. The dosing of (z)-endoxifen also depends upon their ""CYP2D6 genetics""","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03931928",1,"NA","NA","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"366",366,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","CAMRELIZUMAB, NAB-PACLITAXEL, FAMITINIB","UNK, UNK, UNK","II","Advanced, First line","ORR","NCT04129996","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04129996",1,"DB14776,NA,DB11741","NA, 36314, 16662431","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"367",367,"RECURRENT OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","protein expression&amplification/protein expression","RECOMBINANT ANTI-HER2 HUMANIZED MONOCLONAL ANTIBODY CONJUGATE","ERBB2","I","Advanced, First&Second line","Maximum Tolerated Dose, Dose-Limiting Toxicity, Immunogenicity assessment, Titer of ADA positive sample, Peak Plasma Time, Peak Plasma Concentration, half-life time, Mean Residence Time( MRT), Area under the plasma concentration versus time curve (AUC), elimination rate constant, clearance rate(CL/F), Objective Remission Rate (ORR): to be defined as the percentage of patients with complete response or partial response. Patients with CR or PR for the first evaluation will be confirmed after 4weeks. Patients without any evaluations are regarded as none-response, Disease Control rate(DCR): to be defined as the percentage of patients with complete response, partial response or stable disease, Duration of response(DOR): to be defined as the duration from the first evaluation time when the patient has CR or PR to the first evaluation time when the patient has disease progression or death, Progression-free survival:to be defined as the duration from the time of first infusion to the first recording time when the patient has disease progression or death","NCT03953833","Just had to stop chemo/hormone therapy before start of the trial","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03953833",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"368",368,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","NAB-PACLITAXEL, EPIRUBICIN, CARBOPLATIN","UNK, UNK, UNK","II","First line","pCR (pathological complete response)","NCT04138719","The purpose of this therapy is to make part of patients operable and to facilitate breast-conserving surgery. Study had different arms, all had to be TNBC","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04138719",1,"NA,DB00445,DB00958","36314, 65348, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"369",369,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, negative/positive, negative/positive","AND, AND","protein expression&amplification/protein expression, protein expression, protein expression","PEGYLATED LIPOSOMAL DOXORUBICIN, TRASTUZUMAB","UNK, UNK","II","Advanced, First line","Objective response rate (ORR)","NCT03933319","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03933319",1,"NA,DB00072","NA, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","failed drug"
"370",370,"ADVANCED BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","protein expression, protein expression","CRIZOTINIB, FULVESTRANT","UNK, oestrogen receptor","II","Advanced, First line","Percentage of Participants With Objective Response Assessed Using RECIST v1.1","NCT03620643","also looked at gastric cancer, but was in separate study arm","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03620643",1,"DB08865,DB00947","11626560, 104741","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"371",371,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","protein expression&amplification/protein expression","PYROTINIB MALEATE, NAB-PACLITAXEL","UNK, UNK","II","Advanced, First line","Progress-free survival(PFS)","NCT03919253","could have been treated for HR in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03919253",1,"NA,NA","138115215, 36314","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"372",372,"METASTATIC BREAST CANCER","ERBB2, APOBEC3B, ER","Negative, Positive, negative/positive","AND, AND","protein expression, mutation, protein expression","PEMBROLIZUMAB","UNK","II","Advanced, Second line","Overall response rate (ORR)","NCT03989089","researchers listed APOBEC3BE as a biomarker in this trial","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03989089",1,"DB09037","NA","ENSG00000141736, ENSG00000179750, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND APOBEC3B MUTATION POSITIVE AND ER PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"373",373,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE, OLAPARIB","UNK, UNK, UNK, UNK","II/III","Advanced, First line","Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 , Overall Survival (OS)","NCT04191135","looked at different drug combinations. Both arms required the same biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04191135",1,"DB09037,DB00958,DB00441,DB09074","NA, 56840877, 60750, 23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"374",374,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","TQB2450, ANLOTINIB HYDROCHIORIDE","PDL1, UNK","I","Second Line","Overall Response Rate(ORR)","NCT03855358","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03855358",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"375",375,"EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, negative/positive, negative/positive","AND, AND","protein expression&amplification/protein expression, protein expression, protein expression","PYROTINIB, TRASTUZUMAB, VINORELBINE","HER1/HER2, UNK, UNK","UNK","First Line","Objective Response Rate","NCT03947242","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03947242",1,"DB14993,DB00072,DB00361","51039030, 3001322, 5311497","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"376",376,"EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","ERBB2","Positive","NA","protein expression&amplification/protein expression","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK, UNK","UNK","First Line","Percentage of Participants With Pathological Complete Response","NCT03847818","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03847818",1,"DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"377",377,"LOCALLY ADVANCED","ERBB2, ESR1","Positive, negative/positive","AND","protein expression&amplification/protein expression, protein expression","DOCETAXEL, ATEZOLIZUMAB, TRASTUZUMAB SC, PERTUZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, HERCEPTIN SC","UNK, UNK, UNK, UNK, UNK, UNK, UNK","I/II","First Line","Pathologic CR(pCR) rate of neo-adjuvant chemotherapy","NCT03881878","Patients with locally advanced breast cancer (T2-3N0-3), Patients with early breast cancer with high-risk (T1cN1), Patients with locally advanced inflammatory breast cancer","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03881878",1,"DB01248,DB11595,NA,DB06366,DB00997,DB00531,NA","148124, NA, NA, NA, 443939, 2907, NA","ENSG00000141736, ENSG00000091831","EFO_0005856","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"378",378,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, negative/positive, negative/positive","AND, AND/OR","Protein expression, protein expression, protein expression","TUCATINIB, T-DM1","UNK, UNK","III","Advanced, Second line","Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessment","NCT03975647","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03975647",1,"DB11652,DB05773","51039094, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"379",379,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, negative, negative","AND, AND","Protein expression, protein expression, protein expression","SPARTALIZUMAB, LAG525, NIR178, CAPMATINIB, MCS110, CANAKINUMAB","UNK, UNK, UNK, UNK, UNK, UNK","I","Advanced, Second line","Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety, Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety, Incidence of dose limiting toxicities (DLTs) of treatment, Frequency of dose interuptions, Frequency of dose reductions, Dose intensities","NCT03742349","Different treatment arms, all had the same biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03742349",1,"DB14892,NA,NA,DB11791,NA,DB06168","NA, NA, NA, 25145656, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"380",380,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein expression, protein expression, protein expression","TAMOXIFEN CITRATE","aromatase","II","First Line","Ten year breast cancer free interval, Ten year contralateral breast cancer incidence","NCT03917082","Must be older than 50 at diagnosis","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03917082",1,"NA","2733525","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"381",381,"EARLY OR LOCALLY ADVANCED INVASICE BREAST CANCER","ERBB2","Positive","NA","protein expression&amplification","SIBP-01, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK","III","First Line","Total pathologic complete response (tpCR","NCT03989037","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03989037",1,"NA,DB01248,DB00958","NA, 148124, 56840877","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","failed drug"
"382",382,"BREAST CANCER","NA","NA","NA","NA","DOCETAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, HUMAN RECOMBIANT ENOSTATIN","UNK, UNK, UNK","II/III","First Line","Clinical/pathological response","NCT01907529","no biomarkers noted","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT01907529",1,"DB01248,DB00445,DB00531,NA","148124, 65348, 2907, NA","ENSG00000183023","MONDO_0007254","NA NA NA","pass"
"383",383,"METASTATIC BREAST CANCER","ERBB2","negative","NA","protein expression","NAVELBINE","UNK","II","Advanced, Second line","Disease Control Rate","NCT03854617","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03854617",1,"NA","5311497","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"384",384,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","CARBOPLATIN, PACLITAXEL","UNK, UNK","III","First line","3-year disease-free survival","NCT03876886","complete tumor removal by either modified radical mastectomy or local excision plus axillary lymph node dissection","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03876886",1,"DB00958,DB01229","56840877, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"385",385,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","BERZOSERTIB","ATR Kinase","I","Second line","Recommended phase II dose of ATR kinase inhibitor M6620","NCT04052555","must be done with radiation therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04052555",1,"DB11794","59472121","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"386",386,"BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein expression, Protein expression","BERZOSERTIB","ATR Kinase","I","Second line","Recommended phase II dose of ATR kinase inhibitor M6620","NCT04052555","must be done with radiation therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04052555",1,"DB11794","59472121","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"387",387,"LOCALLY RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","ERYASPASE, GEMCITABINE, CARBOPLATIN","UNK, UNK, UNK","II/III","Advanced, First line","Objective response rate (ORR) ","NCT03674242","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03674242",1,"NA,DB00441,DB00958","NA, 60750, 56840877","ENSG00000141736, NA, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","failed drug"
"388",388,"LUMINAL B BREAST CANCER","ERBB2, ERS1, Ki67, PDL1","Negative, Positive, Negative/Positive, Positive","AND, AND, AND","Protein Expression, Protein expression, Protein expression, Protein Expression","OLECLUMAB, DURVALUMAB","CD73, PDL1","II","First line","Safety Run-in: Immune related or radiation therapy related toxicity of special interest, Safety Run-in: Primary surgery, Phase II: Tumour response in arms 2 or 3 versus arm 1","NCT03875573","Confirmed Mammaprint genomic high risk score according to central testing (Ki67 >20%). Different arms with different drugs, all combined with radiotherapy. The trial called for a phase I ""saftey check"" with 6 participants, but did not lay out the biomarkers for that phase. It seemed that all would have the same biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03875573",1,"DB15088,DB11714","NA, NA","ENSG00000141736, NA, ENSG00000148773, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"389",389,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","CARBOPLATIN, IPATASERTIB, PACLITAXEL","UNK, UNK, UNK","I/II","Advanced, Second Line","Recommended phase II dose (RP2D) of ipatasertib (Phase I), Progression-free survival (PFS) (Phase II)","NCT03853707","different experimental groups with the same biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03853707",1,"DB00958,DB11743,DB01229","56840877, 24788740, 36314","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"390",390,"ADVANCED BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","PALBOCICLIB, ENDOCRINE THERAPY","UNK, UNK","II","Advanced, First line","PFS (Progression-free survival)","NCT03809988","endocrine therapy is letrozole or fulvestrant","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03809988",1,"DB09073,NA","11478676, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"391",391,"LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","CAPIVASERTIB, PACLITAXEL","UNK, UNK","III","Advanced, Second Line","Progression-Free Survival (PFS), Overall Survival (OS) ","NCT03997123","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03997123",1,"DB12218,DB01229","25227436, 36314","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"392",392,"EARLY BREAST CANCER","ERBB2, ERS1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","DOXORUBICIN LIPOSOME, CYCLOPHOSPHAMIDE, TRASTUZUMAB, DOCETAXEL","UNK, UNK, UNK, UNK","II","First line","Pathological Complete Response rate (pCR)","NCT04172259","HR status just needed to be known","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04172259",1,"NA,DB00531,DB00072,DB01248","NA, 2907, 3001322, 148124","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","failed drug"
"393",393,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR, AR, PTEN","Negative,Positive,Positive, Positive, Positive","AND, AND/OR, AND, AND","Protein Expression, Protein expression, Protein expression, Protein Expression, Mutation","ALPELISIB, ENZALUTAMIDE","Phosphoinositide 3-kinase, UNK","I","Advanced, Second Line","Maximum tolerated dose (MTD) of alpelisib in combination with enzalutamide","NCT03207529","AR positivity is defined as >= 1% of nuclear staining","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03207529",1,"DB12015,DB08899","56649450, 15951529","ENSG00000141736, NA, ENSG00000082175, ENSG00000169083, ENSG00000171862","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","pass"
"394",394,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR, AR, PTEN","Negative, Negative, Negative, Positive, Positive","AND, AND/OR, AND, AND","Protein Expression, Protein expression, Protein expression, Protein Expression, Mutation","ALPELISIB, ENZALUTAMIDE","Phosphoinositide 3-kinase, UNK","I","Advanced, Second Line","Maximum tolerated dose (MTD) of alpelisib in combination with enzalutamide","NCT03207529","AR positivity is defined as >= 1% of nuclear staining","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03207529",1,"DB12015,DB08899","56649450, 15951529","ENSG00000141736, NA, ENSG00000082175, ENSG00000169083, ENSG00000171862","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","pass"
"395",395,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","IPATASERTIB, RUCAPARIB","UNK, UNK","I","Advanced, Second Line","Percentage of Participants with Adverse Events, Percentage of Participants with Dose-Limiting Toxicities (DLTs) that Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination, Percentage of Participants with Prostate-Specific Antigen (PSA) Response","NCT03840200","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03840200",1,"DB11743,DB12332","24788740, 9931954","ENSG00000141736, NA, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"396",396,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND/OR","Protein Expression, Protein expression, Protein expression","IPATASERTIB, RUCAPARIB","UNK, UNK","I","Advanced, Second Line","Percentage of Participants with Adverse Events, Percentage of Participants with Dose-Limiting Toxicities (DLTs) that Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination, Percentage of Participants with Prostate-Specific Antigen (PSA) Response","NCT03840200","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03840200",1,"DB11743,DB12332","24788740, 9931954","ENSG00000141736, NA, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE","pass"
"397",397,"ADVANCED BREAST CANCER","ERBB2, ERS1, PGR, PTEN, PIK3CA","Positive, Negative/Positive, Negative/Positive, Positive, Positive","AND, AND, AND, AND","Protein expression&amplification, Protein Expression, Protein expression, Mutation, Mutation","PERTUZUMAB, TRASTUZUMAB, COPANLISIB","UNK, ERBB2, UNK","I/II","Advanced, First line","Incidence of adverse events and serious adverse events (Phase Ib), Incidence of dose limiting toxicities (DLTs) (Phase Ib), Progression-free survival (PFS) (Phase II)","NCT04108858","PHASE IB/SAFETY RUN-IN ONLY: Molecular biomarker selection will not be mandated, did select for phase II","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04108858",1,"DB06366,DB00072,DB12483","NA, 3001322, 135565785","ENSG00000141736, NA, ENSG00000082175, ENSG00000171862, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PTEN MUTATION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"398",398,"METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","ERBB2","Negative","NA","Protein Expression","PACLITAXEL, TALIMOGENE LAHERPAREPVEC","UNK, UNK","I","Advanced, Second Line","Distribution for the maximum observed grade for each adverse event of talimogene laherparepvec in both arms, Maximum tolerated volume defined as the highest volume (up to 4mL) that results in ≤ 1 dose limiting toxicity in 6 treated patients for each treatment cohort","NCT03554044","had different cohorts with different drug combinations, depending upon biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03554044",1,"DB01229,DB13896","36314, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"399",399,"METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","ERBB2, ERS1","Negative, Positive","AND","Protein Expression, Protein Expression","TAMOXIFEN, TALIMOGENE LAHERPAREPVEC, LETROZOLE, FULVESTRANT, EXEMESTANE, ANASTROZOLE","UNK, UNK, UNK, UNK, UNK, UNK","I","Advanced, Second Line","Distribution for the maximum observed grade for each adverse event of talimogene laherparepvec in both arms, Maximum tolerated volume defined as the highest volume (up to 4mL) that results in ≤ 1 dose limiting toxicity in 6 treated patients for each treatment cohort","NCT03554044","had different cohorts with different drug combinations, depending upon biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03554044",1,"DB00675,DB13896,DB01006,DB00947,DB00990,DB01217","2733526, NA, 3902, 104741, 60198, 2187","ENSG00000141736, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","pass"
"400",400,"METASTATIC BREAST CANCER","ERBB2, ERS1, PIK3CA, PTEN","Negative, Positive, Negative/Positive, Negative/Positive","AND, AND, AND","Protein Expression, Protein Expression, Mutation, Mutation","COPANLISIB, FULVESTRANT","PI3K, UNK","I/II","Advanced, Second Line","Dose limiting toxicity (DLT)","NCT03803761","post menopausal only","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03803761",1,"DB12483,DB00947","135565785, 104741","ENSG00000141736, NA, ENSG00000121879, ENSG00000171862","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION NEGATIVE/POSITIVE AND PTEN MUTATION NEGATIVE/POSITIVE","pass"
"401",401,"STAGE IV TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","AVELUMAB, BINIMETINIB, PF-04518600, UTOMILUMAB","UNK, UNK, OX40, UNK","II","Advanced, Second Line","Best Overall Response Rate (BORR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","NCT03971409","different experimental groups with the same biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03971409",1,"DB11945,DB11967,NA,DB15113","NA, 10288191, NA, NA","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"402",402,"ADVANCED INVASIVE BREAST CANCER","ERBB2, ERS1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","PYROTINIB, TRASTUZUMAB, AROMATASE INHIBITORS","UNK, UNK, Aromatase","II","Advanced, First line","Progression-Free Survival (PFS)","NCT04088110","aromatase inhibitors include : anastrozole, letrozole or exemestane","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04088110",1,"DB14993,DB00072,NA","51039030, 3001322, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"403",403,"ADVANCED BREAST CANCER","ERBB2, ERS1","Negative, Positive","AND","Protein Expression, Protein Expression","ODM-209","UNK","I/II","Advanced, Second Line","Maximum tolerated dose (MTD) ","NCT03878823","drug is co-administered with glucocorticoid and mineralocorticoid. Different cancers are treated in this trial. However, BC has a separate cohort and specific biomarkes","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03878823",1,"NA","NA","ENSG00000141736, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","failed drug"
"404",404,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","LEFLUNOMIDE","dihydroorotate dehydrogenase","I/II","Advanced, Second Line","Maximum Tolerated Dose (MTD), Clinical Benefit Rate (CBR)","NCT03709446","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03709446",1,"DB01097","3899","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"405",405,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR, PDL1","Negative, Negative, Negative, Negative/positive","AND, AND, AND","Protein Expression, Protein expression, Protein expression, protein expression","TESETAXEL, NIVOLUMAB, PEMBROLIZUMAB, ATEZOLIZUMAB","UNK, UNK, UNK, UNK","II","Advanced, First line","Cohort 1: ORR , Cohort 1: PFS, Cohort 2: ORR","NCT03952325","Cohorts are separated by age and biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03952325",1,"DB12019,DB09035,DB09037,DB11595","6918574, NA, NA, NA","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"406",406,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","TESETAXEL","UNK, UNK, UNK, UNK","II","Advanced, First line","Cohort 1: ORR , Cohort 1: PFS, Cohort 2: ORR","NCT03952325","Cohorts are separated by age and biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03952325",1,"DB12019","6918574","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"407",407,"BREAST DUCTAL CARCINOMA IN SITU","BRCA1, BRCA2, ESR1","Negative, Negative, Positive","AND, AND","Mutation, Mutation, Protein Expression","TAMOXIFEN","UNK","III","First line","Breast tumor recurrence","NCT04046159","was compared to radiotherapy, must be newly diagnosed","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04046159",1,"DB00675","2733526","ENSG00000012048, ENSG00000139618, ENSG00000091831","EFO_0000432","BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"408",408,"EARLY STAGE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","CELECOXIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, RECOMBINANT INTERFERON ALFA-2B, RINTATOLIMOD","UNK, UNK, UNK, UNK, UNK, UNK, UNK","I","First line","Tumor-infiltrating CD8+ cytotoxic T lymphocyte (CTL)s pre-treatment vs post-treatment","NCT04081389","chemokine modulation therapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04081389",1,"DB00482,DB00531,DB00997,NA,DB01229,NA,NA","2662, 2907, 443939, 443939, 36314, NA, 135537060","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"409",409,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR, PDL1","Positive, Negative/Positive, Negative/Positive, Positive","AND, AND, AND","Protein expression&amplification, Protein Expression, Protein expression, protein expression","ATEZOLIZUMAB, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB","UNK, UNK, UNK, ERBB2","III","Advanced, Second Line","Progression free survival ","NCT03199885","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03199885",1,"DB11595,DB01229,DB06366,DB00072","NA, 36314, NA, 3001322","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"410",410,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","CYCLOPHOSPHAMIDE, LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN","UNK, UNK","I","Advanced, First line","Incidence of adverse events assessed by CTCAE v 5.0 , Incidence of dose limiting toxicities, Incidence of necessity for dose adjustments, delay or early cessation, Incidence and severity of post-procedural pain, Patient reported tolerability via an adapted version of the Cancer Therapy Satisfaction Questionnaire (CTSQ), Patient reported tolerability via the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire, Incidence of cardiotoxity, Description of MR thermometry data (describing the temperatures achieved), Duration of procedures on a treatment day , Number of completed cycles with MR-HIFU induced hyperthermia, The number of cycles in which hyperthermia was sufficient: at least 30 minutes at the target temperature of 40-42°C","NCT03749850","Used with MR-HIFU induced hyperthermia","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03749850",1,"DB00531,NA","2907, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"411",411,"STAGE IIB-III TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","ATORVASTATIN","UNK","II","Advanced&Non-advanced, Second line","Proportions of patients with undetectable circulating tumor cells (CTC","NCT03872388","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03872388",1,"DB01076","60823","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"412",412,"LOCALIZED BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","UNK, UNK, UNK","I","First line","Incidence and severity of adverse events (AEs)","NCT04185311","includes different biomarker combonations","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04185311",1,"DB06186,DB09035,DB13896","NA, NA, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"413",413,"LOCALIZED BREAST CANCER","ERBB2, ERS1","Negative, Positive","AND","Protein Expression, Protein Expression","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","UNK, UNK, UNK","I","First line","Incidence and severity of adverse events (AEs)","NCT04185311","includes different biomarker combonations","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04185311",1,"DB06186,DB09035,DB13896","NA, NA, NA","ENSG00000141736, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","pass"
"414",414,"BREAST CANCER","ERBB2","Positive","NA","Mutation","POZIOTINIB HYDROCHLORIDE","UNK","II","Advanced, First&Second  line","Objective Response Rate (ORR)","NCT04172597","included other cancers, but had the specific breast cancer trial specifically explained. ""Patients with breast or gastric cancers with HER2 copy number alterations/amplifications/over expressions and no HER2 activating mutations.""","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04172597",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 MUTATION POSITIVE","failed drug"
"415",415,"LOCALLY ADVANCED","ERBB2, ERS1","Negative, Positive","AND","Protein Expression, Protein Expression","ALRN-6924, PACLITAXEL","MDM2/MDMX, UNK","I","Advanced, First&Second line","Maximum tolerated dose (MTD) of combination of ALRN-6924 and paclitaxel, defined as the isotonic estimate of the toxicity rate closest to 0.30","NCT03725436","Expansion cohort only: estrogen receptor (ER) positive (> 1%), human epidermal growth factor 2 (HER2) negative, WT TP53 metastatic or inoperable locally advanced or locally recurrent breast cancer. Patients can be HER2 0+ or 1+, 2+ or FISH non-amplified to be considered HER2 negative.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03725436",1,"NA,DB01229","NA, 36314","ENSG00000141736, NA","EFO_0005856","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","failed drug"
"416",416,"REFRACTORY OR RELAPSED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE, GX-I7","UNK, UNK, UNK","I/II","Advanced&Non-Advanced,, Second Line","Incidence and nature of DLTs, Incidence, nature and severity of adverse events, Objective response rate (ORR)","NCT03752723","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03752723",1,"DB09037,DB00531,NA","NA, 2907, NA","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"417",417,"EARLY BREAST CANCER","ERBB2","Positive","NA","Protein Expression","TRASTUZUMAB","UNK","III","First line","Rate of Adverse Events, Immunogenicity Assessments, Disease-Free Survival, Overall Survival","NCT04109391","did not say HER+ in criteria, but stated it explictly throughout the trial","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04109391",1,"DB00072","3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"418",418,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","RUCAPARIB, SACITUZUMAB GOVITECAN","UNK, UNK","I/II","Advanced, Second Line","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Number of participants who experience dose limiting toxicity as defined in the protocol, Overall Response Rate","NCT03992131","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03992131",1,"DB12332,DB12893","9931954, 91668186","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"419",419,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","PYROTINIB, TRASTUZUMAB, AROMATASE INHIBITOR","UNK, UNK, Aromatase","II","Advanced, First line","Progression-Free Survival (PFS)","NCT03910712","The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane)","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03910712",1,"DB14993,DB00072,NA","51039030, 3001322, NA","ENSG00000141736, NA, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"420",420,"BREAST CANCER","ERBB2, ERS1, PGR, Ki67","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein expression, Protein expression, Protein Expression","PALBOCICLIB, LETROZOLE","UNK. UNK","I","Second line","Complete Cell Cycle Arrest (CCCA)","NCT04130152","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04130152",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, NA, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"421",421,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR, EphA2","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein expression, Protein expression, Protein Expression","BT5528, NIVOLUMAB","EphA2, UNK","I/II","Advanced, First&Second  line","Number of participants receiving BT5528 alone and in combination with nivolumab with treatment-emergent adverse events, Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities from BT5528 treatment alone and in combination with nivolumab , Objective response rate by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab, Duration of response by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab, Clinical benefit rate by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab , Time to tumor progression by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab, Progression free survival by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab, Progression free survival at 6 months by RECIST 1.1 in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab, Overall survival at 1 year in participants with selected solid tumor indications receiving BT5528 treatment alone and in combination with nivolumab","NCT04180371","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04180371",1,"NA,DB09035","NA, NA","ENSG00000141736, NA, ENSG00000082175, ENSG00000142627","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND EPHA2 PROTEIN EXPRESSION POSITIVE","failed drug"
"422",422,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","ATEZOLIZUMAB, G100","UNK, UNK","II","Advanced, First&Second line","Assessment of the antitumor activity of atezolizumab combined with G100 and radiotherapy (independently for each population).","NCT03915678","Included other cancers, but had the specific breast cancer trial specifically explained, also required radiotherapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03915678",1,"DB11595,NA","NA, 159968","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"423",423,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","DKY709, PDR001","UNK, PDL1/PDL2","I","Advanced, Second Line","Safety of DKY709 single agent treatment or DKY709 in combination with PDR001, incidence of Dose Limiting Toxicities, Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR00","NCT03891953","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03891953",1,"NA,NA","NA, NA","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"424",424,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","TRX518, CYCLOPHOSPHAMIDE, AVELUMAB","UNK, UNK, UNK","I/II","Advanced, Second Line","Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0), Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ± avelumab, Efficacy in Breast and Ovarian Cancer Groups: objective response rate","NCT03861403","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03861403",1,"NA,DB00531,DB11945","NA, 2907, NA","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"425",425,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein expression, Protein expression","TRX518, CYCLOPHOSPHAMIDE, AVELUMAB","UNK, UNK, UNK","I/II","Advanced, Second Line","Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0), Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ± avelumab, Efficacy in Breast and Ovarian Cancer Groups: objective response rate","NCT03861403","Included other cancers, but had the specific breast cancer trial specifically explained. Only postmenopausal women are eligible","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03861403",1,"NA,DB00531,DB11945","NA, 2907, NA","ENSG00000141736, NA, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"426",426,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","TREMELIMUMAB, DURVALUMAB","CTLA4, PDL1","II","Advanced, Second Line","Objective tumour response rate","NCT03982173","Included other cancers, but had the specific breast cancer trial specifically explained","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03982173",1,"DB11771,DB11714","NA, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"427",427,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein expression, Protein expression","CB-839, TALAZOPARIB","UNK, UNK","I/II","Advanced, First&Second line","Safety and tolerability of CB-839 in combination with talazoparib: Number of participants with treatment related adverse events, Maximum tolerated dose and/ or Recommended Phase 2 Dose","NCT03875313","Exclusions: Receipt of any anticancer therapy within the following windows: small molecule tyrosine kinase inhibitor therapy (including investigational) within the prior 2 weeks or 5 half-lives prior to C1D1, whichever is longer; any type of anti-cancer antibody or cytotoxic chemotherapy within 4 weeks prior to C1D1; radiation therapy for bone metastasis within 2 weeks prior or any other external radiation therapy within 4 weeks prior to C1D1; patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03875313",1,"NA,DB11760","71577426, 135565082","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"428",428,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","IPATASERTIB, FULVESTRANT, LETROZOLE, PALBOCICLIB","AKT, UNK, Aromatase, CDK4/CDK6","I","Advanced, Second line","Incidence of Treatment-Emergent Adverse Events ","NCT03959891","Had different drug combinations, for postmenopausal women only","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03959891",1,"DB11743,DB00947,DB01006,DB09073","24788740, 104741, 3902, 11478676","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"429",429,"INVASIVE DUCTAL BREAST CANCER (STAGES I-III)","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","TAMOXIFEN CITRATE, LETROZOLE, EXEMESTANE","UNK, UNK, UNK","II","Advanced&Non-advanced, First Line","Change in percent expression of Ki67 measured by immunohistochemistry, Change in percent expression of Ki67 measured by single-gene read out","NCT04129216","Trial treats pts, but were also studying the changes in genetic profiles","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04129216",1,"NA,DB01006,DB00990","2733525, 3902, 60198","ENSG00000141736, NA, ENSG00000082175","EFO_0000186","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"430",430,"NON-METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PELAREOREP, LETROZOLE, ATEZOLIZUMAB","UNK, UNK, UNK","II","First Line","Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with operable early breast cancer treated with pelareorep in combination with different therapies. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery","NCT04102618","only postmenopausal women","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04102618",1,"NA,DB01006,DB11595","NA, 3902, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"431",431,"NON-METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, PELAREOREP","UNK, UNK","II","First Line","Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with operable early breast cancer treated with pelareorep in combination with different therapies. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery","NCT04102618","only postmenopausal women","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04102618",1,"DB11595,NA","NA, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"432",432,"NON-METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Positive, Positive, Positive","AND, AND","Protein Expression&amplification, protein expression, protein expression","PELAREOREP, TRASTUZUMAB, ATEZOLIZUMAB","UNK, UNK, UNK","II","First Line","Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with operable early breast cancer treated with pelareorep in combination with different therapies. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery","NCT04102618","only postmenopausal women","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04102618",1,"NA,DB00072,DB11595","NA, 3001322, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"433",433,"NON-METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression&amplification, protein expression, protein expression","PELAREOREP, TRASTUZUMAB, ATEZOLIZUMAB","UNK, UNK, UNK","II","First Line","Changes from baseline in a score for tumor cellularity and tumor infiltrating lymphocytes (CelTIL score) in women with operable early breast cancer treated with pelareorep in combination with different therapies. [ Time Frame: The CelTIL score will be measured from on-treatment tumor biopsies collected at baseline (pre-treatment), day 3, and at time of surgery","NCT04102618","only postmenopausal women","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04102618",1,"NA,DB00072,DB11595","NA, 3001322, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"434",434,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ERS1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND/OR","Protein Expression&amplification, protein expression, protein expression","PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, CARBOPLATIN, PEGFILGRASTIM","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","II","First Line","pCR rates ","NCT03329378","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03329378",1,"DB06366,DB00072,DB01229,DB00997,DB00531,DB01248,DB00958,DB00019","NA, 3001322, 36314, 443939, 2907, 148124, 56840877, NA","ENSG00000141736, NA, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"435",435,"INVASIVE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, OLAPARIB, AZD6738","PDL1, PARP, ATR","II","First Line","Cohorts B and C co-primary endpoint #1: Change in mean proliferation index (as measured by tumour cell Ki67 immunohistochemistry) post WOP intervention within post-treatment biopsy compared to pre-treatment baseline biopsy, Cohorts B and C co-primary endpoint #2: Changes in the proliferation gene expression signature post WOP intervention within the post-treatment biopsy compared to pre-treatment baseline biopsy, Cohort D co-primary endpoint #1: Change in CD8+ TILs post anti-PD-L1 immunotherapy within the post-treatment biopsy compared to pre-treatment baseline biopsy, assessed using immunohistochemistry, Cohort D co-primary endpoint #2: Changes in the interferon gamma-positive (IFNγ+) signature post WOP intervention within the post-treatment biopsy compared to pre-treatment baseline biopsy","NCT03740893","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03740893",1,"DB11714,DB09074,NA","NA, 23725625, 54761306","ENSG00000141736, NA, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"436",436,"METASTATIC BREAST CANCER","ERBB2, ERS1","Negative, Positive","AND","Protein Expression, Protein Expression","NIVOLUMAB, NAB-PACLITAXEL, IPILIMUMAB","UNK, UNK, UNK","I","Advanced, Second line","Incidence of Adverse Events (AEs), Incidence of Serious Adverse Events (SAEs), Adverse Events (AEs) leading to dose and asset limiting toxicity (DALT), Adverse Events (AEs) leading to discontinuation, Incidence of laboratory abnormalities","NCT04132817","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04132817",1,"DB09035,NA,DB06186","NA, 36314, NA","ENSG00000141736, NA","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","pass"
"437",437,"METASTATIC BREAST CANCER","ERBB2, ERS1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LY3295668 ERBUMINE, MIDAZOLAM, ENDOCRINE THERAPY","UNK, UNK, UNK, UNK","I","Advanced, First line","Number of Participants with Dose Reductions , Part II: Number of Participants with Dose Limiting Toxicities (DLTs), Overall Response Rate (ORR), Duration of Response (DoR)","NCT03955939","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03955939",1,"NA,DB00683,NA","NA, 4192, NA","ENSG00000141736, NA, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"438",438,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ERS1, PGR, FGFR2","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","FUTIBATINIB, FULVERSTRANT","FGFR, UNK","II","Advanced, Second line","Overall Response Rate (ORR) , Clinical Benefit Rate (CBR), 6-month Progression-free Survival (PFS) rate","NCT04024436","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04024436",1,"DB15149,NA","71621331, NA","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"439",439,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ERS1, PGR, FGFR2","Negative, Negative, Negative, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","FUTIBATINIB","FGFR","II","Advanced, Second line","Overall Response Rate (ORR) , Clinical Benefit Rate (CBR), 6-month Progression-free Survival (PFS) rate","NCT04024436","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04024436",1,"DB15149","71621331","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"440",440,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ERS1, PGR, FGFR1","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","FUTIBATINIB, FULVERSTRANT","FGFR, UNK","II","Advanced, Second line","Overall Response Rate (ORR) , Clinical Benefit Rate (CBR), 6-month Progression-free Survival (PFS) rate","NCT04024436","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04024436",1,"DB15149,NA","71621331, NA","ENSG00000141736, NA, ENSG00000082175, ENSG00000077782","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"441",441,"UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ERS1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","GEDATOLISIB, TALAZOPARIB","PI3K/mTOR, PARP","I/II","Advanced, Second line","Maximum Tolerated Dose (MTD) of talazoparib in combination with gedatolisib, Objective Response Rate (ORR) (Phase II)","NCT03911973","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03911973",1,"DB11896,DB11760","44516953, 135565082","ENSG00000141736, NA, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"442",442,"UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Mutation, Mutation","GEDATOLISIB, TALAZOPARIB","PI3K/mTOR, PARP","I/II","Advanced, Second line","Maximum Tolerated Dose (MTD) of talazoparib in combination with gedatolisib, Objective Response Rate (ORR) (Phase II)","NCT03911973","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03911973",1,"DB11896,DB11760","44516953, 135565082","ENSG00000141736, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"443",443,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression&amplification","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","UNK, UNK, UNK","II","First Line","Pathological complete response (ypT0/is ypN0) rate","NCT03907800","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03907800",1,"NA,DB00958,NA","36314, 56840877, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"444",444,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","UNK, UNK, UNK","II","First Line","Pathological complete response (ypT0/is ypN0) rate","NCT03907800","had different cohorts with different biomarkers","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03907800",1,"NA,DB00958,NA","36314, 56840877, NA","ENSG00000141736, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE","pass"
"445",445,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, B7H3","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ABBV-155, PACLITAXEL","UNK, UNK","I","Advanced, Second Line","MTD and/or RPTD of ABBV-155, Objective Response Rate (ORR)","NCT03595059","locally advanced or metastatic HR-positive/HER2-negative breast cancer after failing cyclindependent kinase (CDK)4/6 inhibitor-based therapy. Other cancers studied, BC is in phase 2b.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03595059",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000103855","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND B7H3 PROTEIN EXPRESSION POSITIVE","failed drug"
"446",446,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","FLX475, PEMBROLIZUMAB","UNK, UNK","I, II","Advanced, Second Line","Safety and tolerability of FLX475 as a single agent and in combination with pembrolizumab measured by the incidence of adverse events, including dose-limiting toxicities and maximum tolerated dose, Overall response rate in subjects treated with FLX475 as a single agent and in combination with pembrolizumab","NCT03674567","FLX475 is also tested as a monotherapy. Must be ineligible for standard therapies","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03674567",1,"DB15570,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"447",447,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER, INFLAMMATORY BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","REBASTINIB, PACLITAXEL","UNK, UNK","I, II","Advanced, First Line, Second Line","Adverse Events (Part 1 and Part 2) , Objective response rate (ORR) (Part 2)","NCT03601897","Other cancers studied, Breast cancer is in experiment 2","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03601897",1,"DB13005,DB01229","25066467, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"448",448,"ADVANCED BREAST CANCER","FGFR","Positive","NA","missing","EOC317","UNK","I","Advanced, Second Line","DLT","NCT03583125","""confirmed FGFR alterations"". Patients who have disease progression after previous standard of care therapy, or are unable to tolerate standard of care therapy, or have no available standard of care therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03583125",1,"NA","23653175","ENSG00000068078","MONDO_0007254","FGFR MISSING POSITIVE","pass"
"449",449,"ADVANCED BREAST CANCER","ERBB2","Negative","NA","Protein Expression","E7130","UNK","I","Advanced, Second Line","Part 1: Number of participants assigned to the every 2 weeks regimen with dose-limiting toxicities (DLTs), Part 1: Number of participants assigned to the every 3 weeks regimen with DLTs, Part 1 and Part 2: Number of participants with adverse events (AEs), Part 1 and Part 2: Number of participants with any clinically significant clinical laboratory test value, Part 1 and Part 2: Number of participants with any clinically significant vital sign value, Part 1 and Part 2: Change from Baseline in arterial oxygen saturation, Part 1 and Part 2: Change from Baseline in body weight, Part 1 and Part 2: Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value , Part 1 and Part 2: Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)","NCT03444701","Breast cancer is studied in part two of this trial. Experiments differ on length of regimen. Female participants who had received at least an anthracycline and/or taxane treatment for the neoadjuvant/adjuvant or chemotherapy for refractory or relapse breast cancer and progressed radiographically. Active viral hepatitis (B or C) (*) as demonstrated by positive serology or requiring treatment (*)hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs)/hepatitis B core antibody (HBcAb) and anti-hepatitis C virus (HCV) antibody test","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03444701",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"450",450,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","absent","NA","NA","NA","DURVALUMAB, TREMELIMUMAB, METRONOMIC VINORELBINE","UNK, UNK, UNK","I, II","Advanced, Second Line","Maximum Tolerated Dose (MTD) and the phase II recommended dose (RP2D), CBR-24week","NCT03518606","must be resistant to conventional therapies. Multiple cancers, breast cancer is listed in a separate cohort","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03518606",1,"DB11714,DB11771,NA","NA, NA, NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"451",451,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","INCAGN02385","UNK","I","Advanced, Second Line","Number of treatment-emergent adverse events (TEAEs) ","NCT03538028","Disease progression after treatment with available therapies that are known to confer clinical benefit, or intolerant to treatment, or refuse noncurative standard treatment. There is no limit to the number of prior treatment regimens","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03538028",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"452",452,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","INCAGN02390","UNK","I","Advanced, Second Line","Number of treatment-emergent adverse events, Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390","NCT03652077","Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03652077",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"453",453,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NKTR-262, BEMPEGALDESLEUKIN, NIVOLUMAB","TLR7/TLR8, CD122, UNK","I, II","Advanced, Second Line","Safety of NKTR-262 in combination with NKTR-214/nivolumab as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs leading to discontinuation, deaths, and clinical laboratory abnormalities per CTCAE, Tolerability of NKTR-262 in combination with bempegaldesleukin / nivolumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, AEs leading to discontinuation, deaths, clinical laboratory abnormalities per CTCAE 4.03, Efficacy of NKTR-262 in combination with bempegaldesleukin / nivolumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1","NCT03435640","Triple Negative Breast Cancer (1st- and 2nd-line and relapsed/refractory). Differing experiments based on drug combinations. Other cancers are studied","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03435640",1,"NA,DB15140,DB09035","NA, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"454",454,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","XMAB20717","UNK","I","Advanced, First Line, Second Line","Determine the safety and tolerability profile of XmAb20717","NCT03517488","Other cancers studied, Breast cancer cohort is in PART A dose escalation","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03517488",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"455",455,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","COM701, NIVOLUMAB","PVRIG, PD1","I","Advanced, Second Line","Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs), Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with a PD-1 inhibitor)","NCT03667716","Other cancers studied, COM701 is tested as a monotherapy as well, Disease recurrence or progression during or after at least one systemic treatment that included an anthracycline and/or a taxane in the neoadjuvant, adjuvant, or metastatic setting. Subjects must have progressed after a poly ADP-ribose polymerase (PARP) inhibitor for patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutated metastatic breast cancer.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03667716",1,"NA,DB09035","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"456",456,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, B7H4","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","FPA150, PEMBROLIZUMAB","B7H4, PD1","I","Advanced, Second Line","For Phase 1a dose escalation, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150, For Phase 1a dose escalation, dose exploration and combination safety lead-in the number of participants with adverse events as assessed by the latest version of CTCAE, For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150","NCT03667716","Other cancers studied, separate breast cancer cohort, At least two prior lines of systemic chemotherapy with at least one being administered in the metastatic setting","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03667716",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000134258","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND B7H4 PROTEIN EXPRESSION POSITIVE","failed drug"
"457",457,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, B7H4","Positive, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","FPA150, PEMBROLIZUMAB","B7H4, PD1","I","Advanced, Second Line","For Phase 1a dose escalation, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150, For Phase 1a dose escalation, dose exploration and combination safety lead-in the number of participants with adverse events as assessed by the latest version of CTCAE, For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150","NCT03667716","Other cancers studied, separate breast cancer cohort, Patients must have received at least two prior lines of hormonal therapy, Patients must have received at least one prior line of systemic chemotherapy (in the adjuvant or metastatic setting)","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03667716",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000134258","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND B7H4 PROTEIN EXPRESSION POSITIVE","failed drug"
"458",458,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PRS-343, ATEZOLIZUMAB","ERBB2/41BB, PDL1","I","Advanced, Second Line","cidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab","NCT03650348","Other cancers included. Must be previously treated.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03650348",1,"NA,DB11595","NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"459",459,"DCIS","Rb","Positive","NA","Protein Expression","PALBOCICLIB","Kinase","II","First Line, Second Line","Feasibility: recruitment rates","NCT03535506","Must be candidate for surgery","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03535506",1,"DB09073","11478676","ENSG00000139687","EFO_0000432","RB PROTEIN EXPRESSION POSITIVE","pass"
"460",460,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CPI-006, CIFORADENANT, PEMBROLIZUMAB","CD73, UNK, UNK","I","Advanced, Second Line","Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab, Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab, entify the MDL(maximum dose level) of single agent CPI-006","NCT03454451","CPI-006 is used as monotherapy and in combination with one of either of the listed drugs. Other cancers studied as well.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03454451",1,"NA,NA,DB09037","NA, 44537963, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"461",461,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ADCT-301","UNK","I","Advanced, Second Line","Assessment of Dose Limiting Toxicities in Determination of the Maximum Tolerated Dose Dose Limiting toxicities as defined per protocol, as related to ADCT-301, Number of Adverse Events of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above, Number of Serious Adverse Events (SAE), Number of SAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above, Number of Dose Interruptions and/or Dose Reductions, Number of Dose Limiting Toxicities, Number of Participants who Experience a Clinically Significant Change in Baseline in Laboratory Values, Number of Participants who Experience a Clinically Significant Change in Baseline in Vital Signs, Number of Participants who Experience a Clinically Significant Change in Baseline in Electrocardiogram (ECG) Results, Number of Particpants who Experience a Clinically Significant Change in Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status","NCT03621982","Other cancers included. Patients who are refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their conditio","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03621982",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"462",462,"METASTATIC OR UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PTEN, PIK3CB","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","DOCETAXEL, AZD8186","UNK, PIK3CB","I","Advanced, Second Line","Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), Incidence of adverse events","NCT03218826","Other cancers included. PTEN loss of function mutation or PIK3CB gain of function mutation","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03218826",1,"DB01248,NA","148124, 52913813","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000171862, ENSG00000051382","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PTEN MUTATION POSITIVE AND/OR PIK3CB MUTATION POSITIVE","pass"
"463",463,"METASTATIC OR UNRESECTABLE BREAST CANCER","ERBB2, ESR1, PTEN, PIK3CB","Negative, Positive, Positive, Positive","AND, AND, AND/OR","Protein Expression, Protein Expression, Mutation, Mutation","DOCETAXEL, AZD8186","UNK, PIK3CB","I","Advanced, Second Line","Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), Incidence of adverse events","NCT03218826","Other cancers included. PTEN loss of function mutation or PIK3CB gain of function mutation","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03218826",1,"DB01248,NA","148124, 52913813","ENSG00000141736, ENSG00000091831, ENSG00000171862, ENSG00000051382","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE AND/OR PIK3CB MUTATION POSITIVE","pass"
"464",464,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GEN1029","UNK","I, II","Advanced, Second Line","Dose Limiting Toxicities (DLTs), Adverse events (AEs)","NCT03576131","other cancers are studied","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03576131",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"465",465,"ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BA3021","ROR2","I, II","Advanced, Second Line","Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3021), Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Anti-tumor activity","NCT03504488","other cancers included. have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03504488",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"466",466,"LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","MRNA-2752, DURVALUMAB","UNK, UNK","I","Advanced, Second Line","Percentage of subjects with dose limiting toxicities (DLTs), Percentage of subjects with adverse events (AEs)","NCT03739931","Multiple Cancers. Group 1 Triple negative breast cancer: Must have objective evidence of disease progression during or following at least one prior line of therapy for metastatic or locally advanced disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03739931",1,"NA,DB11714","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"467",467,"INFILTRATIVE BREAST CANCER (I-IIIB)","ERBB2","Positive","NA","Protein Expression","CAPECITABINE, VINORELBINE TARTRATE","UNK, UNK","II","Second Line","disease free survival(DFS)","NCT03703427","Study reducing residual cancer burder after surgery. The patient was non-pCR after preoperative chemotherapy including anthracycline agents and paclitaxel or docetaxel; that is, she had undergone primary tumor resection and pathologically confirmed to have residual cancer cells.The previously adminstered preoperative chemotherapy must have involved 8 cycles of EC-T or 6 cycles of TEC.If HER-2 is positive, trastuzumab is applied with T chemotherapy 4. The patient has high risk: young;triple negtive breast caner; positive axillary lymphnode;HER-2 positive;ect. cannot receive if The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03703427",1,"DB01101,NA","60953, 11607738","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"468",468,"INFILTRATIVE TRIPLE NEGATIVE BREAST CANCER (I-IIIB)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE, VINORELBINE TARTRATE","UNK, UNK","II","Second Line","disease free survival(DFS)","NCT03703427","Study reducing residual cancer burder after surgery. The patient was non-pCR after preoperative chemotherapy including anthracycline agents and paclitaxel or docetaxel; that is, she had undergone primary tumor resection and pathologically confirmed to have residual cancer cells.The previously adminstered preoperative chemotherapy must have involved 8 cycles of EC-T or 6 cycles of TEC.If HER-2 is positive, trastuzumab is applied with T chemotherapy 4. The patient has high risk: young;triple negtive breast caner; positive axillary lymphnode;HER-2 positive;ect. cannot receive if The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03703427",1,"DB01101,NA","60953, 11607738","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"469",469,"BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Mutation, Mutation","NIRAPARIB","PARP1/PARP2","I","First Line","Preliminary antitumor activity of niraparib assessed as the tumor response rate based on the change in tumor volume as measured by breast MRI","NCT03329937","Must be primary and operable and non-metastatic","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03329937",1,"DB11793","24958200","ENSG00000141736, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"470",470,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, PF-06952229","UNK, UNK, UNK","I","Advanced, Second Line","Percentage of patients with dose limiting toxicities to determine maximum tolerated dose/recommended Phase 2 dose, Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs), Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities, Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings","NCT03685591","Other cancers included. Breast cancer is included in part 2 of this trial. Patients must have progressed on prior CDK4/6 inhibitor therapy and received greater than or equal to 2 prior lines of therapy in the metastatic setting;","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03685591",1,"DB09073,DB01006,NA","11478676, 3902, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"471",471,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","EDP1503, PEMBROLIZUMAB","UNK, UNK","I, II","Advanced, Second Line","Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0, Safety and tolerability of EDP1503 alone and in combination with pembrolizumab, Evidence of anti-tumor activity of EDP1503 based on ORR","NCT03775850","Other cancer are included. isease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03775850",1,"NA,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"472",472,"BREAST CANCER","ERBB2, ESR1, PGR, CYP2D6*10T/T","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Polymorphism","EXEMESTANE","UNK","III","First Line, Second Line","Disease free survival (DFS)","NCT03137368","Active comparator is Tamoxifen Tablets combined with ovarian function suppression/ablation. Experimental group also recieves ovarian function suppression/ablation. Patients must be premenopausal and have Complete removal of tumor by surgery without local residual","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03137368",1,"DB00990","60198","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND CYP2D6*10T/T POLYMORPHISM POSITIVE","pass"
"473",473,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","OLAPARIB, DURVALUMIB","PARP, UNK","II","Advanced, First Line, Second Line","Objective Response Rate (ORR)","NCT03801369","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03801369",1,"DB09074,NA","23725625, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"474",474,"ADVANCED BREAST CANCER","EBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","G1T48, PALBOCICLIB","ESR1, CDK4/CDK6","I","Advanced, First Line, Second Line","Dose Limiting Toxicity, Recommended Phase 2 dose","NCT03455270","Different experiements for dose escalation, diet effect, G1T48 as a monotherapy, and in combination.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03455270",1,"NA,DB09073","NA, 11478676","NA, ENSG00000091831","MONDO_0007254","EBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug,failed biomarker"
"475",475,"METASTATIC BREAST CANCER (IV)","EBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","HYDROXYCHLOROQUINE, LETROZOLE, PALBOCICLIB","UNK, UNK, UNK","I, II","Advanced, First Line, Second Line","Incidence of adverse events (Phase I), Change in breast tumor proliferation index (Ki67), Change in autophagy (Phase II, Part I), Change in senescence (Phase II, Part I), Change in cell cycle control (Phase II, Part I), Change in proportion of patients achieving tumoral complete cell cycle arrest (Phase II, Part II)","NCT03774472","Must be postmenopausal. Cannot have prior exposure to CDK 4/6 inhibitors. Must be a candidate for treatment with CDK4/6 inhibitor and hormonal therapy with an aromatase inhibitor as standard of care","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03774472",1,"DB01611,DB01006,DB09073","12947, 3902, 11478676","NA, ENSG00000091831","MONDO_0007254","EBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed biomarker"
"476",476,"BREAST CANCER (I-III)","ERBB2, ESR1, Ki67","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","HYDROXYCHLOROQUINE, LETROZOLE, PALBOCICLIB","UNK, UNK, UNK","I, II","First Line","Incidence of adverse events (Phase I), Change in breast tumor proliferation index (Ki67), Change in autophagy (Phase II, Part I), Change in senescence (Phase II, Part I), Change in cell cycle control (Phase II, Part I), Change in proportion of patients achieving tumoral complete cell cycle arrest (Phase II, Part II)","NCT03774472","Must be postmenopausal. Ki67 > 5%","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03774472",1,"DB01611,DB01006,DB09073","12947, 3902, 11478676","ENSG00000141736, ENSG00000091831, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"477",477,"BREAST CANCER (II-III)","ERBB2","Positive","NA","Protein Expression/ Protein Expression & Amplification","M7824","PDL1, TGFbetaRII","I","First Line, Second Line","Change in tumor-infiltrating lymphocytes (TIL) percentage, Laboratory parameters, Vital signs, Electrocardiogram parameters","NCT03620201","Also includes neoadjuvant systemic therapy is planned and will include HER2 targeted therapy in combination with chemotherapy of physician's choice.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03620201",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"478",478,"UNRESECTABLE OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/ Protein Expression & Amplification","DS-8201A","UNK","I","Advanced, Second Line","Number of participants with treatment-related adverse events (AEs)","NCT03368196","refractory to or intolerable with standard treatment, or for which no standard treatment is available","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03368196",1,"NA","132508503","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"479",479,"METASTATIC TRIPLE NEGATIVE BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ERIBULIN MESYLATE, M7824","UNK, PDL1, TGFbetaRII","I","Advanced, First Line, Second Line","Recommended phase II dose (RP2D) defined as highest dose with dose limiting toxicity (DLT) rate =< 30%, Incidence of adverse events (AE)","NCT03579472","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03579472",1,"NA,NA","17755248, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"480",480,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, OLAPARIB","B7H1, PARP","I","Advanced, First Line, Second Line","Proportion of completion of Clinical Laboratory Improvement Act (CLIA) analytics on pre-treatment biopsy before the planned for 4-week biopsy","NCT03544125","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03544125",1,"DB11714,DB09074","NA, 23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"481",481,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, HRR","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","OLAPARIB, AZD6738","UNK, ATR","II","Advanced, Second Line","Progression-Free Survival (PFS) assessment to evaluate the efficacy of AZD6738+olaparib and adavosertib+olaparib combination therapy compared to olaparib monotherapy in BRCAm, Non BRCAm HRRm, Non HRRm patient population.","NCT03330847","Patients must have received at least 1 and no more than 2 prior lines of treatment for metastatic disease with an anthracycline (eg, doxorubicin, epirubicin) and/or a taxane (eg, paclitaxel, docetaxel) unless contraindicated, in either the neo-adjuvant, adjuvant or metastatic setting. Active comparator: Olaparib+adavosertib","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03330847",1,"DB09074,NA","23725625, 54761306","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012504","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND HRR MUTATION POSITIVE/NEGATIVE","pass"
"482",482,"URESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression/ Protein Expression & Amplification","RC48-ADC","UNK","II","Advanced, Second Line","Progression-free Survival (PFS) as Assessed by an IRC","NCT03500380","Active comparator is Lapatinib + Capecitabine. Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include trastuzumab, alone or in combination with another agent.Documented progression of incurable unresectable, locally advanced, or metastatic breast cancer, defined by the investigator: Progression must occur during or after most recent treatment for locally advanced/MBC or within 6 months after completing adjuvant therapy.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT03500380",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","failed drug"
"483",483,"BREAST CANCER (I-II)","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DENOSUMAB","UNK","I","First Line","Antiproliferative and/or pro-apoptotic activity of denosumab","NCT03691311","candidate to radical surgery as first therapeutic approach","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03691311",1,"DB06643","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"484",484,"BREAST (II-IIIA)","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","TRASTUZUMAB, PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","III","Second Line","Pathologic complete response (pCR)","NCT03556358","Planned surgical resection of breast tumor, Planned neoadjuvant chemotherapy, active comparator is Herceptin with paclitaxel, epirubicin, and cyclophosphamide","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03556358",1,"DB00072,DB01229,DB00445,DB00531","3001322, 36314, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0003869","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"485",485,"MESTASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, AROMATASE INHIBITOR","UNK, Aromatase","II","Advanced, First Line, Second Line","ncidence of grade 2 and above toxicities attributed (possible or above) to ribociclib","NCT03477396","aromatase inhibitor is chosen by the treating investigator for each patient","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03477396",1,"DB11730,NA","44631912, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"486",486,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SHR-1210, APATINIB","PD1, VEGFR2","II","Advanced, First Line, Second Line","ORR","NCT03394287","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03394287",1,"NA,DB14765","NA, 45139106","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"487",487,"LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1, CD73","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, CARBOPLATIN, DURVALUMAB, OLECLUMAB","UNK, UNK, PDL1, CD73","I, II","Advanced, First Line","Phase I:The adverse events (AEs), Phase II: Clinical Benefit of oleclumab in combination with chemotherapy and durvalumab by the comparing the CB rate at 24 weeks from the 1st dose of study drug administration between patients treated with or without the anti-CD73 antibody oleclumab","NCT03616886","The SYNERGY trial investigates the role of an anti-CD73 (MEDI9447) in a randomized phase II trial evaluating the efficacy and safety of the combination of chemotherapy (paclitaxel + carboplatin) with immunotherapy (durvalumab [anti-PD-L1] +/- MEDI9447 [anti-CD73]) in previously untreated locally recurrent inoperable or metastatic TNBC. hormone receptor-positive and/or HER2-positive breast cancer are eligible if the tumor biopsy obtained from a local recurrence or distant metastasis site confirms the TNBC disease.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03616886",1,"DB01229,DB00958,DB11714,DB15088","36314, 56840877, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000135318","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND CD73 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"488",488,"RECURRENT OF METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PALBOCICLIB, T-DM1","UNK, UNK","II","Advanced, First Line, Second Line","Compare progression-free survival","NCT03530696","active comparator is palbociclib monotherapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03530696",1,"DB09073,DB05773","11478676, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"489",489,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","absent","NA","NA","NA","BEVACIZUMAB, CARBOPLATIN, PACLITAXEL","UNK, UNK, UNK","II","Advanced, Second Line","progression free survival","NCT03577743","emale patient firstly diagnosed with metastatic TNBC or after adjuvant treatment OF TNBC by immune histochemistry and biopsy, can only receive one line of chemotherapy in adjuvant","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03577743",1,"DB00112,DB00958,DB01229","NA, 56840877, 36314","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"490",490,"LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, LETROZOLE","UNK, UNK","III","Advanced, First Line","Change from baseline ctDNA alterations to progression disease during Core and Extension Phase ","NCT03439046","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03439046",1,"DB11730,DB01006","44631912, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"491",491,"LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, PIK3CA","Negative, Positive, Positive, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","RIBOCICLIB, LETROZOLE, ALPELISIB, FULVESTRANT","UNK, UNK, UNK, UNK","III","Advanced, Second Line","Change from baseline ctDNA alterations to progression disease during Core and Extension Phase ","NCT03439046","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03439046",1,"DB11730,DB01006,DB12015,DB00947","44631912, 3902, 56649450, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"492",492,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","VENETOCLAX, FULVESTRANT","UNK, UNK","II","Advanced, Second Line","Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Stable Disease (SD) lasting >= 24 weeks","NCT03584009","Active Comparator: Fulvestrant, Be postmenopausal or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin, Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03584009",1,"DB11581,DB00947","49846579, 104741","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"493",493,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, CAPECITABINE","PD1, UNK","II","Second Line","Immune activation measured by changes in the peripheral immunoscore (PIS) at week 6","NCT03487666","Both drugs tested as monotherapies and combined. Second line after neoadjuvant therapy. Patients must have received surgery and received neoadjuvant chemotherapy, and still have residual disease. Must be the first adjuvant therapy after disease. Patients cannot be metastatic","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03487666",1,"DB09035,DB01101","NA, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"494",494,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","PEMBROLIZUMAB, NAB-PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First Line","Pathological Complete Response (pCR) rate","NCT03289819","Known, pathogenic BRCA (breast cancer susceptibility gene) mutation. Note: testing is not mandatory for trial participation.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03289819",1,"DB09037,NA,DB00445,DB00531","NA, 36314, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","pass"
"495",495,"MESTASTATIC BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Positive/Negative, Positive/Negative, Positive, Positive","AND, AND/OR, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","OLAPARIB","UNK","III","Advanced, Second Line","Progression-free survival (PFS) in real-world setting in germline BRCA mutated patients","NCT03286842","Prior treatment with a taxane or an anthracycline in either an adjuvant (may include neoadjuvant) or metastatic breast cancer treatment setting","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03286842",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"496",496,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE","UNK","III","First, Second Line","Invasive disease-free survival (IDFS)","NCT03561740","Patients must have adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes, High risk patients: residual invasive lesions in surgical specimens after neoadjuvant treatment (non-pCR ), Lymph node positive, tumor maximal diameter >2cm. If patient get neoadjuvant treatment, Systemic therapy must consist of at least 6 cycles of chemotherapy, with a total duration at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane-based chemotherapy. Patients may have received an anthracycline as part of preoperative therapy in addition to taxane chemotherapy. Patients receiving dose-dense chemotherapy regimens are eligible, provided at least 8 weeks of taxane-based therapy and at least 8 weeks of trastuzumab have been given.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03561740",1,"DB01101","60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"497",497,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression/ Protein Expression & Amplification","ANLOTINIB HYDROCHLORIDE","UNK","II","Advanced, Second Line","Progression free survival (PFS)","NCT04002284","nthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-2 standard chemotherapies after recurrence and metastasis","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT04002284",1,"NA","57380530","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","pass"
"498",498,"MESTASTATIC (IV) OR LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, AROMATASE INHIBITOR","UNK, Aromatase","II","Advanced, First Line","Genetic Mutation","NCT03439735","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03439735",1,"DB09073,NA","11478676, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"499",499,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","PALBOCICLIB, EPIRUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","UNK, UNK, UNK, UNK","UNK","First Line","pCR","NCT03756090","cannot have Metastatic disease (Stage IV) or inflammatory breast cancer. Active comparator has all drugs except Palbociclib","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03756090",1,"DB09073,DB00445,DB00531,DB01229","11478676, 65348, 2907, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"500",500,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, FULVESTRANT","UNK, UNK, UNK","II","Advanced, First Line, Second Line","Incidence of adverse events","NCT03633331","Planning to begin palbociclib for metastatic disease; one prior line of endocrine therapy and/or chemotherapy for metastatic disease is allowed; patients may begin or have already begun endocrine therapy before they start palbociclib treatment, but no more than two weeks prior to registration","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03633331",1,"DB09073,DB01006,DB00947","11478676, 3902, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"501",501,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","EOC202, PACLITAXEL","UNK, UNK","I","Advanced, First Line","DLT","NCT03600090","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03600090",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"502",502,"METASTATIC BREAST CANCER (IV)","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, ERIBULIN","UNK, UNK","I","Adavnced, Second Line","The dose-limiting toxicity (DLT) rate","NCT03430518","Trial also includes Recurrent Ovarian Cancer. HR positive, HER2 negative breast cancer: patients must have received at least one line of therapy for metastatic disease prior to enrollment, including hormonal therapy and a CDK4/6 inhibitor, HR negative, HER2 negative breast cancer: patients must have received at least one prior line of chemotherapy for metastatic disease","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03430518",1,"DB11714,DB08871","NA, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"503",503,"METASTATIC BREAST CANCER","absent","NA","NA","NA","SM-88","UNK","I, II","Advanced, First Line, Second Line","Response Rate, PFS","NCT02562612","SM-88 is a combination of 4 drugs that are not listed","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02562612",1,"NA","3125","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"504",504,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","FULVESTRANT, PALBOCICLIB","UNK, UNK","II","Advanced, Second Line","Progression Free survival","NCT03560856","Must be postmenopausal","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03560856",1,"DB00947,DB09073","104741, 11478676","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"505",505,"LOCALLY RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression, Protein Expression","DAROLUTAMIDE, CAPECITABINE","UNK, UNK","II","Advanced, First Line, Second Line","clinical benefit rate","NCT03383679","Each drug being tested individually","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03383679",1,"DB12941,DB01101","67171867, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"506",506,"TRIPLE NEGATIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB, CARBOPLATIN, ALBUMIN PACLITAXEL","UNK, UNK, UNK","II","First Line","pCR rate","NCT03650738","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03650738",1,"DB14765,DB00958,NA","45139106, 56840877, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"507",507,"MESTASTATIC BREAST CANCER (IV)","ERBB2","Positive","NA","Protein Expression/ Protein Expression & Amplification","PYROTINIB","UNK","II","Advaned, First Line, Second Line","Progression-free survival (PFS)","NCT03412383","There is no standard therapy. Studying HER2 mutant breast cancer, but HER2 negative expression or amplification. Mutant status not listed in inclusion critera","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03412383",1,"DB14993","51039030","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","pass"
"508",508,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression/ Protein Expression & Amplification, Protein Expression, Protein Expression","PEMBROLIZUMAB","PD1","I","First Line, Second Line","PD-1 expression","NCT03197389","Separate Cohorts for patients have have received neoadjuvant chemotherapy and who have clear signs of residual tumor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03197389",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION/ PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"509",509,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","PD1","I","First Line, Second Line","PD-1 expression","NCT03197389","Separate Cohorts for patients have have received neoadjuvant chemotherapy and who have clear signs of residual tumor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03197389",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"510",510,"BREAST CANCER","ESR1","Positive","NA","Protein Expression","PEMBROLIZUMAB","PD1","I","First Line, Second Line","PD-1 expression","NCT03197389","Separate Cohorts for patients have have received neoadjuvant chemotherapy and who have clear signs of residual tumor","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03197389",1,"DB09037","NA","ENSG00000091831","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"511",511,"BREAST CANCER (I-IIIB)","ERBB2","Positive","NA","Protein Expression","CAPECITABINE","UNK","II","Second Line","disease free survival(DFS)","NCT03684863","Stage I-IIIB at the first diagnosis and underwent curative resection.","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03684863",1,"DB01101","60953","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"512",512,"ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","AB928, PEGYLATED LIPOSOMAL DOXORUBICIN, NANOPARTICLE ALBUMIN-BOUND PACLITAXEL, IPI-549","A2aR/A2bR, topoisomerase II, microtubules, phosphoinositide-3kinase-gamma","I","Advanced, First Line, Second Line","Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0","NCT03719326","drugs are tested in different combinations. Other cancers are included","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03719326",1,"NA,NA,NA,NA","135242184, NA, 36314, 91933883","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"513",513,"UNRESECTABLE BREAST CANCER","BRCA1, BRCA2, ERBB2, ESR1, PGR","Positive, Positive, Negative/Positive, Negative/Positive, Negative/Positive","AND/OR, AND, AND, AND","Mutation, Mutation, Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","SAPACITABINE, OLAPARIB","UNK, PARP","I/II","Advanced, First&Second line","Maximum Tolerated Dose , Recommended Phase II dose (RPIID), Objective Response Rate","NCT03641755","must be postmenopausal. No systemic chem within 3 weeks of study entry","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03641755",1,"DB06365,DB09074","153970, 23725625","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION NEGATIVE/POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"514",514,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, CARBOPLATIN","PD1, UNK","II","Advanced, Second line","Progression-free survival (PFS) ","NCT03414684","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03414684",1,"DB09035,DB00958","NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"515",515,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB","PDL1","II","Advanced, First&Second line","Progression Free Survival ","NCT03483012","must also have brain metastases, must also include Stereotatic radiosurgery","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03483012",1,"DB11595","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"516",516,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","PYROTINIB, FULVESTRANT","HER1/HER2/HER4, UNK","II","Advanced, Second line","Progression-Free Survival (PFS)","NCT04033172","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04033172",1,"DB14993,DB00947","51039030, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"517",517,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GEDATOLISIB, PTK7-ADC","UNK, UNK","I","Advanced, Second line","Safety of Gedatolisb + PTK7-ADC using NCI CTCAE v4.0","NCT03243331","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03243331",1,"DB11896,NA","44516953, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"518",518,"ADVANCED BREAST CANCER","ERBB2, PDL1","Positive, Negative/Positive","AND","Protein Expression&Amplification/Protein Expression, Protein Expression","VINORELBINE, TRASTUZUMAB, AVELUMAB, UTOMILUMAB","UNK, UNK, UNK, UNK","II","Advanced, Second line","Progression Free Survival","NCT03414658","different arms with different drug combos","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03414658",1,"DB00361,DB00072,DB11945,DB15113","5311497, 3001322, NA, NA","ENSG00000141736, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"519",519,"BREAST CANCER (STAGE I-III)","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","T-DM1","UNK","II","Advanced&Non-advanced, First line","5-year invasive disease-free survival rate","NCT03587740","For patients with bilateral or multifocal/multicentric breast cancers, one of the following criteria must be met to enroll: (1) each cancer individually meets criteria for enrollment (only ONE tumor has to undergo central confirmation for HER2), OR (2) at least one tumor meets eligibility (per tumor size/nodes/subtype outlined above) and the other foci in the ipsilateral or contralateral breast are also HER2-positive but are too small for enrollment (e.g., a patient is eligible if a cancer is T2N0 and HER2-positive in one breast, but the contralateral breast has a T1a HER2+ cancer that isn't eligible on its own, OR, (3) at least one tumor meets eligibility and the other foci in the ipsilateral or contralateral breast are HER2-negative and do not meet criteria for adjuvant chemotherapy per provider discretion (e.g. if a patient has a HER2-positive tumor meeting eligibility but also has a second, HER2-negative, small, node-negative, ER+, low grade cancer present, she is still eligible for enrollment). However, in the specific case that a second breast cancer is stage III and HER2-negative, that patient is excluded (because the second cancer is high-risk and likely will require non-HER2-directed therapy).","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03587740",1,"DB05773","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"520",520,"BREAST CANCER","BRCA1, BRCA2, ERBB2","Positive, Positive, Negative","AND/OR, AND","Mutation, Mutation, Protein Expression","TALAZOPARIB","PARP","II","First line","Pathological Complete Response (pCR) by Independent Central Reviewer(ICR)","NCT03499353","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03499353",1,"DB11760","135565082","ENSG00000012048, ENSG00000139618, ENSG00000141736","MONDO_0007254","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"521",521,"LOCALLY ADVANCED","ERBB2, ESR1, PGR","Negative, Negative/Positive, Negative/Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","CIRMTUZUMAB, PACLITAXEL","ROR1, UNK","I","Advanced, First&Second line","The rate of dose-limiting toxicities during the first 4 weeks of treatment","NCT02776917","ER/PR+ pts must have exhausted endrocrine therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02776917",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005856","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","failed drug"
"522",522,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, PIK3CA","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","ALPELISIB","UNK","II","Advanced, First&Second line","progression-free survival [","NCT03386162","must be resistant to endrocrine therapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03386162",1,"DB12015","56649450","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"523",523,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","TRASTUZUMAB DERUXTECAN","UNK","III","Advanced, Second line","Progression-free survival (PFS) based on blinded independent central review (BICR)","NCT03523585","had active comparator","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03523585",1,"DB14962","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"524",524,"METASTATIC BREAST CANCER","absent","NA","NA","NA","ERIBULIN MESYLATE","UNK","IV","Advanced, Second line","Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants with TEAEs Related to Laboratory Parameters","NCT03583944","no biomarkers mentioned","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03583944",1,"NA","17755248","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"525",525,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","TRASTUZUMAB DERUXTECAN","NA","III","Advanced, Second line","Progression-free survival (PFS) based on blinded independent central review (BICR)","NCT03529110","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03529110",1,"DB14962","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"526",526,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NANOSOMAL DOCETAXEL LIPID SUSPENSION","UNK","III","Advanced&Non-advanced, Second line","Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm","NCT03671044","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03671044",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"527",527,"BREAST CANCER","absent","NA","NA","NA","LUPIN'S PEGFILGRASTIM","UNK","IV","First line","Primary Immunogenicity Endpoint: Comparison of cumulative Incidence of anti-pegfilgrastim antibodies (binding & neutralizing) at the end of cycle 4 (Day 84)","NCT03511378","adjuvant to standard chemotherapy. Looking at immunogenicity","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03511378",1,"NA","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"528",528,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","RUCAPARIB","UNK","I","First line","defining the maximum tolerated dose (MTD)","NCT03542175","must be with radiation","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03542175",1,"DB12332","9931954","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"529",529,"BREAST CANCER (STAGE I-III)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LETROZOLE","UNK","I","First line","Measure Ki67 index in highly hormone-dependent breast cancers vs. those that are not","NCT03747042","must be postmenopausal","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03747042",1,"DB01006","3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"530",530,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SGN-LIV1A, PEMBROLIZUMAB","UNK, UNK","I/II","Advanced, First line","Confirmed objective response rate , Incidence of adverse events , Incidence of laboratory abnormalities, Incidence of dose-limiting toxicities","NCT03310957","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03310957",1,"DB15409,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"531",531,"LOCALLY ADVANCED BREAST CANCER","absent","NA","NA","NA","ASCORBIC ACID","UNK","I/II","Advanced&Non-advanced, First line","Number of Patients With Adverse Events as a Measure of Safety and Tolerability","NCT03175341","was a supplement to neoadjuvant  chemotherapy, but suggested it may improve survival statistics","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03175341",1,"DB00126","54670067","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"532",532,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","S81694, PACLITAXEL","UNK, UNK","I/II","Advanced, First&Second line","Incidence of DLTs (dose-limiting toxicities), Safety and tolerability assessed by incidence of Adverse Events), Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis) , Abnormalities in physical examination and performance status (ECG) (mm/s), Abnormalities in blood pressure (mmHg), Abnormalities in heart rate (BPM (beat per minute)) , Abnormalities in body temperature (C°degree celsius), Abnormalities in respiration rate (cycles per minute) , Abnormalities in body weight (Kg) , Progression free survival (PFS)","NCT03411161","phase 1 was second line, phase 2 was first line","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03411161",1,"NA,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"533",533,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, AROMATASE INHIBITOR, GOSERELIN","UNK, Aromatase, UNK","II","Advanced, First&Second line","Progressive free survival (PFS) based on local assessment by RECIST 1.1 guideline","NCT03671330","for pre/postmenopausal chinese women. Different groups had different clinical settings. One required no systemic therapy, the other did not mention previous therapies","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03671330",1,"DB11730,NA,DB00014","44631912, NA, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"534",534,"BREAST CANCER","absent","NA","NA","NA","AROMATASE INHIBITORS","aromatase","IV","First line","Tumor Biology","NCT03111615","aromatase inhibitors include: letrozole, anastrazole, all given with a calcium and vitamin D supplement. Different subgroups had varying amounts of time on the inhibitors. Must be postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03111615",1,"NA","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"535",535,"METASTATIC BREAST CANCER","ERBB2, PIK3CA","Positive, Positive","AND","Protein Expression, Mutation","MEN1611, TRASTUZUMAB, FULVESTRANT","PI3K, UNK, UNK","I","Advanced, Second line","Maximum Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D)","NCT03767335","Fulvestrant will be given to those with hormone sensitive disease. However, HR status is not in the criteria","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03767335",1,"NA,DB00072,DB00947","49784945, 3001322, 104741","ENSG00000141736, ENSG00000121879","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"536",536,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","III","First line","disease free survival ","NCT04193059","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04193059",1,"DB01229,DB00958,DB00072,DB06366","36314, 56840877, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"537",537,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","PACLITAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","III","First line","disease free survival ","NCT04193059","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04193059",1,"DB01229,DB00958,DB00072,DB06366","36314, 56840877, 3001322, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"538",538,"METASTATIC BREAST CANCER","absent","NA","NA","NA","ASPIRIN","UNK","II/III","Advanced, First&Second line","Overall Survival","NCT03491410","in combination with standard treatment","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03491410",1,"DB00945","2244","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"539",539,"METASTATIC  TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, MIFEPRISTONE","UNK, UNK","II","Advanced, First&Second line","Rate of overall response based on RECIST 1.1","NCT03225547","two different cohorts with different drug schudules","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03225547",1,"DB09037,DB00834","NA, 55245","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"540",540,"METASTATIC  BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","PEMBROLIZUMAB, MIFEPRISTONE","UNK, UNK","II","Advanced, Second line","Rate of overall response based on RECIST 1.1","NCT03225547","two different cohorts with different drug schudules","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03225547",1,"DB09037,DB00834","NA, 55245","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"541",541,"METASTATIC BREAST CANCER","absent","NA","NA","NA","ALT-P7","UNK","I","Advanced, Second line","Determination of Maximum Tolerated Dose(MTD) and the dose level showing Dose Limiting Toxicity(DLT), or determination of Recommended Phase II Dose(RP2D) as an alternative to MTD establishment","NCT03281824","Says HER2 positive thoroughout the trial, but not in the inclusion criteria","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03281824",1,"NA","NA","ENSG00000104313","EFO_1000984","ABSENT NA NA","failed drug,no biomarker"
"542",542,"BREAST CANCER (STAGE II, IIIA)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT, PALBOCICLIB, GOSERELIN","UNK, UNK, UNK","III","Advanced&Non-advanced, First line","pCR according to Le Chevalier's classification","NCT03447132","must be operable","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03447132",1,"DB00947,DB09073,DB00014","104741, 11478676, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"543",543,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, TAMOXIFEN, GOSERELIN","UNK, UNK, UNK","III","Advanced, Second line","Progression-free survival (PFS)","NCT03423199","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03423199",1,"DB09073,DB00675,DB00014","11478676, 2733526, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"544",544,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","ZN-C5, PALBOCICLIB","UNK, UNK","I/II","Advanced, Second line","Determine a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) for ZN-c5 as a monotherapy, Determine a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) for ZN-c5 when administered in combination with palbociclib","NCT03560531","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03560531",1,"NA,DB09073","NA, 11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"545",545,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CFI-400945","PLK4","II","Advanced, Second line","Objective Response defined by RECIST 1.1","NCT03624543","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03624543II",1,"NA","58486178","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"546",546,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR, PTEN","Negative, Positive, Positive, Negative","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","CFI-400945","PLK4","II","Advanced, Second line","Objective Response defined by RECIST 1.1","NCT03624543","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03624543II",1,"NA","58486178","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000171862","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION NEGATIVE","pass"
"547",547,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR, PTEN","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","CFI-400945","PLK4","II","Advanced, Second line","Objective Response defined by RECIST 1.1","NCT03624543","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03624543II",1,"NA","58486178","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000171862","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","pass"
"548",548,"BREAST CANCER","CEA","Positive","NA","Protein Expression","V3-MOMMO","UNK","II","First&Second line","Effect on tumor size ","NCT03572361","criteria requires ""Confirmed diagnosis of breast cancer positive at least for CEA tumor marker at above normal threshold level"". Does not mention any criteria for clinical setting","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03572361",1,"NA","NA","ENSG00000105388","MONDO_0007254","CEA PROTEIN EXPRESSION POSITIVE","failed drug"
"549",549,"TRIPLE NEGATIVE BREAST CANCER (STAGE I,II,III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEGFILGRASTIM, PEMBROLIZUMAB, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK, UNK","II","First line","Pathological complete response (pCR) rate","NCT03639948","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03639948",1,"DB00019,DB09037,DB01248,DB00958","NA, NA, 148124, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"550",550,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","TRASTUZUMAB, PACLITAXEL, PEGFILGRASTIM","UNK, UNK, UNK","II","First line","Pathological complete response rate (pCR)","NCT03571633","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03571633",1,"DB00072,DB01229,DB00019","3001322, 36314, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"551",551,"BREAST CANCER","absent","NA","NA","NA","FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","II/III","First line","Tumour size measurement","NCT03696004","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03696004",1,"DB00544,DB00445,DB00531","3385, 65348, 2907","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"552",552,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","DHP107, PACLITAXEL","UNK, UNK","II","Advanced, First&Second line","Objective Response Rate(ORR)","NCT03326102","only says pt could have received up to 3 lines of therapy prior for advanced disease","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03326102",1,"NA,DB01229","NA, 36314","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"553",553,"EARLY BREAST CANCER","absent","NA","NA","NA","TRIMIX","UNK","I","First line","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","NCT03788083","mRNA injection","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03788083",1,"NA","174735","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"554",554,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LETROZOLE, PALBOCICLIB, GOSERELIN","UNK, UNK, UNK","II","First line","Complete Cell cycle arrest","NCT03628066","must be premenopausal, cancer must be operable and newly diagnosed","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03628066",1,"DB01006,DB09073,DB00014","3902, 11478676, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"555",555,"EARLY BREAST CANCER","absent","NA","NA","NA","ABRAXANE, XELODA","UNK, UNK","UNK","First line","ORR(CR+PR)","NCT03647514","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03647514",1,"NA,NA","36314, 60953","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"556",556,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","SHR6390, AROMATASE INHIBITORS","UNK, Aromatase","I/II","Advanced, First&Second line","Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1","NCT03481998","aromatase inhibitors include: letrozole, anastrazole, fulvestrant. Different cohorts could be at different clinical states","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03481998",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"557",557,"EARLY BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, ENDOCRINE THERAPY","UNK, Hormone receptors","III","Second line","Invasive Disease-Free Survival","NCT03701334","adjuvant therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03701334",1,"DB11730,NA","44631912, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"558",558,"LOCALLY ADVANCED BREAST CANCER","absent","NA","NA","NA","APATINIB, PACLITAXEL, CARBOPLATIN","VEGFR2, UNK, UNK","II","First line","pCR rate","NCT03735082","title says TNBC, however, it does not mention that as a inclusion criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03735082",1,"DB14765,DB01229,DB00958","45139106, 36314, 56840877","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"559",559,"BREAST CANCER STAGE (II-III)","ER","Positive","NA","Protein Expression","PALBOCICLIB, TAMOXIFEN, AVELUMAB","UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Clinical Complete Response","NCT03573648","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03573648",1,"DB09073,DB00675,DB11945","11478676, 2733526, NA","ENSG00000091831","MONDO_0007254","ER PROTEIN EXPRESSION POSITIVE","pass"
"560",560,"BREAST CANCER","absent","NA","NA","NA","ABRAXANE, EPIRUBICIN","UNK, UNK","UNK","First line","ORR(CR+PR)","NCT03647280","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03647280",1,"NA,DB00445","36314, 65348","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"561",561,"BREAST CANCER (STAGE IIA-IIIB)","absent","NA","NA","NA","APATINIB, DOCETAXEL, CARBOPLATIN","UNK, UNK, UNK","I/II","First line","pCR","NCT03243838","Says TNBC in the title, but does not include that in the inclusion criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03243838",1,"DB14765,DB01248,DB00958","45139106, 148124, 56840877","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"562",562,"METASTATIC  BREAST CANCER","ERBB2","Negative","NA","Protein Expression","CFI-402257, PACLITAXEL","UNK, UNK","I/II","Advanced, First&Second line","Phase I: Safety and tolerability of CFI-402257 assessed by CTCAE, Phase I: Identify the recommended phase II dose , Phase II: Overall Response Rate using RECIST 1.1","NCT03568422","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03568422",1,"NA,DB01229","118086034, 36314","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"563",563,"METASTATIC BREAST CANCER","absent","NA","NA","NA","APATINIB","angiogenesis","II","Advanced, First line","Overall survival (OS)","NCT03457467","Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03457467",1,"DB14765","45139106","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"564",564,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","ELACESTRANT","UNK","III","Advanced, Second line","Progression Free Survival (PFS) in the ESR1-mut subjects, PFS in all (ESR1-mut and ESR1-WT) subjects","NCT03778931","er mut/ er wt","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03778931",1,"DB06374","23642301","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"565",565,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","FASLODEX, ZOLADEX","UNK, UNK","IV","Advanced, First line","Progression free survival","NCT03591549","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03591549",1,"NA,NA","104741, 16052011","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"566",566,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, PACLITAXEL, IPATASERTIB","UNK, UNK, UNK, UNK, UNK","I","Advanced, First&Second line","Cohort 1 and Cohort 4: Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]), as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST), Version (v) 1.1, Cohort 1 and Cohort 4: Duration of Confirmed Objective Response, as Determined by the Investigator According to RECIST v1.1 , Pathological complete response (pCR) rate defined as the percentage of participants who have no residual invasive disease in the breast and no residual disease in the lymph node.","NCT03800836","cohorts had different clinical states","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03800836",1,"DB00997,DB00531,DB11595,DB01229,DB11743","443939, 2907, NA, 36314, 24788740","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"567",567,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","IPATASERTIB, PACLITAXEL, ATEZOLIZUMAB","UNK, UNK, UNK","I","Advanced, First line","Cohort 1 and Cohort 4: Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]), as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST), Version (v) 1.1, Cohort 1 and Cohort 4: Duration of Confirmed Objective Response, as Determined by the Investigator According to RECIST v1.1 , Pathological complete response (pCR) rate defined as the percentage of participants who have no residual invasive disease in the breast and no residual disease in the lymph node.","NCT03800836","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03800836",1,"DB11743,DB01229,DB11595","24788740, 36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","pass"
"568",568,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative/Positive, Negative/Positive, Negative/Positive, Negative/Positive, Negative/Positive","AND, AND, AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","2X-121","PARP1/PARP2/Tankyrase1/Tankyrase2","II","Advanced, First&Second line","Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRP","NCT03562832","they used a 2x-121 DRP® biomarker  to predict drug response. They mention what 2X-121 works on, but do not say what specific tumor biomarker they are using with the 2X-121","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03562832",1,"NA","135565981","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION NEGATIVE/POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND BRCA1 MUTATION NEGATIVE/POSITIVE AND BRCA2 MUTATION NEGATIVE/POSITIVE","pass"
"569",569,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","DHES0815A","UNK","I","Advanced, Second line","Percentage of Participants with Adverse Events (AEs) and Serious Aes, Percentage of Participants with DLT , MTD of DHES0815A, Recommended Phase 2 Dose (RP2D) of DHES0815A","NCT03451162","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03451162",1,"NA","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"570",570,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, FULVESTRANT","UNK, UNK","II","Advanced, Second line","Overall Response Rate","NCT03393845","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03393845",1,"DB09037,DB00947","NA, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"571",571,"EARLY BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","EG12014, HERCEPTIN","UNK, UNK","III","First line","Determination of pathologic complete response (pCR) at time of surgery","NCT03433313","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03433313",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","failed drug"
"572",572,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","D-0502, PALBOCICLIB","UNK, UNK","I","Advanced, First&Second line","Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria","NCT03471663","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03471663",1,"NA,DB09073","NA, 11478676","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"573",573,"METASTATIC BREAST CANCER","ERBB2, ESR1","Positive, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, T-DM1","UNK, UNK, UNK","I/II","Advanced, First&Second line","Rate of Overall Response","NCT03709082","requires some prior therapies, but doesn’t say it requires a first line therapy outright","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03709082",1,"DB09073,DB01006,DB05773","11478676, 3902, NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"574",574,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE, BEVACIZUMAB, PACLITAXEL, RIBOCICLIB, FULVESTRANT, AROMATASE INHIBITOR","UNK, UNK, UNK, UNK, UNK, aromatase","III","Advanced, First line","Efficacy in terms of PFS","NCT03462251","different arms with different drug combos","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03462251",1,"DB01101,DB00112,DB01229,DB11730,DB00947,NA","60953, NA, 36314, 44631912, 104741, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"575",575,"NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ZOLEDRONATE, ATORVASTATIN","UNK, UNK","II","First line","Proof of concept primary activity endpoint - Efficacy endpoint, The proportion of responded patients","NCT03358017","Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03358017",1,"DB00399,DB01076","23649597, 60823","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"576",576,"ADVANCED BREAST CANCER","ERBB2","Negative","NA","Protein Expression","RIBOCICLIB, AROMATASE INHIBITORS, LHRH AGONIST","UNK, Aromatase, LHRH","II","Advanced, First line","Treatment feasibility","NCT03944434","aromatase inhibitors include: femara, arimidex. LHRH includes, triptorelin, leuprolide, goserelin, have to be at least 70 years old. Said HR positive in the rest of the trial, not in the inclusion criteria, however","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03944434",1,"DB11730,NA,NA","44631912, NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"577",577,"INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Negative/Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB","PARP","II","Second line","Invasive Disease-Free Survival","NCT03598257","With or without radiation therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03598257",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"578",578,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","LAG525, SPARTALIZUMAB, CARBOPLATIN","UNK, UNK, UNK","II","Advanced, Second line","Overall response rate (ORR) per RECIST v1.1 per investigators' assessment","NCT03499899","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03499899",1,"NA,DB14892,DB00958","NA, NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"579",579,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","IPILIMUMAB, NIVOLUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE","CTLA4, PD1, UNK, UNK","II","Advanced, First&Second line","Toxicity: CTCAE v4.0, Progression-free survival (PFS)","NCT03409198","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03409198",1,"DB06186,DB09035,NA,DB00531","NA, NA, NA, 2907","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"580",580,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PYROTINIB, CAPECITABINE, EVEROLIMUS, SHR3680, SHR6390, SHR1210, NAB-PACLITAXEL, APATINIB, FAMITINIB, VP-16","EGFR-TKI, UNK, mTOR, AR, CDK4/CDK6, PD1, UNK, VEGFR, UNK,","I/II","Advanced, Second line","Objective Response Rate (ORR) ","NCT03805399","Pts are stratified by other biomarkers that are not listed in the inclusion criteria, and then given different drug combos depending upon there subtypes","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03805399",1,"DB14993,DB01101,DB01590,NA,NA,NA,NA,DB14765,DB11741,NA","51039030, 60953, 6442177, NA, NA, NA, 36314, 45139106, 16662431, 36462","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"581",581,"EARLY-STAGE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Positive, Negative/Positive, Negative/Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, PACLITAXEL, DOXORUBICIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","UNK, UNK, UNK, UNK, UNK, Hormone Receptors","III","First line","Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0, Event-Free Survival (EFS)","NCT03725059","must be done with surgery and radiation. Needs to know the status of PDl1 and PGR","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03725059",1,"DB09037,DB01229,DB00997,DB00445,DB00531,NA","NA, 36314, 443939, 65348, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"582",582,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ONC201","UNK","II","Advanced, Second line","Progression-free survival (PFS)","NCT03394027","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03394027",1,"NA","73777259","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"583",583,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ONC201","UNK","II","Advanced, First&Second line","Overall Response Rate (ORR)","NCT03394027","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03394027",1,"NA","73777259","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"584",584,"METASTATIC BREAST CANCER","BRCA1, BRCA2","Positive, Positive","AND/OR","Mutation, Mutation","PEMBROLIZUMAB, CARBOPLATIN","UNK, UNK","II","Advanced, Second line","The ORR","NCT03732391","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03732391",1,"DB09037,DB00958","NA, 56840877","ENSG00000012048, ENSG00000139618","EFO_1000984","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"585",585,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","HERZUMA","UNK","II","Advanced, Second line","Progression free survival","NCT03755141","combined with treatment of physicians choice","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03755141",1,"NA","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"586",586,"INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative/Positive, Negative/Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, PACLITAXEL, 5-FLUOROURACIL, EPIRUBICINE, CYCLOPHOSPHAMIDE","PD1, UNK, UNK, UNK, UNK","II","First line","Central evaluation of pathological complete response rate, Dose Limiting Toxicity (DLT) rates","NCT03515798","only requires that HR status is known","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03515798",1,"DB09037,DB01229,DB00544,DB00445,DB00531","NA, 36314, 3385, 41867, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"587",587,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB","HER2, HER2, UNK, UNK, UNK, UNK","III","Advanced, First line","Event Free Survival (EFS)","NCT03595592","Requires surgery, only requires known HR staus","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03595592",1,"DB00072,DB06366,DB00958,DB01229,DB00997,DB00531,DB11595","3001322, NA, 56840877, 36314, 443939, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"588",588,"METASTATIC  BREAST CANCER","absent","NA","NA","NA","AZD9833, PALBOCICLIB","UNK, UNK","I","Advanced, First&Second line","The number of subjects with dose-limiting toxicity, as defined in the protocol, The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03","NCT03616587","Lists thorugh the trial ER+, HER2-, however, does not list in the criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03616587",1,"NA,DB09073","NA, 11478676","ENSG00000104313","EFO_1000984","ABSENT NA NA","failed drug,no biomarker"
"589",589,"INVASIVE BREAST CANCER","ER","Positive","NA","Protein Expression","FULVESTRANT, PALBOCICLIB, TAMOXIFEN","UNK, UNK, UNK","II","Advanced&Non advanced, First&Second line","Progression-free survival (PFS)","NCT02913430","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02913430",1,"DB00947,DB09073,DB00675","104741, 11478676, 2733526","ENSG00000091831","EFO_1000307","ER PROTEIN EXPRESSION POSITIVE","pass"
"590",590,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, ANASTROZOLE, LETROZOLE, EXEMESTANE, FULVESTRANT, TAMOXIFEN","UNK, UNK, UNK, UNK, UNK, UNK","II","Advanced, First&Second line","Locally-assessed progression-free survival (PFS)","NCT03555877","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03555877",1,"DB11730,DB01217,DB01006,DB00990,DB00947,DB00675","44631912, 2187, 3902, 60198, 104741, 2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"591",591,"BREAST CANCER STAGE (II-III)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GOSERELIN","LHRH","II","Advanced&Non-advanced, First line","pathologic complete response rate","NCT03444025","adding to standard chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03444025",1,"DB00014","5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"592",592,"BREAST CANCER STAGE (II-III)","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","TRASTUZUMAB, DOCETAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","III","Advanced&Non-advanced, First line","total pathological complete response rate (tpCR)","NCT03013504","only requires that HR status is known","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03013504",1,"DB00072,DB01248,DB00445,DB00531","3001322, 148124, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"593",593,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","XENTUZUMAB, EVEROLIMUS, EXEMESTANE","UNK, UNK, UNK","II","Advanced, Second line","Progression free survival (PFS) as assessed by central review","NCT03659136","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03659136",1,"DB14871,DB01590,DB00990","NA, 6442177, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"594",594,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT","UNK","III","Advanced, Second line","Progression free survival (PFS) ","NCT04263298","taken after first line gives stable disease","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT042632981",1,"DB00947","104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"595",595,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","LETROZOLE, PROMETRIUM, TAMOXIFEN","UNK, UNK, UNK","II","First line","Geometric mean suppression of proliferation marker Ki67","NCT03906669","preoperative therapy. Must be postmenopausal","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03906669",1,"DB01006,NA,DB00675","3902, 5994, 2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"596",596,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ENTINOSTAT, EXEMESTANE","UNK, UNK","III","Advanced, Second line","PFS (The Randomized Double-blinded Part)","NCT03538171","natural menopause","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03538171",1,"DB11841,DB00990","4261, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"597",597,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, PACLITAXEL, CAPIVASERTIB, OLECLUMAB, TRASTUZUMAB DERUXTECAN","UNK, UNK, UNK, UNK, UNK","I/II","Advanced, Second line","Incidence of adverse events, Laboratory findings","NCT03742102","had different arms for different drug combos","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03742102",1,"DB11714,DB01229,DB12218,DB15088,DB14962","NA, 36314, 25227436, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"598",598,"METASTATIC BREAST CANCER","ESR1","Positive","NA","Protein Expression","CAPECITABINE, AROMATASE INHIBITOR","UNK, Aromatase","II","Advanced, First line","Progress-free survival","NCT04012918","if premenopausal, they will also be given an LHRH agonist","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04012918",1,"DB01101,NA","60953, NA","ENSG00000091831","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"599",599,"RELAPSED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SCT200","EGFR","II","Advanced, Second line","Objective response rate (ORR)","NCT03692689","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03692689",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"600",600,"UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ONC201","Akt/ERK","II","Advanced, First&Second line","Overall Response Rate (ORR)","NCT03733119","also given a methionine-restricted diet","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03733119",1,"NA","73777259","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"601",601,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","IV","First line","The primary endpoint is pathological complete remission (pCR)","NCT03799679","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03799679",1,"NA,DB00445,DB00531","NA, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"602",602,"METASTATIC  TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB, CAPECITABINE","VEGFR2, UNK","II","Advanced, Second line","progression-free survival","NCT03775928","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03775928",1,"DB14765,DB01101","45139106, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"603",603,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, DOXORUBICIN, DOCETAXEL, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB SC, HORMONE THERAPY","UNK, UNK, UNK, UNK, UNK, UNK, UNK","III","First line","Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7","NCT03493854","hormone therapy includes tamoxifen or aromatase inhibitors, also combined with radiation and therpay. HR status only needed to be known","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03493854",1,"DB00531,DB00997,DB01248,DB01229,DB06366,NA,NA","2907, 443939, 148124, 36314, NA, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"604",604,"RECURRENT TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, JS001","UNK, UNK","III","Advanced, First&Second line","Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intend to Treat patients.","NCT04085276","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04085276",1,"NA,NA","36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"605",605,"ADVANCED BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","SHR9549","UNK","I","Advanced, Second line","Dose Limited Toxicity (DLT), Maximum Tolerated Dose (MTD)","NCT03596658","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03596658",1,"NA","NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"606",606,"PRIMARY INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, CARBOPLATIN","UNK, UNK","IV","First line","The primary endpoint is pathological complete remission (pCR)","NCT03799692","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03799692",1,"NA,DB00958","NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"607",607,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ADAGLOXAD SIMOLENIN, OBI-821","UNK, UNK","III","Second line","Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.","NCT03562637","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03562637",1,"NA,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"608",608,"NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER STAGE (II-III)","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, PACLITAXEL, DOXORUBICIN, EPIRUBICIN","PDL1, UNK, UNK, UNK","III","Advanced&Non advanced, First&Second line","Invasive Disease-Free Survival (iDFS)","NCT03498716","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03498716",1,"DB11595,DB01229,DB00997,DB00445","NA, 36314, 443939, 65348","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"609",609,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, SGN-LIV1A, BEVACIZUMAB, CAPECITABINE, RO6874281, COBIMETINIB, SELICRELUMAB, IPATASERTIB","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","I/II","Advanced, First&Second line","Objective Response Rate (ORR)","NCT03424005","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03424005",1,"DB11595,DB15409,DB00112,DB01101,NA,DB05239,DB14958,DB11743","NA, NA, NA, 60953, NA, 71491931, NA, 24788740","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"610",610,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","PYROTINIB, TRASTUZUMAB, DOCETAXEL","HER1/HER2, UNK, UNK","II","Advanced&Non-advanced, First line","Pathological Complete Response (pCR)","NCT03735966","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03735966",1,"DB14993,DB00072,DB01248","51039030, 3001322, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"611",611,"RECURRENT TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Negative/Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, GEMCITABINE, CAPECITABINE, CARBOPLATIN","UNK, UNK, UNK, UNK","III","Advanced, First line","Overall survival (OS) in the population with programmed death-ligand 1 (PD-L1)-positive tumour status, Overall survival (OS) in modified intent-to-treat (mITT) popluation","NCT03371017","PDL1 with be used to stratify pts after the trial starts","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03371017",1,"DB11595,DB00441,DB01101,DB00958","NA, 60750, 60953, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"612",612,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative/Positive, Negative/Positive, Positive, Positive","AND, AND/OR, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","BGB-290","UNK","II","Advanced, First&Second line","Objective response rate [","NCT03575065","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03575065",1,"NA","135565554","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"613",613,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BRCA1, BRCA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","BGB-290","UNK","II","Advanced, First&Second line","Objective response rate [","NCT03575065","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03575065",1,"NA","135565554","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"614",614,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","PYROTINIB, TRASTUZUMAB, DOCETAXEL","UNK, UNK, UNK","III","Advanced&Non-advanced, First line","Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by independent review committee(IRC)","NCT03588091","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03588091",1,"DB14993,DB00072,DB01248","51039030, 3001322, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"615",615,"LOCALLY ADVANCED","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","BAT8001","UNK","III","Advanced&Non-advanced, Second line","Progression-free survival (PFS) ","NCT04185649","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04185649",1,"NA","NA","ENSG00000141736","EFO_0005856","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"616",616,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","M7824","PDL1","I","Advanced, Second line","Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer, Safety and tolerability in patients with metastatic HR+/HER2- breast cancer","NCT03524170","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03524170",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"617",617,"LOCALLY ADVANCED","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","PERTUZUMAB, TRASTUZUMAB","UNK, UNK","II","Advanced&Non-advanced, Second line","Percentage of Participants Who Indicated They Preferred the Pertuzumab and Trastuzumab Fixed-Dose Combination Subcutaneous (FDC SC) Administration as Assessed in Question 1 of the Patient Preference Questionnaire","NCT03674112","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03674112",1,"DB06366,DB00072","NA, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005856","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"618",618,"BREAST CANCER STAGE (II-III)","ERBB2, ESR1, PGR","Positive, Negative/Positive, Negative/Positive","AND, AND","Protein Expression&Amplification,Protein Expression, Protein Expression","PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","UNK, HER2, HER2","I","Advanced&Non-advanced, First line","Adjuvant chemotherapy Received ","NCT03716180","Bilateral breast cancers are allowed as long as both cancers are HER2-positive (as defined in 3.1.2), or the contralateral cancer is a <1 cm, ER+, and HER2- tumor.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03716180",1,"DB01229,DB00072,DB06366","36314, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","pass"
"619",619,"METASTATIC BREAST CANCER","absent","NA","NA","NA","VINORELBINE, GEMCITABINE, CISPLATIN, CAPECITABINE","UNK, UNK, UNK, UNK","II/III","Advanced, Second line","Disease-free survival (DFS)","NCT03423849","said biomarkers thorughout the study, but not in the criteria. Also listed other drugs to be used in cases of HER2+ or HR+ cancers, however, did not list them as a experimental drug in this study","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03423849",1,"DB00361,DB00441,DB00515,DB01101","5311497, 60750, 135804801, 60953","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"620",620,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB","UNK, UNK","II","Advanced, First&Second line","Overall Response Rate","NCT03316586","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03316586",1,"DB09035","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"621",621,"METASTATIC BREAST CANCER","ERBB2, ESR1","Positive, Positive","AND","Protein Expression/Protein Expression&Amplification, Protein Expression","NERATINIB, FULVESTRANT","HER2, UNK","II","Advanced, Second line","Progression Free Survival","NCT03289039","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03289039",1,"DB11828,DB00947","9915743, 104741","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"622",622,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","FULVESTRANT, ENZALUTAMIDE","UNK, UNK","II","Advanced, First&Second line","Clinical benefit rate of the combination of enzalutamide/ fulvestrant ","NCT02953860","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02953860",1,"DB00947,DB08899","104741, 15951529","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"623",623,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, ENDOCRINE THERAPY","CDK4/CDK6, Hormone Receptors","II","First&Second line","Number of Participants That Complete 12 Months of Treatment","NCT03285412","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03285412",1,"DB11730,NA","44631912, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"624",624,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","ERIBULIN MESYLATE, PEMBROLIZUMAB","UNK, PD1","II","Advanced, Second line","Progression Free Survival","NCT03051659","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03051659",1,"NA,DB09037","17755248, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"625",625,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, NAB-PACLITAXEL","PD1, Microtubles","I","First line","Change in PD-L1 Expression By Immunohistochemistry From Baseline Biopsy to Biopsy After 2-Week Treatment (biopsy 2","NCT02999477","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02999477",1,"DB09037,NA","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"626",626,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","TRASTUZUMAB, IBRUTINIB","UNK, BTK","I/II","First&Second line","Phase I: Maximum Tolerated Dose","NCT03379428","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03379428",1,"DB00072,DB09053","3001322, 24821094","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"627",627,"METASTATIC BREAST CANCER","absent","NA","NA","NA","DISULFIRAM","UNK","II","Advanced, First line","clinical response rate, clinical benefit rate ","NCT03323346","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03323346",1,"DB00822","3117","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"628",628,"EARLY STAGE BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Positive, Positive/Negative","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, ADJUVANT ENDOCRINE THERAPY","UNK, Hormone Receptors","III","First&Second line","Invasive Disease Free Survival (IDFS)","NCT03155997","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03155997",1,"DB12001,NA","46220502, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"629",629,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB, PACLITAXEL, CISPLATIN","UNK, UNK, UNK","II/III","Advanced&Non-advanced, First line","The primary endpoint is pathological complete remission (pCR)","NCT03580395","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03580395",1,"DB14765,DB01229,DB00515","45139106, 36314, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"630",630,"INVASIVE BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","APATINIB, PACLITAXEL, CISPLATIN","UNK, UNK, UNK","II/III","Advanced&Non-advanced, First line","The primary endpoint is pathological complete remission (pCR)","NCT03580395","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03580395",1,"DB14765,DB01229,DB00515","45139106, 36314, 135804801","ENSG00000141736","EFO_1000307","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"631",631,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","APATINIB, PACLITAXEL, CISPLATIN","UNK, UNK, UNK","II/III","Advanced&Non-advanced, First line","The primary endpoint is pathological complete remission (pCR)","NCT03580395","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03580395",1,"DB14765,DB01229,DB00515","45139106, 36314, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"632",632,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DAROLUTAMIDE","UNK","I","First line","Explore/Define Molecular Alterations in Core Tissue Tumor Samples Following Darolutamide Administration","NCT03004534","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03004534",1,"DB12941","67171867","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"633",633,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CISPLATIN, AZD1775","DNA, WEE1","II","Advanced&Non-advanced, First line","Objective response rate","NCT03012477","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03012477",1,"DB00515,NA","135804801, 24856436","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"634",634,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","EPALRESTAT","UNK","II","Advanced, First&Second line","Progression-free survival (PFS)","NCT03244358","does not require prior chemo, only requires that last treatment was 21 days prior","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03244358",1,"DB15293","1549120","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"635",635,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","FULVESTRANT, ENZALUTAMIDE","UNK, UNK","II","Advanced, First&Second line","Document the number of patients in both treatment arms separately who have a PEPI score equal to 0 at post treatment","NCT02955394","preoperative, must be postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02955394",1,"DB00947,DB08899","104741, 15951529","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"636",636,"INFLAMMATORY BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","RUXOLITINIB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Assess JAK Inhibition With Ruxolitinib On pStat3+ Expression","NCT02876302","pts can be metastatic./non metastatic","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02876302",1,"DB08877,DB01229,DB00997,DB00531","25126798, 36314, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"637",637,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE","PDL1, UNK, UNK","II","Advanced, Second line","Assessment of toxicity of combined treatment with Atezolizumab, pegylated liposomal doxorubicin and cyclophosphamide, Progression-free survival (PFS)","NCT03164993","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03164993",1,"DB11595,NA,DB00531","NA, NA, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"638",638,"UNRESECTABLE BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","I","Advanced, Second line","Change in tumor infiltrating lymphocytes","NCT03237572","must be combined with high-intensity focused ultrasound","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03237572",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"639",639,"METASTATIC BREAST CANCER","AR","Positive","NA","Protein Expression","PROXALUTAMIDE","UNK","I","Advanced, first line","Dose-limiting Toxicity(DLT), maximum tolerated dose (MTD), Disease Control Rate(DCR)","NCT04103853","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT04103853",1,"NA","60194102","ENSG00000169083","EFO_1000984","AR PROTEIN EXPRESSION POSITIVE","pass"
"640",640,"BREAST CANCER","HER2","Positive","NA","Protein Expression","TAXOTERE, CARBOPLATIN, HERCEPTIN, PERTUZUMAB, METFORMIN","UNK, UNK, UNK, UNK, UNK","II","First line","Pathologic complete response (pCR)","NCT03238495","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03238495",1,"NA,DB00958,NA,DB06366,DB00331","148124, 56840877, NA, NA, 14219","ENSG00000141736","MONDO_0007254","HER2 PROTEIN EXPRESSION POSITIVE","pass"
"641",641,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Positive/Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","I/II","First line","Number of patients who do not necessitate a delay in standard of care treatment after receiving the investigational combination of preoperative Pembrolizumab and radiation, Changes in Tumor Infiltrating Lymphocytes (TIL)","NCT03366844","with radiation","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03366844",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"642",642,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","I/II","First line","Number of patients who do not necessitate a delay in standard of care treatment after receiving the investigational combination of preoperative Pembrolizumab and radiation, Changes in Tumor Infiltrating Lymphocytes (TIL)","NCT03366844","with radiation","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03366844",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"643",643,"INVASIVE BREAST CANCER","ESR1","Positive","NA","Protein Expression","TAMOXIFEN, TOREMIFENE","UNK, UNK","III","Second line","Disease-Free Survival","NCT03351062","Polymorphism analysis showed that patients are CYP2D6 * 4, * 5, * 10, * 14, * 17, * 41 allele carriers;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03351062",1,"DB00675,DB00539","2733526, 3005573","ENSG00000091831","EFO_1000307","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"644",644,"INVASIVE BREAST CANCER (STAGE I-IIIA)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, LETROZOLE","UNK, UNK","II","Advanced&Non-advanced, First line","Rate of ROR-low according to the Prosigna test.","NCT03248427","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03248427",1,"DB11730,DB01006","44631912, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"645",645,"LOCALLY ADVANCED","ERBB2, ESR1, PGR, RB","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB","CDK4/CDK6","II","Advanced, Second line","Objective Response Rate","NCT03130439","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03130439",1,"DB12001","46220502","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000139687","EFO_0005856","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND RB PROTEIN EXPRESSION POSITIVE","pass"
"646",646,"INVASIVE BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","TAMOXIFEN","UNK","II","First&Second line","Endocrine Therapy response ","NCT03211572","says newly diagnosed, but only excludes previous treatment within the last 6 months","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03211572",1,"DB00675","2733526","ENSG00000141736, ENSG00000091831","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"647",647,"BREAST CANCER (STAGE III-IV)","ERBB2, ESR1, PGR, GR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","MIFEPRISTONE, NAB-PACLITAXEL","UNK, UNK","II","Advanced, First&Second line","Progression-free survival (PFS)","NCT02788981","GR is glucocorticoid receptor","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02788981",1,"DB00834,NA","55245, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000113580","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND GR PROTEIN EXPRESSION POSITIVE","pass"
"648",648,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","I","First line","Number of subjects with significant mean percent change in TILs","NCT02977468","done with intraoperative radiation therapy , weekly positive for the estrogen or progesterone receptor (i.e., < or = 10%) are eligible.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02977468",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"649",649,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, HLAA2","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, PVX-410","PD1, UNK","I","Advanced, Second line","Immune Response following treatment with PVX-410 in combination with pembrolizumab","NCT03362060","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03362060",1,"DB09037,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND HLAA2 PROTEIN EXPRESSION POSITIVE","pass"
"650",650,"METASTATIC BREAST CANCER","E-cadherin","Negative","NA","Protein Expression","CARBOPLATIN, ATEZOLIZUMAB","UNK, UNK","II","Advanced, First&Second line","Number of patients free of progression at 6 months","NCT03147040","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03147040",1,"DB00958,DB11595","56840877, NA","ENSG00000039068","EFO_1000984","E-CADHERIN PROTEIN EXPRESSION NEGATIVE","pass"
"651",651,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","CAPECITABINE, AROMATASE INHIBITOR","UNK, Aromatase","III","Advanced, First line","Progress-free survival ","NCT02767661","Aromatase inhibitors include: anastrozole, letrozole, exemestane, On a luteinizing hormone releasing hormone (LHRH) agonist for at least 28 days","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02767661",1,"DB01101,NA","60953, NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"652",652,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, ENDOCRINE THERAPY","CDK4/CDK6, Hormone Receptors","II","Second line","Preliminary safety and tolerability of the ribociclib + ET in patients that were randomized to ribociclib + ET prior to the early closure of enrollment.","NCT03078751","Endorcrine therapy includes: anastrozole, letrozole, exemestane, On a luteinizing hormone releasing hormone (LHRH) agonist for at least 28 days. In premenopausal women, adjuvant endocrine therapy will include GnRH","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03078751",1,"DB11730,NA","44631912, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"653",653,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","PERTUZUMAB, HERCEPTIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, ANASTROZOLE, LETROZOLE, EXEMESTANE, PACLITAXEL, TAMOXIFEN, LEUPORELIN ACETATE, GOSERELIN","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","II","First line","Pathological complete response (pCR)","NCT03272477","with surgery","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03272477",1,"DB06366,NA,DB00445,DB00531,DB01217,DB01006,DB00990,DB01229,DB00675,NA,DB00014","NA, NA, 65348, 2907, 2187, 3902, 60198, 36314, 2733526, NA, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"654",654,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB","UNK","II","First line","To identify biomarkers of resistance to a 4-month preoperative treatment of palbociclib plus endocrine therapy defined as stable or progressive disease by ultrasound (based on WHO criteria) using RNA-seq of the baseline tumour biopsy","NCT03065621","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03065621",1,"DB09073","11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"655",655,"INVASIVE BREAST CANCER (STAGE I-II)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ANASTROZOLE, LETROZOLE, EXEMESTANE, TAMOXIFEN","UNK, UNK, UNK, UNK","II","First line","The proportion of upregulated HER proteins after treatment.","NCT03219476","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03219476",1,"DB01217,DB01006,DB00990,DB00675","2187, 3902, 60198, 2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"656",656,"UNRESECTABLE BREAST CANCER","ERBB2","Positive","NA","Protein Expression","DS-8201A","UNK","II","Advanced, First&Second line","Objective Response Rate as Confirmed by Independent Central Review Following Intravenous Administration of 5.4 mg/kg DS-8201a in Participants With Metastatic Breast Cancer (Enrolled Analysis Set)","NCT03248492","being done with TDM1 resistant/refractory . Not clear with clinical state other than it being advance. Must be resistant to TDM1","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03248492",1,"NA","132508503","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"657",657,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, CAPECITABINE, VINORELBINE","UNK, UNK, UNK","II","Advanced, First&Second line","Time to treatment failure (TTF) compared between treatment groups.","NCT02954055","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02954055",1,"DB00531,DB01101,DB00361","2907, 60953, 5311497","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"658",658,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","TAMOXIFEN","UNK","II","Advanced, Second line","Progression-free Survival (PFS)","NCT03045653","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03045653",1,"DB00675","2733526","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"659",659,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive/Negative","AND","Protein Expression, Protein Expression","CYCLOPHOSPHAMIDE, PEMBROLIZUMAB","UNK, PD1","II","Advanced, First&Second line","Severe Toxicities (ST) in Run-In Phase Part, 24-week Clinical Benefit Rate (CBR24w) in Phase II part","NCT03139851","Patients with ER-positive tumors must have received at least one prior endocrine therapy, either in the adjuvant setting or in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03139851",1,"DB00531,DB09037","2907, NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"660",660,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, FGFR1","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Protein Expression&Amplification","ERDAFITINIB, PALBOCICLIB, FULVESTRANT","FGFR, CDK4/CDK6, UNK","I","Advanced, Second line","Incidence of Treatment-Emergent Adverse Events [Safety]","NCT03238196","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03238196",1,"DB12147,DB09073,DB00947","67462786, 11478676, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000077782","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"661",661,"UNRESECTABLE BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB, LETROZOLE, ANASTROZOLE, EXEMESTANE, FULVESTRANT","UNK, HER2, HER2, UNK, UNK, UNK, UNK","III","Advanced, Second line","Progression-free survival (PFS) as assessed by Investigator","NCT02947685","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02947685",1,"DB09073,DB00072,DB06366,DB01006,DB01217,DB00990,DB00947","11478676, 3001322, NA, 3902, 2187, 60198, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"662",662,"BREAST CANCER (STAGE I-III)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","TAK-228, TAMOXIFEN","MTOR1/2, Estrogen","II","Advanced&Non-advanced, First&Second line","Change in Ki67 expression","NCT02988986","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02988986",1,"NA,DB00675","45375953, 2733526","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"663",663,"INVASIVE BREAST CANCER (STAGES I-III)","absent","NA","NA","NA","BOSWELLIA","UNK","I","First line","Change in tumor proliferation rate","NCT03149081","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03149081",1,"NA","17973666","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"664",664,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, LETROZOLE, LEUPRORELIN","UNK, UNK, UNK, UNK, UNK","II","First line","pathologic complete remission (pCR) ","NCT03497702","neoadjuvant chemotherapy with AC followed by Docetaxel","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03497702",1,"DB00997,DB00531,DB01248,DB01006,DB00007","443939, 2907, 148124, 3902, 657181","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"665",665,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","TUCATINIB, PALBOCICLIB, LETROZOLE","HER2, CDK4/CDK6, aromatase","I/II","Advanced, Second line","The number of patients in the Pase 1b part of the study with any adverse events (AE), The number of patients with progression-free survival (PFS)","NCT03054363","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03054363",1,"DB11652,DB09073,DB01006","51039094, 11478676, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"666",666,"UNRESECTABLE BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","DS-8201A","UNK","I","Advanced, Second line","Average baseline-adjusted QT interval corrected for heart rate by Fridericia's formula (QTcF ), Maximum Concentration (Cmax), Time to Cmax (Tmax), Area under the drug concentration time curve (AUC) at the last observation (AUClast), AUC extrapolated to infinity (AUCinf), Half-life (T1/2), Clearance (CL) of DS8201a, Volume of DS-8201a at steady state (Vss)","NCT03366428","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03366428",1,"NA","132508503","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"667",667,"BREAST CANCER","ERBB2, ESR1, Ki67","Negative, Positive, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, COBIMETINIB, IPATASERTIB, BEVACIZUMAB","PDL1, MEK1/MEK2, AKT, VEGF","II","First line","2-fold Increase in GzmB+ CD8+ T cell levels","NCT03395899","getting different drug combos. Patients with either: (a) Luminal B breast cancer defined as: high Ki67 defined as ≥20% and /or histological grade 3 and / or Luminal B according to PAM50 assay or (b) Non-Luminal B breast cancer","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03395899",1,"DB11595,DB05239,DB11743,DB00112","NA, 71491931, 24788740, NA","ENSG00000141736, ENSG00000091831, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"668",668,"METASTATIC BREAST CANCER","absent","NA","NA","NA","IRINOTECAN","UNK","II","Advanced, Second line","Objective response rate (ORR)","NCT03562390","Patients with locally recurrent or metastatic breast cancer who have been treated with at least two chemotherapy regimens","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03562390",1,"DB00762","60838","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"669",669,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","APATINIB, ETOPOSIDE","VEGFR2, UNK","II","Advanced, Second line","Progression free survival (PFS) among metastatic HER2 negative breast cancer treated with apatinib and oral etoposide","NCT03535961","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03535961",1,"DB14765,DB00773","45139106, 36462","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"670",670,"INFILTRATING PRIMARY BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","TRASTUZUMAB, DOCETAXEL","UNK, UNK","II","First line","Disease-free Survival ","NCT03367676","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03367676",1,"DB00072,DB01248","3001322, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"671",671,"IVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","LAPATINIB, HERCEPTIN","UNK, UNK","II/III","First line","DFS","NCT03085368","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03085368",1,"DB01259,NA","208908, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"672",672,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, PIK3CA","Negative, Positive, Positive, Positive","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","ALPELISIB, FULVESTRANT, GOSERELIN, LEUPROLIDE","UNK, UNK, UNK, UNK","II","Advanced, First&Second line","The percentage of patients who are alive without disease progression","NCT03056755","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03056755",1,"DB12015,DB00947,DB00014,DB00007","56649450, 104741, 5311128, 657181","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION POSITIVE","pass"
"673",673,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR, BCRA1, BCRA2","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation/Methylation, Mutation/Methylation","OLAPARIB","UNK","II","Advanced, Second line","Overall Response Rate to olaparib defined as the percentage of patients with a complete or partial response out of the total of patients of the efficacy population","NCT03205761","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03205761",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BCRA1 MUTATION/METHYLATION POSITIVE AND/OR BCRA2 MUTATION/METHYLATION POSITIVE","pass"
"674",674,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, FGFR","Negative, Positive, Positive, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Protein Expression&Amplification","FULVESTRANT, DEBIO 1347","UNK, UNK","I/II","Advanced, First&Second line","Number of patients experiencing Dose Limiting Toxicity (Phase I), proportion of patients who have a best overall response (Phase II)","NCT03344536","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03344536",1,"DB00947,NA","104741, 66555680","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000068078","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND FGFR PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"675",675,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","CAPECITABINE, NERATINIB","UNK, UNK","I/II","Advanced, First&Second line","Maximum Tolerated Dose (MTD)","NCT03377387","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03377387",1,"DB01101,DB11828","60953, 9915743","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"676",676,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, HORMONE THERAPY","PD1, Hormone receptors","I/II","Advanced&Non-advanced, Second line","Phase Ib : dose-limiting toxicity rate","NCT03430479","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03430479",1,"DB09035,NA","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"677",677,"METASTATIC BREAST CANCER","ERBB2, ESR1","Positive, Positive","AND","Protein Expression/Protein Expression&Amplification, Protein Expression","HEMAY022, EXEMESTANE","UNK, UNK","I","Advanced, Second line","Number of participants with adverse events","NCT03308201","pt must be postmenopausal","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03308201",1,"NA,DB00990","NA, 60198","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"678",678,"METASTATIC  BREAST CANCER","ESR1","Positive","NA","Protein Expression","OPC","UNK","I","Advanced, First&Second line","AGE level reduction","NCT03092635","AGEs are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to see if certain drug (OPC) has an effect on the AGE levels in your blood and to see if those AGE levels have an effect on your cancer.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03092635",1,"NA","2754","ENSG00000091831","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"679",679,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","PEMETREXED, VINORELBINE","folate, UNK","II","Advanced, Second line","progression free survival","NCT03242616","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03242616",1,"DB00642,DB00361","135413520, 5311497","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"680",680,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB, PACLITAXEL","UNK, UNK","II","Advanced, First line","objective response rate","NCT03348098","testing as a neoadjuvant therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03348098",1,"DB14765,DB01229","45139106, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"681",681,"RELAPSED TRIPLE-NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","SACITUZUMAB GOVITECAN","UNK","III","Advanced, Second line","Progression-Free Survival (PFS)","NCT02574455","Refractory to or relapsed after at least two prior standard therapeutic regimens for advanced/metastatic TNBC.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02574455",1,"DB12893","91668186","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"682",682,"BREAST CANCER","absent","NA","NA","NA","CURCUMIN, PACLITAXEL","NA","II","Advanced&Non-advanced, Second line","Objective response rate","NCT03072992","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03121989",1,"DB11672,DB01229","969516, 36314","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"683",683,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ALBUMIN-BOUND PACLITAXEL, PHENELZINE SULFATE","UNK, UNK","I","Advanced&Non-advanced, First&Second line","Dose-Limiting Toxicity (DLT) events","NCT03505528","can be TNBC or not, but must be her2- , Women with metastatic breast cancer or inoperable locally advanced breast cancer who have not received any cytotoxic therapy in the last 3 weeks;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03505528",1,"NA,NA","NA, 61100","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"684",684,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","LETROZOLE, CAPECITABINE","UNK, UNK","II/III","First line","objective response rate","NCT03507465","Capecitabine given as Low-Dose Metronomic Capecitabine","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03507465",1,"DB01006,DB01101","3902, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"685",685,"BREAST CANCER (STAGE II-IV)","absent","NA","NA","NA","LEUCOSTIM","UNK","III","Advanced&Non-advanced, First line","Mean duration of Grade 4 Neutropenia","NCT03343145","requirement to: Be scheduled to receive TAC regimen as adjuvant therapy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03343145",1,"NA","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"686",686,"UNRESECTABLE BREAST CANCER","ERBB2","Positive","NA","Protein Expression","TRASTUZUMAB, PERTUZUMAB, TOCILIZUMAB","UNK, UNK, UNK","I","Advanced, First&Second line","Recommended Phase II Dose of Tocilizumab ","NCT03135171","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03135171",1,"DB00072,DB06366,DB06273","3001322, NA, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"687",687,"BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","MEGESTROL ACETATE, LETROZOLE","UNK, aromatase","II","First&Second line","Determination of change in tumour proliferation measured by Ki67 immunohistochemical (IHC) assessment (%) at baseline compared to Day 15 (+ ≤4 days).","NCT03306472","postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03306472",1,"DB00351,DB01006","11683, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"688",688,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","DURVALUMAB, TREMELIMUMAB, FULVESTRANT","PDL1, CTLA4, UNK","II","Advanced, First&Second line","Response rate based on RECIST1.1","NCT03430466","Patients who have plans of 2nd hormone therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03430466",1,"DB11714,DB11771,DB00947","NA, NA, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"689",689,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT","UNK","II","Advanced, First line","Tumour assessment","NCT03202862","postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03202862",1,"DB00947","104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"690",690,"BREAST CANCER (STAGE I-IV)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","TAK-228, LETROZOLE","mTOR, aromatase","I","Advanced&Non-advanced, First line","Evaluation of Treatment-Related Adverse Events as Assessed by NCI CTCAE v4.0","NCT02619669","postmenopausal, with surgical resection, The invasive cancer must be HER2-low, defined as IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been performed.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02619669",1,"NA,DB01006","45375953, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"691",691,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","SAR439859, PALBOCICLIB, MIDAZOLAM","UNK, UNK, UNK","I/II","Advanced, First&Second line","Part A : To determine the RD of SAR439859, Part C : To determine the RD of SAR439859 in combination with palbociclib, Part B : to evaluate the ORR of SAR439859, Part D: Adverse Events, Part E: AUClast and AUC of midazolam","NCT03284957","different combos with SAR439859","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03284957",1,"NA,DB09073,DB00683","130232326, 11478676, 4192","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"692",692,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GDC-9545, PALBOCICLIB","UNK, UNK","I","Advanced, First&Second line","Number of Participants with Adverse Events by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0), Dose Escalation: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of GDC-9545 When Administered as a Single Agent or in Combination with Palbociclib, Dose Escalation: Number of Participants with Dose-Limiting Toxicities When GDC-9545 is Administered as a Single Agent or in Combination with Palbociclib, Change from Baseline in Systolic Blood Pressure Over Time, Change from Baseline in Diastolic Blood Pressure Over Time, Change from Baseline in Body Temperature Over Time, Change from Baseline in Pulse Rate Over Time, Change from Baseline in Respiration Rate Over Time , Change from Baseline in Electrocardiogram (ECG) Results Over Time: Heart Rate, Change from Baseline in ECG Results Over Time: PR Duration, Change from Baseline in ECG Results Over Time: QRS Duration, Change from Baseline in ECG Results Over Time: QT Duration, Change from Baseline in ECG Results Over Time: QTcF Duration, Change from Baseline in ECG Results Over Time: RR Duration, Number of Participants with Clinical Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v4.0, Number of Participants with Clinical Laboratory Abnormalities in Blood Chemistry Tests by Highest Grade According to NCI-CTCAE v4.0, Number of Participants with Clinical Laboratory Abnormalities in Urinalysis Tests by Highest Grade According to NCI-CTCAE v4.0","NCT03332797","for pts who are premenopausal: LHRH Agonist.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03332797",1,"NA,DB09073","NA, 11478676","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"693",693,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","TRASTUZUMAB EMTANSINE","UNK","I","Advanced, Second line","Area Under the Concentration-Time Curve [AUC] of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1, Maximum Serum Concentration (Cmax) Immediately After Dosing of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1, Minimum (Trough) Concentration (Cmin) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1, Clearance (CL) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1 , Volume of Distribution at Steady-State (Vss) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1, Half-Life (t1/2) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1","NCT03153163","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03153163",1,"DB05773","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"694",694,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","RIBOCICLIB, CAPECITABINE","UNK, UNK","I","Advanced, First&Second line","Determination of the maximum tolerated dose (MTD) and the recommended dose for phase 2 (RP2D) of ribociclib and capecitabine combination","NCT02754011","Progressive patients who are eligible to a treatment with capecitabine: after failure to taxanes (neoadjuvant, adjuvant or metastatic setting) and failure to prior anthracycline-based chemotherapy (unless contraindicated)","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02754011",1,"DB11730,DB01101","44631912, 60953","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"695",695,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, ENTINOSTAT, FULVESTRANT, IPATASERTIB, BEVACIZUMAB, EXEMESTANE, TAMOXIFEN, ABEMACICLIB","PDL1, UNK, UNK, UNK, UNK, UNK, UNK, UNK","I/II","Advanced, Second line","Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1","NCT03280563","Says HR positive","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03280563",1,"DB11595,DB11841,DB00947,DB11743,DB00112,DB00990,DB00675,DB12001","NA, 4261, 104741, 24788740, NA, 60198, 2733526, 46220502","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"696",696,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","ESTETROL","UNK","I/II","Advanced, Second line","The number of patients with a dose limiting toxicity (DLT)","NCT02718144","postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02718144",1,"DB12235","27125","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"697",697,"UNRESECTABLE BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification","TRASTUZUMAB EMTANSINE","UNK","III","Advanced, Second line","Progression-free survival (PFS)","NCT03084939","has an active comparator","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03084939",1,"DB05773","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","pass"
"698",698,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT","UNK, UNK","II","Advanced, Second line","Progression free survival (PFS), as assessed locally by the investigator.","NCT03322215","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03322215",1,"DB09073,DB00947","11478676, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"699",699,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PU-H71, NAB-PACLITAXEL","UNK, UNK","I","Advanced, Second line","Maximum Tolerated Dose (MTD)","NCT03166085","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03166085",1,"DB12638,NA","9549213, 36314","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"700",700,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL","UNK","II/III","Advanced, First line","[Phase II] Objective Response Rate (ORR), [Phase III] Progression Free Survival (PFS)","NCT03315364","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03315364",1,"DB01229","36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"701",701,"BREAST CANCER (STAGE II-III)","ERBB2, ESR1","Positive, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, GOSERELIN","UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Pathologic complete response (pCR) rate ","NCT02907918","with surgery","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02907918",1,"DB09073,DB01006,DB00072,DB00014","11478676, 3902, 3001322, 5311128","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"702",702,"LOBULAR","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DURVALUMAB","UNK, UNK, UNK, UNK","I/II","First line","Adverse events, Pathological response","NCT03356860","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03356860",1,"DB01229,DB00445,DB00531,DB11714","36314, 65348, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0008509","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"703",703,"LOBULAR","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DURVALUMAB","UNK, UNK, UNK, UNK","I/II","First line","Adverse events, Pathological response","NCT03356860","comparing with standard therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03356860",1,"DB01229,DB00445,DB00531,DB11714","36314, 65348, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0008509","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"704",704,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","ABRAXANE","UNK","II","Advanced, Second line","Progression Free Survival (PFS)","NCT02687490","needs to be visceral dominant metastases. From Criteria: Patients who are expected to acquire benefit from chemotherapy: ER and/or PR positive patients who developed resistance after prior endocrine therapy; HER2+ patients who experienced disease progression on prior target therapy and are not suitable for subsequent target therapy; mTNBC patients who relapsed after platinum therapy;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02687490",1,"NA","36314","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"705",705,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","ABRAXANE","UNK","II","Advanced, Second line","Progression Free Survival (PFS)","NCT02687490","needs to be visceral dominant metastases. From Criteria: Patients who are expected to acquire benefit from chemotherapy: ER and/or PR positive patients who developed resistance after prior endocrine therapy; HER2+ patients who experienced disease progression on prior target therapy and are not suitable for subsequent target therapy; mTNBC patients who relapsed after platinum therapy;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02687490",1,"NA","36314","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"706",706,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ABRAXANE","UNK","II","Advanced, Second line","Progression Free Survival (PFS)","NCT02687490","needs to be visceral dominant metastases. From Criteria: Patients who are expected to acquire benefit from chemotherapy: ER and/or PR positive patients who developed resistance after prior endocrine therapy; HER2+ patients who experienced disease progression on prior target therapy and are not suitable for subsequent target therapy; mTNBC patients who relapsed after platinum therapy;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02687490",1,"NA","36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"707",707,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","SYD985","UNK","III","Advanced, Second line","Progression Free Survival","NCT03262935","Patients should have had either progression during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease or progression during or after (ado-)trastuzumab emtansine treatment for locally advanced or metastatic disease;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03262935",1,"NA","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","failed drug"
"708",708,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND","Protein Expression, Protein Expression","CDK 4/6 INHIBITOR, NON-STEROIDAL AROMATASE INHIBITOR, FULVESTRANT","CDK4/CDK6, aromatase, UNK","III","Advanced, First line","Progression-free survival after two lines of treatment (PFS2)","NCT03425838","CDK4/6 Inhibitors: palbociclib,Ibrance,ribociclib,Kisqali,abemaciclib,Verzenio. Aromatase inhibitors: NSAI, letrozole, Femara®, anastrozole, Arimidex®","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03425838",1,"NA,NA,DB00947","NA, NA, 104741","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"709",709,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","HYDROXYCHLOROQUINE, EVEROLIMUS","UNK, UNK","II","Second line","Number of Adverse Events ","NCT03032406","pt couldn’t have received Prior treatment with an mTOR inhibitor, Evidence of residual disease in the breast on pathological assessment after neoadjuvant chemotherapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03032406",1,"DB01611,DB01590","12947, 6442177","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"710",710,"INVASIVE BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","HYDROXYCHLOROQUINE, EVEROLIMUS","UNK, UNK","II","Second line","Number of Adverse Events ","NCT03032406","pt couldn’t have received Prior treatment with an mTOR inhibitor, Evidence of residual disease in the breast on pathological assessment after neoadjuvant chemotherapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03032406",1,"DB01611,DB01590","12947, 6442177","ENSG00000141736, ENSG00000091831","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"711",711,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","XENTUZUMAB, ABEMACICLIB, LETROZOLE, ANASTROZOLE, FULVESTRANT","UNK, UNK, UNK, UNK, UNK","I","Advanced&Non-advanced, First&Second line","Maximum Tolerated Dose (MTD), Number of patients with dose limiting toxicities (DLT) in the Maximum Tolerated Dose (MTD) evaluation period , Progression-free survival (PFS) rate, objective response (OR), defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.","NCT03099174","Had multiple cohorts, 3 for BC, which had different drug combos. Cohort F only: Postmenopausal with locally advanced or metastatic HR+ breast cancer and refractory to aromatase inhibitors therapy and CDK4/6 inhibitor treatment (e.g.,palbociclib or ribociclib) for locally advanced or metastatic breast cancer.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03099174",1,"DB14871,DB12001,DB01006,DB01217,DB00947","NA, 46220502, 3902, 2187, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"712",712,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","TAK-228, TAK-117, CISPLATIN, NAB PACLITAXEL","Homologous Recombination, Homologous Recombination, UNK, UNK","II","Advanced, Second line","Efficacy (objective response rate)","NCT03193853","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03193853",1,"NA,NA,DB00515,NA","45375953, 70798655, 135804801, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION NEGATIVE","pass"
"713",713,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, CA6","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","566658","UNK","II","Advanced, Second line","Objective response rate (ORR)","NCT02984683","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02984683",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000131686","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND CA6 PROTEIN EXPRESSION POSITIVE","failed drug"
"714",714,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ENTINOSTAT, EXEMESTANE","UNK, UNK","II","Advanced, Second line","Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)","NCT03291886","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03291886",1,"DB11841,DB00990","4261, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"715",715,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB","UNK","III","First line","Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0), Event-free survival (EFS)","NCT03281954","given with neoadjuvant chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03281954",1,"DB11595","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"716",716,"METASTATIC BREAST CANCER","ESR1","Positive","NA","Protein Expression","TTC-352","ER","I","Advanced, Second line","MTD","NCT03201913","have a diagnosis of metastatic ER+ breast cancer in patients who received and progressed on at least two lines of endocrine therapy, with one that included a CDK4/CDK6 inhibitor (e.g., palbociclib or ribociclib);","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03201913",1,"NA","NA","ENSG00000091831","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"717",717,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, PEMBROLIZUMAB, NAB-PACLITAXEL","UNK, UNK, UNK","II","Advanced, First&Second line","Determine overall response rate (ORR) in patients treated with CNP","NCT03121352","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03121352",1,"DB00958,DB09037,NA","56840877, NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"718",718,"EARLY TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, NAB-PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM, PEGFILGRASTIM","PDL1, UNK, UNK, UNK, UNK, UNK","III","First line","Percentage of Participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System, Percentage of Participants with pCR in Subpopulation with PD-L1-Positive Tumor Status (tumor-infiltrating immune cell [IC] 1/2/3) Using AJCC Staging System","NCT03197935","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03197935",1,"DB11595,NA,DB00997,DB00531,DB00099,DB00019","NA, 36314, 443939, 2907, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"719",719,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ATEZOLIZUMAB, PACLITAXEL","PDL1, UNK","III","Advanced, First line","Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation with Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","NCT03125902","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03125902",1,"DB11595,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"720",720,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","VINORELBINE, APATINIB","UNK, UNK","II","Advanced, Second line","Progression Free Survival","NCT03254654","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03254654",1,"DB00361,DB14765","5311497, 45139106","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"721",721,"METASTATIC  BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","FLUVESTRANT, VINORELBINE","UNK, UNK","II","Advanced, First&Second line","Progression-free survival (PFS)","NCT03939871","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03939871",1,"NA,DB00361","104741, 5311497","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"722",722,"METASTATIC BREAST CANCER","absent","NA","NA","NA","SPARC1613","UNK","I","Advanced, First&Second line","Maximum observed concentration (Cmax) ","NCT03109249","only requirement is that chemo is 30 days out","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03109249",1,"NA","NA","ENSG00000104313","EFO_1000984","ABSENT NA NA","failed drug,no biomarker"
"723",723,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, DOXORUBICIN, EPIRUBICIN, CYCLOPHOSPHAMIDE, FILGRASTIM/PEGFILGASTRIM","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK/UNK","III","Advanced, First&Second line","Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0, Event-free Survival (EFS) as assessed by Investigator","NCT03036488","only requirement is no chemo within 30 days","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03036488",1,"DB09037,DB00958,DB01229,DB00997,DB00445,DB00531,NA","NA, 56840877, 36314, 443939, 65348, 2907, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"724",724,"LOCALLY ADVANCED","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","ATEZOLIZUMAB, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","II","Advanced, First&Second line","Number of participants with treatment-related adverse events, Antitumor activity of atezolizumab plus the standard regimen of paclitaxel, trastuzumab, and pertuzumab","NCT03125928","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03125928",1,"DB11595,DB01229,DB00072,DB06366","NA, 36314, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005856","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"725",725,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","G1T38, FULVESTRANT","UNK, UNK","I/II","Advanced, First&Second line","Dose Limiting Toxicity, Recommended Phase 2 dose, Recommended Phase 2 dose interval, Number of Treatment Related Adverse Event, including Abnormal Laboratory Events","NCT02983071","Pre- or perimenopausal women can be enrolled if amenable to be treated with goserelin","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02983071",1,"NA,DB00947","86269224, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"726",726,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RAD140","UNK","I","Advanced, First&Second line","Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment, Number of adverse events related to study treatment, Number participants with dose interruptions and dose adjustments","NCT03088527","postmenopausal, only requires last chemo was tkane 28 days prior","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03088527",1,"NA","44200882","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"727",727,"INVASIVE BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","AZD9496","UNK","I","First line","Pharmacodynamics changes to estrogen receptor (ER) expression following treatment with AZD9496 or fulvestrant","NCT03236974","Patients with newly diagnosed resectable primary breast cancer scheduled to undergo treatment with curative intent by surgery. Must be postmenopasual","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03236974",1,"NA","86287635","ENSG00000141736, ENSG00000091831","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"728",728,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, PACLITAXEL","UNK, UNK","II","Advanced, First&Second line","Grade 3 or 4 treatment-related adverse event","NCT03018080","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03018080",1,"DB09037,DB01229","NA, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"729",729,"METASTATIC  BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PYROTINIB, CAPECITABINE","UNK, UNK","III","Advanced, Second line","Progression Free Survival(PFS)","NCT03080805","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03080805",1,"DB14993,DB01101","51039030, 60953","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"730",730,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","T-DM1, PEMBROLIZUMAB","UNK, UNK","I","Advanced, First&Second line","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","NCT03032107","must have been tested for ER and PR, does not require them to be +/-. Patients must have either received one line of prior therapy for metastatic breast cancer, or have developed a disease recurrence during or within 6 months after completing adjuvant therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03032107",1,"DB05773,DB09037","NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"731",731,"BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, CISPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK, UNK, UNK","III","First line","Number of Participants With Disease-Free Survival (DFS) Events","NCT03201861","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03201861",1,"DB01229,DB00515,DB00445,DB00531","36314, 135804801, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"732",732,"INVASIVE BREAST CANCER (STAGE I-III)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","TAMOXIFEN, ENDOCRINE THERAPY, LETROZOLE, PALBOCICLIB","UNK, Hormone Receptors, UNK, UNK","II","Advanced&Non-advanced, First line","Window Phase:To evaluate the difference in anti-proliferative activity of letrozole versus tamoxifen within cohorts of hormone receptor positive breast cancer for patients with invasive lobular and ductal carcinoma. [ Time Frame: 2 years ], Treatment Phase: To evaluate the pathologic complete response (pCR) of endocrine therapy plus palbociclib and of endocrine therapy alone in breast cancer patients diagnosed with hormone receptor positive invasive breast cancer [ Time Frame: 2 Years ]","NCT02764541","different treatment arms got different drug combinations. Preoperative study","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02764541",1,"DB00675,NA,DB01006,DB09073","2733526, NA, 3902, 11478676","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"733",733,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","ENDOSTAR","angiogenesis","II","Advanced, First&Second line","Progression-free Survival (PFS)","NCT03907098","concurrent with a chemo of the physician's choice. Chemotherapy for recurrent and metastatic lesions should be discontinued for more than 2 weeks.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03907098",1,"DB11727","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"734",734,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR, TP53","Positive/Negative, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","CYCLOPHOSPHAMIDE","UNK","II","Advanced, Second line","Objective response rate (ORR) measured clinically (with calipers) or radiologically per RECIST guidelines.","NCT02965950","if HR +, it must have progessed on endrocrine therapies. Known tumor ER, PGR and HER2 status in the current situation, i.e. archival and historic breast cancer tissue can not be used for patients with relapse of the disease. However, patients can be included regardless of hormone receptor and HER2 status; in case such information lacks at inclusion, it may be analysed on the biopsy retrospectively.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02965950",1,"DB00531","2907","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000141510","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND TP53 MUTATION POSITIVE/NEGATIVE","pass"
"735",735,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, FULVESTRANT","UNK, UNK","II","Advanced, First&Second line","Percent progression-free at 24 weeks","NCT02632045","Postmenopausal status or receiving ovarian ablation with a GnRH agonist such as goserelin","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02632045",1,"DB11730,DB00947","44631912, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"736",736,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, T-DM1, TRASTUZUMAB, FULVESTRANT","UNK, UNK, UNK, UNK","I/II","Advanced, Second line","Maximum Tolerated Dose (Mtd) And/Or Recommended Phase2 Dose (RP2D), Clinical Benefit Rate (CBR) By RECIST","NCT02657343","different treatment arms got different drug combinations. Preoperative study","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02657343",1,"DB11730,DB05773,DB00072,DB00947","44631912, NA, 3001322, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"737",737,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE","UNK, UNK","IV","Advanced, First line","Percentage of patients with treatment-emergent averse events (AEs) or serious adverse events (SAEs)","NCT02679755","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02679755",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"738",738,"BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","ENTINOSTAT, EXEMESTANE","UNK, UNK","I","Second line","Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination","NCT02833155","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02833155",1,"DB11841,DB00990","4261, 60198","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"739",739,"METASTATIC BREAST CANCER","ERBB2","Positive/Negative","NA","Protein Expression","ACY-1215, NAB-PACLITAXEL","HDAC6, UNK","I","Advanced, First&Second line","Maximum tolerated dose (MTD) of ACY-1215 (Ricolinostat)","NCT02632071","Study allows all cancer subtypes. However, only lists HER2 specfically in the inclusion criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02632071",1,"NA,NA","53340666, 36314","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"740",740,"ADVANCED","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","GEMCITABINE, CISPLATIN","UNK, UNK","III","Advanced, First line","PFS (Progression Free Survival)","NCT02546934","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02546934",1,"DB00441,DB00515","60750, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0003149","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"741",741,"BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Negative, Positive","AND, AND, OR","Protein Expression, Protein Expression, Protein Expression, Protein Expression","CAELYX","UNK","II","First line","Feasibility of adjuvant PLD (Caelyx®)","NCT03712956","Patients must have had surgery for primary breast cancer with no known clinical residual loco-regional disease","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03712956",1,"NA","31703","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE OR KI67 PROTEIN EXPRESSION POSITIVE","pass"
"742",742,"BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Positive, Positive, Positive/Negative, Positive/Negative","AND, AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression, Protein Expression","CAELYX","UNK","II","First line","Feasibility of adjuvant PLD (Caelyx®)","NCT03712956","Patients must have had surgery for primary breast cancer with no known clinical residual loco-regional disease","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03712956",1,"NA","31703","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"743",743,"BREAST CANCER (STAGE I-III)","absent","NA","NA","NA","PEGFILGRASTIM, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK","II","Advanced&Non-advanced, First line","the incidence of febrile neutropenia (FN) ","NCT03575520","primarily looking at neutropenia","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03575520",1,"DB00019,DB00997,DB00531","NA, 443939, 2907","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"744",744,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","VISMODEGIB, PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Number of patients with treatment-related adverse events as assessed by CTCAE v4.0","NCT02694224","Patients with oligometastatic disease (1-2 resectable metastases) could be included","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02694224",1,"DB08828,DB01229,DB00445,DB00531","24776445, 36314, 65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"745",745,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, EGFR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","ANTI-EGFR-IL-DOX","EGFR","II","Advanced, First line","Progression-free survival (PFS) ","NCT02833766","Anti-EGFR-immunoliposomes Loaded With Doxorubicin","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02833766",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146648","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND EGFR PROTEIN EXPRESSION POSITIVE","failed drug"
"746",746,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE","UNK, UNK","III","Advanced, First&Second line","Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment","NCT02600923","postmenopausal, Patients must be appropriate candidates for letrozole therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02600923",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"747",747,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE, ENDOCRINE THERAPY","UNK, UNK","II","Advanced, Second line","Progression-free survival(PFS)","NCT03204734","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03204734",1,"DB01101,NA","60953, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"748",748,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","PACLITAXEL, TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Percent of patients who achieve a pCR","NCT02789657","with surgery. Lists ER/PR testing, but does does not list -/+ requirement","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02789657",1,"DB01229,DB00072,DB06366,DB00958,DB00997,DB00531","36314, 3001322, NA, 56840877, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"749",749,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","HUMANIZED ANTI-PD-1 ANTIBODY JS001","PD1","I","Advanced, Second line","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","NCT02838823","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02838823",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","failed drug"
"750",750,"INVASIVE BREAST CANCER (II-III)","absent","NA","NA","NA","PEGYLATED LIPOSOMAL DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL","UNK, UNK, UNK","IV","Advanced&Non-advanced, First line","Pathological complete response rate","NCT03123770","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03123770",1,"NA,DB00531,DB01248","NA, 2907, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"751",751,"TRIPLE NEGATIVE INVASIVE BREAST CANCER (STAGE I-IIIB)","absent","NA","NA","NA","DOCETAXEL, CARBOPLATIN","UNK, UNK","II","Advanced&Non-advanced, First line","pathologic complete response","NCT03154749","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03154749",1,"DB01248,DB00958","148124, 56840877","ENSG00000104313","EFO_0005537","ABSENT NA NA","no biomarker"
"752",752,"INVASIVE BREAST CANCER (STAGE II-IIIB)","ERBB2","Positive","NA","Protein Expression","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB","UNK, UNK, UNK","II","Advanced&Non-advanced, First line","pathologic complete response","NCT03140553","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03140553",1,"DB01248,DB00958,DB00072","148124, 56840877, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"753",753,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","POZIOTINIB","UNK","II","Advanced, Second line","Objective Response Rate","NCT02659514","At least two prior HER2-directed therapy regimens for breast cancer, including trastuzumab and trastuzumab emtansine (TDM-1, KADCYLA®)","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02659514",1,"DB12114","25127713","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"754",754,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","VINORELBINE","UNK","II","Advanced, First line","Clinical Benefit Rate (CBR) ","NCT03007992","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03007992",1,"DB00361","5311497","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"755",755,"METASTATIC BREAST CANCER","ESR1","Positive","NA","Protein Expression","ENTINOSTAT, EXEMESTANE","HDAC, aromatase","I","Advanced, Second line","Cmax, maximum plasma concentration, Tmax, time at which maximum plasma concentration was observed, AUC0-t, area under the plasma concentration-time curve from time zero to the last measurable concentration , AUC0-inf, area under the plasma concentration-time curve from time zero extrapolated to infinity, T1/2, elimination half-life, lambda z , apparent terminal phase elimination constant (λz), AUC0-τ where τ=168 hours for entinostat and τ=24 hours for exemestane , Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs resulting in the permanent discontinuation of study drug, and deaths occurring within 30-days of the last dose of study drug, Changes from baseline in laboratory, vital signs, and electrocardiogram (ECG) values","NCT02820961","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02820961",1,"DB11841,DB00990","4261, 60198","ENSG00000091831","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"756",756,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT","UNK, UNK","II","Advanced, Second line","Progression-free survival, Prevalence of ESR1 and PI3K mutations","NCT02738866","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02738866",1,"DB09073,DB00947","11478676, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"757",757,"INVASIVE BREAST CANCER (STAGE IIA-IIIC)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","EXEMESTANE/ANASTROZOLE, GOSERELIN","UNK/UNK, UNK","III","Advanced&Non-advanced, First line","Overall response rate(ORR)","NCT02532400","Premenopause status (estradiol in premenopausal range or with normal menstrual cycle in the past 6 months with no use of hormonal drugs)","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02532400",1,"NA,DB00014","NA, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"758",758,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","LOW-DOSE-BEVACIZUMAB, PEMETREXED","UNK, UNK","II","Advanced, Second line","Objective response rare (ORR)","NCT02829008","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02829008",1,"NA,DB00642","NA, 135413520","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","failed drug"
"759",759,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative,Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB","UNK","II","Advanced, First&Second line","progression-free survival","NCT02878057","If hormone receptor is positive, endocrine therapy must have been performed for the patients with recurrence or metastasis, or the recurrence or metastasis occurred in less than two years of endocrine therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02878057",1,"DB14765","45139106","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"760",760,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR, D1","Negative, Positive, Positive/Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","FULVESTRANT","UNK","I","First line","Change in Ki67 cell percentage","NCT02936206","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02936206",1,"DB00947","104741","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000110092","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND D1 PROTEIN EXPRESSION POSITIVE","pass"
"761",761,"BREAST CANCER","ESR1, PGR","Positive/Negative, Negative","AND","Protein Expression, Protein Expression","MIFEPRISTONE","ER","UNK","First line","Measurable decrease in tumor cell proliferation from baseline to time of surgery ","NCT02651844","Tumors with higher expression PR > 50 % measured by IHC and PRA/RPB ratio equal or higher than 1.5. measured by WB. Must be done with surgery. ER + excluded if PRA/PRB ration is below 1.5","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02651844",1,"DB00834","55245","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"762",762,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB, PACLITAXEL, CARBOPLATIN","PARP, UNK, UNK","II/III","Advanced, First line","Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03. , Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol., Stage 3 - Efficacy analysis based on pCR at surgery. To be assessed by central review of pathology reports.","NCT03150576","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03150576",1,"DB09074,DB01229,DB00958","23725625, 36314, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"763",763,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR, BCRA1, BCRA2","Negative, Positive/Negative, Positive/Negative, Positive, Positive","AND, AND, AND, AND/OR","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","OLAPARIB, PACLITAXEL, CARBOPLATIN","PARP, UNK, UNK","II/III","Advanced, First line","Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03. , Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol., Stage 3 - Efficacy analysis based on pCR at surgery. To be assessed by central review of pathology reports.","NCT03150576","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03150576",1,"DB09074,DB01229,DB00958","23725625, 36314, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BCRA1 MUTATION POSITIVE AND/OR BCRA2 MUTATION POSITIVE","pass"
"764",764,"INVASIVE BREAST CANCER","CK5/6, EGFR, AR","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB, PACLITAXEL, CARBOPLATIN","PARP, UNK, UNK","II/III","Advanced, First line","Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03. , Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol., Stage 3 - Efficacy analysis based on pCR at surgery. To be assessed by central review of pathology reports.","NCT03150576","Availability of CK 5/6 and EGFR +/- Androgen Receptor IHC score.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03150576",1,"DB09074,DB01229,DB00958","23725625, 36314, 56840877","NA, ENSG00000146648, ENSG00000169083","EFO_1000307","CK5/6 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND EGFR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed biomarker"
"765",765,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT","UNK, UNK","II","Advanced, First&Second line","Progression Free Survival (PFS)","NCT02536742","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02536742",1,"DB09073,DB00947","11478676, 104741","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"766",766,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, Ki67, PDL1","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND,AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Protein Expression","MEDI4736","PDL1","II","First line","pathological complete response (pCR= ypT0 ypN0)","NCT02685059","Prior chemotherapy for any malignancy","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02685059",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"767",767,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LETROZOLE, ATORVASTATIN","aromatase, UNK","II","Advanced, First line","Clinical benefit rate.","NCT02958852","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02958852",1,"DB01006,DB01076","3902, 60823","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"768",768,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE","UNK, UNK, UNK","II","Advanced, First&Second line","Objective Response Rate, Incidence of Treatment-Related Adverse Events","NCT02755272","Patients received up to 2 prior regimens for their disease in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02755272",1,"DB09037,DB00958,DB00441","NA, 56840877, 60750","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"769",769,"BREAST CANCER (STAGE II-III)","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LETROZOLE, EVEROLIMUS, TRC105","UNK,  UNK, UNK","I/II","Advanced&Non-advanced, First line","Maximum tolerated dose (MTD)","NCT02520063","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02520063",1,"DB01006,DB01590,NA","3902, 6442177, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"770",770,"METASTATIC BREAST CANCER","ERBB2, ESR1, AR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","BICALUTAMIDE, AROMATASE INHIBITOR","UNK, Aromatase","II","Advanced, Second line","clinical benefit rate（CBR）","NCT02910050","Aromatase inhibitors include: anastrozole, letrozole, exemestane","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02910050",1,"DB01128,NA","56069, NA","ENSG00000141736, ENSG00000091831, ENSG00000169083","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"771",771,"BREAST CANCER (STAGE II-III)","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression&Amplification, Protein Expression, Protein Expression","TRASTUZUMAB, DOCETAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","III","Advanced&Non-advanced, First line","pathologic Complete Response","NCT03425656","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03425656",1,"DB00072,DB01248,DB00997,DB00531","3001322, 148124, 443939, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"772",772,"INVASIVE BREAST CANCER (II-III)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LETROZOLE, RIBOCICLIB","Aromatase, CDK","II","Advanced&Non-advanced, First line","Rate of Pre-operative Endocrine Prognostic Index (PEPI) score 0 at surgery between ribociclib containing arms (combined) vs letrozole alone arm","NCT02712723","neoadjuvant chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02712723",1,"DB01006,DB11730","3902, 44631912","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"773",773,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Negative, Positive, Positive, Positive/Negative","AND, AND/OR, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","VINORELBINE, LETROZOLE","UNK, UNK","I","First line","Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by PAM50","NCT02802748","Postmenopausal. Excludes: Patients for whom upfront chemotherapy is clinically judged appropriate as optimal neoadjuvant treatment","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02802748",1,"DB00361,DB01006","5311497, 3902","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"774",774,"INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","CARBOPLATIN, ABRAXANE, ATEZOLIZUMAB, ANTHRA","UNK, UNK, PDL1, UNK","III","Advanced, First line","Event Free Survival (EFS) ","NCT02620280","Anthra: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide)","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02620280",1,"DB00958,NA,DB11595,NA","56840877, 36314, NA, 5359985","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"775",775,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, DURVALUMAB","UNK, UNK","I/II","Advanced, Second line","Number of patients with adverse events (severe and non-severe)","NCT02628132","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02628132",1,"DB01229,DB11714","36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"776",776,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GEDATOLISIB, PALBOCICLIB, LETROZOLE, FULVESTRANT","UNK, UNK, UNK, UNK","I","Advanced, Second line","Number of participants with dose limiting toxicities , Objective response rate observed in patients in the dose expansion portion , Objective response rate observed in patients in the dose expansion portion","NCT02684032","different arms with different prior treatment requirements","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02684032",1,"DB11896,DB09073,DB01006,DB00947","44516953, 11478676, 3902, 104741","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"777",777,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, EVEROLIMUS, EXEMESTANE","UNK, UNK, UNK","I/II","Advanced, Second line","Phase I: Maximum Tolerated Dose (MTD) and/or the Recommended Phase II Dose (RP2D) for the triplet combination , Phase II: Clinical Benefit Rate (CBR) among subjects receiving triplet therapy","NCT02732119","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02732119",1,"DB11730,DB01590,DB00990","44631912, 6442177, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"778",778,"ADVANCED","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, PACLITAXEL, CAPECITABINE","UNK, UNK, UNK","I/II","Advanced, First&Second line","Treatment-Associated Adverse Events, Number of patients who complete chemotherapy without a dose delay of more than 21 days.","NCT02734290","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02734290",1,"DB09037,DB01229,DB01101","NA, 36314, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0003149","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"779",779,"INVASIVE BREAST CANCER (STAGE I-III)","absent","NA","NA","NA","DENOSUMAB","RANKL","I","Advanced&Non-advanced, First line","Pharmacodynamic markers of RANKL inhibition determination","NCT02900469","with surgery. Exclusion criteria: Consideration for neoadjuvant therapy. Trying to prevent pro-metastatic mechanisims","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02900469",1,"DB06643","NA","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"780",780,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PD-0332991, FULVESTRANT","UNK, UNK","II","Advanced, First line","Efficacy in terms of the rate of Progression-Free Survival (PFS) ","NCT02690480","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02690480",1,"NA,DB00947","5330286, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"781",781,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","L-NMMA, DOCETAXEL, AMLODIPINE, PEGFILGRASTIM, ENTERIC-COATED ASPIRIN","Nitric Oxide Synthase, Mitosis, calcium channels, colony-stimulation, inflammation mechanisims","II","Advanced, First&Second line","MTD, Clinical Benefit Rate","NCT02834403","Female patients with pathologically determined advanced (progressive disease or refractory to 3 cycles of standard chemotherapy) or metastatic (any line) triple negative breast cancer (TNBC). TNBC is defined as: Estrogen receptor negative and progesterone receptor negative (<10% staining by immunohistochemistry [IHC]).","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02834403",1,"DB11815,DB01248,DB00381,DB00019,NA","132862, 148124, 60496, NA, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"782",782,"UNRESECTABLE","ERBB2, ESR1, PGR, ERBB3","Negative, Positive/Negative, Positive/Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","U3-1402","UNK","I/II","Advanced, Second line","Number of participants experiencing adverse events (AEs), Number of participants with tumor response throughout the study using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1","NCT02980341","had different cohorts with different biomarkers. Like TNBC + HR+. But had to be ERBB2 - and ERBB3 +","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02980341",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000065361","MONDO_0002691","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB3 PROTEIN EXPRESSION POSITIVE","failed drug"
"783",783,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","IXAZOMIB, CARBOPLATIN","UNK, UNK","I/II","Advanced, First&Second line","Maximum tolerated dose (MTD)","NCT02993094","At least one prior line of chemotherapy for metastatic or locally advanced disease or disease progression within 12 months of completion of adjuvant chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02993094",1,"DB09570,DB00958","56844015, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"784",784,"LOCALLY ADVANCED BREAST CANCER","absent","NA","NA","NA","CYCLOPHOSPHAMIDE, DOCETAXEL","UNK, UNK","IV","Advanced&Non-advanced, First line","Incidence of Grade 3 and 4 Neutropenia and Febrile Neutropenia, Association Between Scores - Chemotherapy Risk Assessment Scale for High-Age Patients, Association Between Scores - Instrumental Activities of Daily Living, Association Between Scores - Cumulative Illness Rating Scale for Geriatrics","NCT02502864","looking at Docetaxel dosing . Must have histologically confirmed localized or locally advanced breast cancer for which the treatment plan includes chemotherapy with 4 cycles of standard TC (docetaxel 75 mg/m^2 and cyclophosphamide 600mg/m^2)","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02502864",1,"DB00531,DB01248","2907, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"785",785,"NON-METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, SUNITINIB","UNK,  UNK, VEGFR","II","Advanced&Non-advanced, First line","Clinical response rate","NCT02790580","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02790580",1,"DB00997,DB00531,DB01268","443939, 2907, 5329102","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"786",786,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, LETROZOLE, GOSERELIN","UNK, UNK, UNK","III","Advanced, First&Second line","Clinical Benefit Rate (CBR) in women and men with hormone receptor positiv, HER-2 negative breast cancer treated with ribocilib and letrozole","NCT03096847","goserelin for premenopausal pts.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03096847",1,"DB11730,DB01006,DB00014","44631912, 3902, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"787",787,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","OLAPARIB","PARP","II","Advanced, First&Second line","Correlation between baseline gene and protein expression profile and clinical response","NCT02681562","only requirement for treatment line: Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02681562",1,"DB09074","23725625","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"788",788,"LOCALLY ADVANCED BREAST CANCER","BRCA1, BRCA2","Positive, Positive","OR","Mutation, Mutation","OLAPARIB","PARP","II","Advanced, First&Second line","Correlation between baseline gene and protein expression profile and clinical response","NCT02681562","only requirement for treatment line: Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02681562",1,"DB09074","23725625","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","pass"
"789",789,"NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOCETAXEL, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, EPIRUBICIN","UNK, UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Pathological complete response (pCR) rate","NCT02897050","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02897050",1,"DB01248,DB01101,DB00531,DB00544,DB00445","148124, 60953, 2907, 3385, 65348","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"790",790,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","APATINIB, VINORELBINE","VEGFR2, UNK","II","Advanced, Second line","Progression free survival (PFS) among metastatic HER2 negative breast cancer treated with apatinib and oral vinorelbine","NCT02768415","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02768415",1,"DB14765,DB00361","45139106, 5311497","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"791",791,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ALISERTIB, MLN0128","TORC1/TORC2, AURORA A","I","Advanced, Second line","Determine the maximum tolerated dose (MTD) in the combination of MLN0128 and Alisertib in patients with advanced solid tumors measured by treatment adverse events as assessed by the CTCAE v4.03","NCT02719691","was apart of a study with pancreatic cancer. However, was in a separate cohort with separate conditions","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02719691",1,"DB05220,NA","24771867, 45375953","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"792",792,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Positive/Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB","UNK","II","First line","Anti-proliferative response","NCT02831530","pre-surgical study","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02831530",1,"DB12001","46220502","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"793",793,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","BCD-115","CDK8/CDK19","I","Advanced, Second line","Area under the plasma concentration versus time curve (AUC0-t), Peak Plasma Concentration (Cmax) , The incidence and severity of Aes, The incidence of grade 3-4 AEs","NCT03065010","Postmenopausal, Progression of advanced breast cancer on first line endocrine therapy for advanced breast cancer.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03065010",1,"NA","NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"794",794,"BREAST INFILTRATING DUCTAL CARCINOMA (STAGE II-III)","absent","NA","NA","NA","VINORELBINE, CISPLATIN, CAPECITABINE, GEMCITABINE, TRASTUZUMAB","UNK, UNK, UNK, UNK, UNK","III","Advanced&Non-advanced, First line","Surgical specimens of breast primary tumors and axillary lymph nodes as measured by Pathological examination","NCT03006614","PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03006614",1,"DB00361,DB00515,DB01101,DB00441,DB00072","5311497, 135804801, 60953, 60750, 3001322","ENSG00000104313","EFO_0000305","ABSENT NA NA","no biomarker"
"795",795,"NON-METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","EVEROLIMUS, LETROZOLE","UNK, UNK","II","First line","Feasibility of the trial ","NCT02742051","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02742051",1,"DB01590,DB01006","6442177, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"796",796,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","HLX02, DOCETAXEL","UNK, UNK","III","Advanced, First line","calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1.","NCT03084237","could have had hormone therapy before","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03084237",1,"NA,DB01248","NA, 148124","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"797",797,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","And, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, AROMATASE INHIBITOR, FULVESTRANT","CDK4/CDK6, aromatase, UNK","III","Advanced, First&Second line","Progression Free Survival (PFS)","NCT02763566","different arms had different drug combos. AIs include : Letrozole, anastrozole. Different conditions for clinical state for different arms","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02763566",1,"DB12001,NA,DB00947","46220502, NA, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"798",798,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ENTINOSTAT, ATEZOLIZUMAB","HDAC, PDL1","I/II","Advanced, First&Second line","Determination of DLT and the MTD and/or RP2D, Duration of Progression-free survival using RECIST 1.1","NCT02708680","could not have received chemo within 3 weeks, and antibodies within 30 days","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02708680",1,"DB11841,DB11595","4261, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"799",799,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","IMMU-132","UNK","II","Advanced, Second line","Progression Free Survival","NCT02161679","Two or more prior chemotherapy, immunotherapy and/or monoclonal antibody therapy for the treatment of the subjects' metastatic breast cancer;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02161679",1,"NA","91668186","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"800",800,"BREAST CANCER (STAGE I-IV)","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GEDATOLISIB, FULVESTRANT, PALBOCICLIB, ZOLADEX","PI3K, ER, CDk4/CDK6, UNK","I","Advanced&Non-advanced, First line","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","NCT02626507","Zoladex is for pre menopausal subjects. the disease is previously untreated for breast cancer, operable and intend to undergo surgery for her disease (e.g., a mastectomy or lumpectomy) after completion of neoadjuvant therapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02626507",1,"DB11896,DB00947,DB09073,NA","44516953, 104741, 11478676, 16052011","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"801",801,"BREAST CANCER (STAGES IIB-IIIC)","absent","NA","NA","NA","DOXORUBICIN HYDROCHLORIDE LIPOSOME, CYCLOPHOSPHAMIDE","UNK, UNK","IV","Advanced&Non-advanced, First line","pathological complete response","NCT02903524","for a Neoadjuvant Chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02903524",1,"NA,DB00531","NA, 2907","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"802",802,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","FULVESTRANT, MLN0128","UNK, UNK","II","Advanced, Second line","Progression Free Survival","NCT02756364","Postmenopausal, Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02756364",1,"DB00947,NA","104741, 45375953","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"803",803,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, 5-FU","UNK, UNK, UNK, UNK","IV","First line","Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC, Participant satisfaction","NCT02688803","Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02688803",1,"DB00997,DB00531,DB01229,DB00544","443939, 2907, 36314, 3385","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"804",804,"LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, NAB-PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, CARBOPLATIN","UNK, UNK, UNK, UNK, UNK","I","Advanced, First line","Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)","NCT02622074","neoadjuvant chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02622074",1,"DB09037,NA,DB00997,DB00531,DB00958","NA, 36314, 443939, 2907, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"805",805,"METASTATIC  BREAST CANCER","ERBB2","Positive","NA","Protein Expression","DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","UNK, UNK, UNK","III","Advanced, First line","Progression-Free Survival, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Percentage of Participants With 1 Year of Progression-Free Survival, as Determined by the Investigator Using RECIST v1.1","NCT02896855","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02896855",1,"DB01248,DB06366,DB00072","148124, NA, 3001322","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"806",806,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","SFX-01, AROMATASE INHIBITORS, FULVESTRANT, TAMOXIFEN","UNK, Aromatase, UNK, UNK","II","Advanced, First&Second line","Treatment-Emergent Adverse Events [Safety and Tolerability]), Clinical benefit rate","NCT02970682","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02970682",1,"NA,NA,DB00947,DB00675","NA, NA, 104741, 2733526","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","failed drug"
"807",807,"INVASIVE BREAST CANCER","p95ERBB2, PI3K, PTEN, ERBB2, ESR1, PGR","Positive, Positive, Positive, Positive, Positive/Negative, Positive/Negative","OR, OR, AND, AND, AND","Mutation, Mutation, Mutation, Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","LAPATINIB, PACLITAXEL, EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK, UNK, UNK","II","First line","pathological complete response (pCR)","NCT03273595","loss of PTEN","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03273595",1,"DB01259,DB01229,DB00445,DB00531","208908, 36314, 65348, 2907","NA, ENSG00000121879, ENSG00000171862, ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","P95ERBB2 MUTATION POSITIVE OR PI3K MUTATION POSITIVE OR PTEN MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed biomarker"
"808",808,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LETROZOLE/ANASTROZOLE, VINORELBINE","Aromatase/Aromatase, UNK","II","Advanced, First line","progression-free survival (PFS)","NCT02730091","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02730091",1,"NA,DB00361","NA, 5311497","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"809",809,"INFLAMMATORY","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","TRASTUZUMAB, FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, PERTUZUMAB, DOCETAXEL","UNK, UNK, UNK, UNK, UNK, UNK","II","Advanced&Non-advanced, First line","Tumor Infiltrating lymphocites (TIL) rate on residual disease after either IV trastuzumab or SC trastuzumab (see related paragraph)","NCT03144947","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03144947",1,"DB00072,DB00544,DB00445,DB00531,DB06366,DB01248","3001322, 3385, 65348, 2907, NA, 148124","ENSG00000141736","EFO_0003767","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"810",810,"STAGE IV BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","DURVALUMAB, TREMELIMUMAB","UNK, UNK","II","Advanced, Second line","Objective response rate (ORR) by RECIST 1.1","NCT03608865","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03608865",1,"DB11714,DB11771","NA, NA","ENSG00000091831, ENSG00000082175","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"811",811,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","UNK, UNK, UNK, UNK, UNK, UNK","III","Advanced&Non-advanced, First line","Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)","NCT02586025","with surgery","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02586025",1,"DB00544,DB00445,DB00531,DB01248,DB06366,DB00072","3385, 65348, 2907, 148124, NA, 3001322","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"812",812,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","APATINIB, CAPECITABINE","UNK, UNK","II","Advanced, Second line","Progression free survival","NCT03086785","Pathologically diagnosed with her-2 negative, ER/PR negative, ER/PR positive after the failure of endocrine treatment, and had not more than three chemotherapy regimens (must include anthracycline-based and yew class), and the final failure of chemotherapy regimens in patients with advanced breast cancer; Note: treatment failure include (1) during or after the completion of six months or less disease progress of neoadjuvant or adjuvant therapy; (2) rescue treatment in progress within 3 months or less","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03086785",1,"DB14765,DB01101","45139106, 60953","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"813",813,"METASTATIC  BREAST CANCER","PIK3CA","Positive","NA","Mutation","GDC-0077","UNK","I","Advanced, Second line","Stage 1: Percentage of Participants With Dose Limiting Toxicities, Recommended Phase II Dose of GDC-0077 , Percentage of Participants With Adverse Events and Serious Adverse Events","NCT03006172","with other cancers, but clearly seperated","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03006172",1,"DB15275","124173720","ENSG00000121879","EFO_1000984","PIK3CA MUTATION POSITIVE","pass"
"814",814,"METASTATIC  BREAST CANCER","PIK3CA, ERBB2, ESR1, PGR","Positive, Negative, Positive, Positive","AND, AND, AND/OR","Mutation, Protein Expression, Protein Expression, Protein Expression","GDC-0077, FULVESTRANT, PALBOCICLIB, METFORMIN","UNK, UNK, UNK, UNK","I","Advanced, First&Second line","Stage 1: Percentage of Participants With Dose Limiting Toxicities, Recommended Phase II Dose of GDC-0077 , Percentage of Participants With Adverse Events and Serious Adverse Events","NCT03006172","with other cancers, but clearly seperated","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03006172",1,"DB15275,DB00947,DB09073,DB00331","124173720, 104741, 11478676, 14219","ENSG00000121879, ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","PIK3CA MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"815",815,"METASTATIC  BREAST CANCER","ERBB2, ESR1, PGR, RB","Positive/Negative, Positive/Negative, Positive/Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","RIBOCICLIB, PACLITAXEL","UNK, UNK","I","Advanced, First&Second line","Number of Adverse Events","NCT02599363","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02599363",1,"DB11730,DB01229","44631912, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000139687","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND RB PROTEIN EXPRESSION POSITIVE","pass"
"816",816,"METASTATIC BREAST CANCER","ERBB2","Positive/Negative","NA","Protein Expression","FULVESTRANT, NERATINIB, AZD5363, OLAPARIB","UNK, UNK, UNK","II","Advanced, First&Second line","he primary endpoint for Cohorts A to E is confirmed objective response rate as defined by RECIST v1.1 for each cohort separately","NCT03182634","did not list what cohorts HER2 was in, just that her2 could be +/-","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03182634",1,"DB00947,DB11828,NA,DB09074","104741, 9915743, 25227436, 23725625","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"817",817,"METASTATIC BREAST CANCER","ESR1","Positive","NA","Protein Expression","FULVESTRANT, NERATINIB, AZD5363","UNK, UNK, UNK","II","Advanced, First&Second line","The primary endpoint for Cohorts A to E is confirmed objective response rate as defined by RECIST v1.1 for each cohort separately","NCT03182634","Specifically listed what cohorts ER had to be +","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03182634",1,"DB00947,DB11828,NA","104741, 9915743, 25227436","ENSG00000091831","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"818",818,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE, ANASTROZOLE, EXEMESTANE, FULVESTRANT","UNK, UNK, UNK, UNK, UNK","II","Advanced, First&Second line","Clinical Benefit Rate (CBR)","NCT02894398","Patients scheduled for palliative treatment with an combination partner for first- or later-line","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02894398",1,"DB09073,DB01006,DB01217,DB00990,DB00947","11478676, 3902, 2187, 60198, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","pass"
"819",819,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PQR309, ERIBULIN","PI3K/mTOR, microtubles","I/II","Advanced, Second line","Number of patients with treatment related Adverse Events and Serious Adverse Events as assessed by NCI CTCAEV4.03, RECIST the Response criteria for solid tumors will be used to identify clinical benefit rate (CBR) including complete Response (CR), partial Response (PR) and stable disease (SD)","NCT02723877","Received at least 2 and no more than 5 prio chemotherapeutic regimens in locally advanced and/or metastatic setting. Says TNBC is in an expansion cohort, but never lists biomarkers for the 1st phase","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02723877",1,"NA,DB08871","58507717, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"820",820,"METASTATIC","ERBB2","Positive","NA","Protein Expression","DURVALUMAB, TRASTUZUMAB","UNK, HER2","I","Advanced, First&Second line","Confirm the recommended phase II dose of durvalumab given to patients with advanced/recurrent HER-2 positive metastatic breast cancer (MBC) who are receiving treatment with trastuzuma","NCT02649686","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02649686",1,"DB11714,DB00072","NA, 3001322","ENSG00000141736","EFO_0009709","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"821",821,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","17B-ESTRADIOL, LETROZOLE, ANASTROZOLE, EXEMESTANE","Aromatase, Aromatase,Aromatase,Aromatase","II","Advanced, First&Second line","Clinical benefit","NCT02188745","is not very specific on whether all will be given,. Only says ""one aromatase inhibitor is preferred""","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02188745",1,"NA,DB01006,DB01217,DB00990","5757, 3902, 2187, 60198","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"822",822,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, EXEMESTANE, LEUPROLIDE","UNK, UNK, UNK","I/II","Advanced, Second line","The PFS rate at 8 months","NCT02990845","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02990845",1,"DB09037,DB00990,DB00007","NA, 60198, 657181","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"823",823,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative,Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","CAPECITABINE, CYCLOPHOSPHAMIDE","UNK, UNK","II","Advanced, Second line","Proportion of patients with adverse events, Assessment of PK parameter: maximum concentration (Cmax) , Assessment of PK parameter: time to reach Cmax (Tmax)","NCT02664103","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02664103",1,"DB01101,DB00531","60953, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"824",824,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, TAMOXIFEN, PROPHYLACTIC LOPERAMIDE","UNK, UNK, UNK","II","Advanced, Second line","Progression Free Survival (PFS)","NCT02747004","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02747004",1,"DB12001,DB00675,NA","46220502, 2733526, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"825",825,"NON-METASTATIC BREAST CANCER","absent","NA","NA","NA","PERTUZUMAB, TRASTUZUMAB","UNK, UNK","I","Second line","Area Under the Concentration from Time Zero to Time Infinity (AUC0-inf) of Pertuzumab SC, Maximum Serum Concentration (Cmax) of Pertuzumab SC, Time to Reach Cmax (Tmax) of Pertuzumab SC, Minimum Serum Concentration (Cmin) of Pertuzumab SC, AUC0-inf of Pertuzumab IV, Cmax of Pertuzumab IV , Tmax of Pertuzumab IV, Cmin of Pertuzumab IV","NCT02738970","trial was for dose finding","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02738970",1,"DB06366,DB00072","NA, 3001322","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"826",826,"METASTATIC BREAST CANCER","ERBB2, BRCA1, BRCA2","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Mutation, Mutation","RUCAPARIB","PARP","II","Advanced, Second line","Clinical Benefit Rate","NCT02505048","exclusion- BRCA1 or 2 germline known mutation. It must be a somatic mutation","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02505048",1,"DB12332","9931954","ENSG00000141736, ENSG00000012048, ENSG00000139618","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","pass"
"827",827,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND,AND","Protein Expression, Protein Expression, Protein Expression","PEMETREXED, SORAFENIB","UNK, UNK","II","Advanced, Second line","The percentage of objective response either Partial Response (PR) or Complete Response(CR)","NCT02624700","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02624700",1,"DB00642,DB00398","135413520, 406563","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"828",828,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LSZ102, LEE011, BYL719","UNK, UNK, UNK","I","Advanced, First&Second line","Incidence of dose limiting toxicities (DLTs) , Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719","NCT02734615","never defines clinical state","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02734615",1,"NA,NA,NA","118574930, 44631912, 56649450","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"829",829,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE","UNK, UNK","II","Advanced, Second line","The Progression Free Survival (PFS)","NCT02768701","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02768701",1,"DB09037,DB00531","NA, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"830",830,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive/Negative,Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ERIBULIN MESILATE","microtubules","II","Advanced, First line","Disease Control (DC)","NCT02404506","in elderly pts.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02404506",1,"NA","17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"831",831,"METASTATIC  BREAST CANCER","ERBB2","Positive","NA","Protein Expression","LAPATINIB, CAPECITABINE/VINORELBINE","UNK, UNK/UNK","II","Advanced, First&Second line","progression-free survival","NCT02362958","Recurrence within 1 year completing adjuvant trastuzumab OR rapid progress following first-line trastuzumab-based care.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02362958",1,"DB01259,NA","208908, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"832",832,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, BCRA1, BCRA2","Negative, Negative, Negative, Positive/Negative, Positive/Negative","AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","OLAPARIB, MEDI4736","DNA, UNK","I/II","Advanced, First&Second line","Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of MEDI4736/olaparib (MEDI-O) and MEDI4736/cediranib (MEDI-C) in patients with advanced solid tumors , Ph II Determine overall response rate of MED-O and MEDI-C in patients with recurrent ovarian cancer","NCT02484404","didn’t really describe a clinical state, only that it was advanced. Was in a trial with multiple cancers, but had a specific cohort","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02484404",1,"DB09074,NA","23725625, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, NA, NA","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BCRA1 MUTATION POSITIVE/NEGATIVE AND BCRA2 MUTATION POSITIVE/NEGATIVE","pass"
"833",833,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ZOLEDRONIC ACID","UNK","III","Second line","disease free survival","NCT02595138","pts must finish standard chemotherapy","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02595138",1,"DB00399","68740","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"834",834,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","DOCETAXEL, DOXORUBICIN/EPIRUBICIN, CYCLOPHOSPHAMIDE, GEMCITABINE, CISPLATIN","UNK, UNK/UNK, UNK, UNK, UNK","II/III","First Line","Recurrence free survival","NCT02641847","drug arms seperated by risk level","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02641847",1,"DB01248,NA,DB00531,DB00441,DB00515","148124, NA, 2907, 60750, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"835",835,"METASTATIC BREAST CANCER","ERBB2","Negative","NA","Protein Expression","NAB-PACLITAXEL, NIVOLUMAB","UNK, UNK","I","Advanced, First&Second line","Evaluate Dose Limiting Toxicity (DLT) of each combination regimen, Evaluate the safety of the nab-paclitaxel/nivolumab combination regimens, Grade 3 or 4 TEAE","NCT02309177","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02309177",1,"NA,DB09035","36314, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"836",836,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","EVEROLIMUS, EXEMESTANE, FULVESTRANT","UNK, UNK, UNK","III","Advanced, First line","Progression-free survival (PFS1), Total Progression-free survival (PFST)","NCT02404051","with LABC or MBC not amenable to curative treatment by surgery or radiotherapy, refractory to NSAI","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02404051",1,"DB01590,DB00990,DB00947","6442177, 60198, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"837",837,"INVASIVE BREAST CANCER (IB-IIIC)","ERBB2, ESR1","Positive, Positive","AND","Protein Expression&Amplification/Protein Expression, Protein Expression","TRASTUZUMAB, LETROZOLE","UNK, UNK","II","Advanced&Non-advanced, First line","The rate of pathologic complete response","NCT02214004","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02214004",1,"DB00072,DB01006","3001322, 3902","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"838",838,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","UNK, UNK, UNK","III","Advanced, First line","Incidence of adverse events (AEs), Incidence and severity of adverse events Grade >/= 3, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 , Incidence of cardiac events","NCT02402712","May have been on hormone therapy prior to trial in the metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02402712",1,"DB01248,DB06366,DB00072","148124, NA, 3001322","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"839",839,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, EGFR","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression/Mutation","AFATINIB","ErbB","II","First line","Efficacy of pathologic response of the combination of afatinib and weekly paclitaxel","NCT02511847","The first TNBC 20 patients with or without EGFR expression or mutation are eligible,  Interim analysis of response rate will be calculated to determine the criteria of 21 to 40 patients.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02511847",1,"DB08916","10184653","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146648","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND EGFR PROTEIN EXPRESSION/MUTATION POSITIVE/NEGATIVE","pass"
"840",840,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","FULVESTRANT","UNK","III","Advanced, Second line","Maintenance-progression-free survival (mPFS)","NCT02383030","One line chemotherapy for metastatic disease discontinued for 21-28 days. Patient has to have response or stability from the first-line chemotherapy. The patient may have received prior systemic chemotherapy in the neo-adjuvant or adjuvant setting;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02383030",1,"DB00947","104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"841",841,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, AR","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","BICALUTAMIDE","AR","II","Advanced, Second line","Clinical benefit rate(CBR), Progression-free survival","NCT02353988","Patients with metastatic disease progressed after one therapeutic regimen for metastatic disease, and there is no limit for the regimens of prior therapy.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02353988",1,"DB01128","56069","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000169083","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"842",842,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1","Positive, Positive","AND","Protein Expression&Amplification/Protein Expression, Protein Expression","TRASTUZUMAB, PERTUZUMAB, PALBOCICLIB, FULVESTRANT","UNK, UNK,CDK4/CDK6, UNK","II","Advanced, First line","Serial measures of Ki67, Serial measures of apoptosis","NCT02530424","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02530424",1,"DB00072,DB06366,DB09073,DB00947","3001322, NA, 11478676, 104741","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"843",843,"LOCALLY ADVANCED BREAST CANCER","ERBB2, ESR1, PGR, Ki67","Positive, Positive, Positive, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","TRASTUZUMAB, PERTUZUMAB, PALBOCICLIB, FULVESTRANT","UNK, UNK,CDK4/CDK6, UNK","II","Advanced, First line","Serial measures of Ki67, Serial measures of apoptosis","NCT02530424","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02530424",1,"DB00072,DB06366,DB09073,DB00947","3001322, NA, 11478676, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","pass"
"844",844,"METASTATIC BREAST CANCER","ERBB2, ESR1","Positive/Negative, Positive","AND","Protein Expression, Protein Expression","TAMOXIFEN, PEMBROLIZUMAB, VORINOSTAT","estrogen receptors, PD1, HDAC","II","Advanced, First&Second line","Overall Response Rate, Adverse Events","NCT02395627","had different drug cohorts for different biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02395627",1,"DB00675,DB09037,DB02546","2733526, NA, 5311","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"845",845,"METASTATIC BREAST CANCER","ERBB2, ESR1, PDL1","Positive/Negative,Negative, Positive/Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, VORINOSTAT","PD1, HDAC","II","Advanced, First&Second line","Overall Response Rate, Adverse Events","NCT02395627","had different drug cohorts for different biomarkers","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02395627",1,"DB09037,DB02546","NA, 5311","ENSG00000141736, ENSG00000091831, ENSG00000120217","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"846",846,"BREAST CANCER","ERBB2","Negative","NA","Protein Expression","CARBOPLATIN, PACLITAXEL, BEVACIZUMAB","UNK, UNK, UNK","II","First line","2-year progression free survival in patients treated with weekly carboplatin and paclitaxel combined with either trastuzumab and pertuzumab for HER2-positive patients or bevacizumab for HER2-negative patients in the neoadjuvant setting","NCT02436993","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02436993",1,"DB00958,DB01229,DB00112","56840877, 36314, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"847",847,"BREAST CANCER","ERBB2","Positive","NA","Protein Expression","CARBOPLATIN, PACLITAXEL, TRASTUZUMAB, PERTUZUMAB","UNK, UNK, UNK, UNK","II","First line","2-year progression free survival in patients treated with weekly carboplatin and paclitaxel combined with either trastuzumab and pertuzumab for HER2-positive patients or bevacizumab for HER2-negative patients in the neoadjuvant setting","NCT02436993","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02436993",1,"DB00958,DB01229,DB00072,DB06366","56840877, 36314, 3001322, NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"848",848,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PI3K","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation/Protein Expression/Amplification","EVEROLIMUS, ERIBULIN","UNK, UNK","I","Advanced, First&Second line","The recommended dose of everolimus in combination with eribulin in metastatic triple negative breast cancer","NCT02616848","Patients must not have received more than 3 prior chemotherapy regimens for triple negative metastatic breast cancer.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02616848",1,"DB01590,DB08871","6442177, 17755248","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PI3K MUTATION/PROTEIN EXPRESSION/AMPLIFICATION POSITIVE/NEGATIVE","pass"
"849",849,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","VINORELBINE, DDP","UNK, UNK","II","Advanced, Second line","Progression Free Survival (PFS)","NCT02607215","Patients must have progressed after 1or 2 prior chemotherapy regimens for metastatic disease, cis/carbo-platin pretreated only 1 previous line prior to randomisation. Platinum sensitive in this study is defined as complete or partial or stable disease following completion (a minimum of 4 treatment cycles) of previous platinum-based chemotherapy and disease progression greater than 3 months after completion of their last dose of platinum chemotherapy (last dose).","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02607215",1,"DB00361,DB12117","5311497, 6918194","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"850",850,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","POZIOTINIB","HER","II","Advanced, Second line","Progression free survival (PFS)","NCT02418689","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02418689",1,"DB12114","25127713","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"851",851,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, AND/OR","Protein Expression/Protein Expression&Amplification, Protein Expression, Protein Expression","PERTUZUMAB, TRASTUZUMAB, DOCETAXEL, PACLITAXEL, VINORELBINE, CAPECITABINE, EXEMESTANE, RIBOCICLIB, FULVESTRANT, ANASTROZOLE, LETROZOLE, NAB-PACLITAXEL, ERIBULIN, LEUPRORELIN, GOSERELIN","HER2, HER2, UNK, UNK, UNK, UNK, UNK, CDK4/CDK6, UNK, UNK, UNK, UNK, UNK, UNK, UNK","III","Advanced, First&Second line","Number of Participants with Adverse Events","NCT02344472","Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. Different arms getting different drug combos","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02344472",1,"DB06366,DB00072,DB01248,DB01229,DB00361,DB01101,DB00990,DB11730,DB00947,DB01217,DB01006,NA,DB08871,DB00007,DB00014","NA, 3001322, 148124, 36314, 5311497, 60953, 60198, 44631912, 104741, 2187, 3902, 36314, 17755248, 657181, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"852",852,"METASTATIC BREAST CANCER","BRCA1, BRCA2, ERBB2, ESR1, PGR","Positive, Positive, Positive/Negative, Positive/Negative, Positive/Negative","AND/OR, AND, AND, AND","Mutation, Mutation,  Protein Expression, Protein Expression, Protein Expression","LY2606368","Chk1/Chk2","II","Advanced, First&Second line","Objective response rate (CR+PR)","NCT02203513","There is no limit on the number of prior therapies.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02203513",1,"NA","46700756","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"853",853,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR,  BRCA1, BRCA2","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","LY2606369","Chk1/Chk2","II","Advanced, Second line","Objective response rate (CR+PR)","NCT02203514","There is no limit on the number of prior therapies.","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02203513",1,"NA","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","failed drug"
"854",854,"METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","EVEROLIMUS","UNK","II","Advanced, Second line","cumulative rate Mucositis grade 2-4 (WHO's oral toxicity scale (OTS))","NCT02387099","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02387099",1,"DB01590","6442177","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"855",855,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive/Negative","AND","Protein Expression, Protein Expression","MEDI4736, TREMELIMUMAB","B7H1, CTLA4","II","Advanced, First&Second line","Response rate of MEDI4736 in combination with Tremelimumab","NCT02536794","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02536794",1,"NA,DB11771","NA, NA","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","failed drug"
"856",856,"ADVANCED BREAST CANCER","PIK3CA, ESR1","Positive, Positive","AND","Mutation, Protein Expression","PALBOCICLIB, TASELISIB, PICTILISIB","CDK4/CDK6, PI3K, PI3K","I","Advanced, Second line","Recommended dose for Phase II, Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0), Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer","NCT02389842","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02389842",1,"DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ENSG00000121879, ENSG00000091831","MONDO_0007254","PIK3CA MUTATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"857",857,"ADVANCED BREAST CANCER","PIK3CA, ESR1, ERBB2","Positive, Positive/Negative, Positive/Negative","AND, AND","Mutation, Protein Expression, Protein Expression","PALBOCICLIB, TASELISIB, PICTILISIB","CDK4/CDK6, PI3K, PI3K","I","Advanced, Second line","Recommended dose for Phase II, Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0), Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer","NCT02389842","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02389842",1,"DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ENSG00000121879, ENSG00000091831, ENSG00000141736","MONDO_0007254","PIK3CA MUTATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"858",858,"ADVANCED TRIPLE NEGATIVE  BREAST CANCER","ERBB2, ESR1, PGR, PIK3CA","Negative, Negative, Negative, Positive","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Mutation","PALBOCICLIB, TASELISIB, PICTILISIB","CDK4/CDK6, PI3K, PI3K","I","Advanced, Second line","Recommended dose for Phase II, Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0), Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer","NCT02389842","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02389842",1,"DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000121879","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PIK3CA MUTATION POSITIVE","pass"
"859",859,"ADVANCED BREAST CANCER","ESR1, ERBB2","Positive, Negative","AND","Protein Expression, Protein Expression","PALBOCICLIB, TASELISIB, PICTILISIB","CDK4/CDK6, PI3K, PI3K","I","Advanced, Second line","Recommended dose for Phase II, Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0), Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer","NCT02389842","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02389842",1,"DB09073,DB12108,DB11663","11478676, 51001932, 17755052","ENSG00000091831, ENSG00000141736","MONDO_0007254","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","pass"
"860",860,"METASTATIC  BREAST CANCER","ESR1, AR","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, BICALUTAMIDE","UNK, UNK","I/II","Advanced, First&Second line","recommended phase II dose (RP2D) (phase I), progression free survival (phase II)","NCT02605486","had other biomarkers listed, but they were testing them in a phase I trial that was not theraputic","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02605486",1,"DB09073,DB01128","11478676, 56069","ENSG00000091831, ENSG00000169083","EFO_1000984","ESR1 PROTEIN EXPRESSION NEGATIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"861",861,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NAB-PACLITAXEL, ATEZOLIZUMAB","UNK, PDL1","III","Advanced, First line","Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in all Randomized Participants , PFS According to RECIST v1.1 in Participants with Detectable Programmed Death-Ligand 1 (PD-L1), Overall Survival (OS) in all Randomized Participants, OS in Participants with Detectable PD-L1","NCT02425891","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02425891",1,"NA,DB11595","36314, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"862",862,"ADVANCED BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","HEMAY022","EGFR","I","Advanced, Second line","Number of participants with adverse events, Observed maximum concentration of Hemay022, Time of maximum concentration of Hemay022 , Area under the plasma concentration versus time curve of Hemay022, Trough Plasma Concentrations of Hemay022, Predose plasma concentration","NCT02476539","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02476539",1,"NA","NA","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"863",863,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","ABEMACICLIB, LOPERAMIDE, ANASTROZOLE","UNK, UNK, UNK","II","First line","Percent Change From Baseline to 2 Weeks in Ki67 Expression","NCT02441946","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02441946",1,"DB12001,DB00836,DB01217","46220502, 71421, 2187","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"864",864,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB, CAPECITABINE, ERIBULIN, GEMCITABINE, VINORELBINE","UNK, UNK, UNK, UNK, UNK","III","Advanced, Second line","Overall Survival (OS)","NCT02555657","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02555657",1,"DB09037,DB01101,DB08871,DB00441,DB00361","NA, 60953, 17755248, 60750, 5311497","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"865",865,"METASTATIC BREAST CANCER","ERBB2, ESR1, AR","Negative, Positive, Positive","AND, AND","Protein Expression, Protein Expression, Protein Expression","GTX-024","UNK","II","Advanced, Second line","Clinical benefit rate, in centrally confirmed AR+ subjects","NCT02463032","Postmenopausal","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02463032",1,"NA","11326715","ENSG00000141736, ENSG00000091831, ENSG00000169083","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE","pass"
"866",866,"ADVANCED TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","MCS110, CARBOPLATIN, GEMCITABINE","UNK, UNK, UNK","II","Advanced, First line","Progression free survival (PFS) as per RECIST v1.1","NCT02435680","NA","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02435680",1,"NA,DB00958,DB00441","NA, 56840877, 60750","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","failed drug"
"867",867,"ADVANCED BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","LEE011, LETROZOLE, TAMOXIFEN, FULVESTRANT, GOSERELIN","UNK, UNK, UNK, UNK, UNK","I","Advanced, First line","Phase Ib Dose escalation - Frequency of dose limiting toxicities (DLTs), Phase Ib Dose Expansion: Number of participants with adverse events (AEs), Phase Ib Dose Expansion: Number of participants with serious adverse events (SAEs)","NCT02333370","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02333370",1,"NA,DB01006,DB00675,DB00947,DB00014","44631912, 3902, 2733526, 104741, 5311128","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"868",868,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","MITOXANTRONE HYDROCHLORIDE LIPOSOME","UNK","II","Advanced, Second line","ORR(Objective reponse rate)","NCT02596373","Advanced recurrent or Metastatic breast cancer, comfirmed by histological analysis and/or cytology analysis. Have failed for at least two chemotherapy regimen aimed to the advanced recurrent or metastatic focus;","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02596373",1,"NA","NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","failed drug"
"869",869,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PACLITAXEL, ALISERTIB","UNK, UNK","II","Advanced, First line","Time to Disease Progression - Tumor Response based on RECIST criteria","NCT02187991","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02187991",1,"DB01229,DB05220","36314, 24771867","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"870",870,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","PACLITAXEL, ALISERTIB","UNK, UNK","II","Advanced, First line","Time to Disease Progression - Tumor Response based on RECIST criteria","NCT02187991","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02187991",1,"DB01229,DB05220","36314, 24771867","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"871",871,"ADVANCED BREAST CANCER","ERBB2","Positive","NA","Protein Expression","PYROTINIB, CAPECITABINE","HER2/HER1, UNK","I/II","Advanced, Second line","Safety(adverse Events [AEs] and Serious Adverse Events [SAEs]), Objective Response Rate (ORR)","NCT02422199","Histologically or cytologic confirmed HER2 positive advanced breast cancer which failed prior therapies.","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02422199",1,"DB14993,DB01101","51039030, 60953","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"872",872,"METASTATIC  BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","GEMCITABINE, TRASTUZUMAB, PERTUZUMAB","UNK, HER2, HER2","II","Advanced, First&Second line","Progression-free survival (PFS)","NCT02252887","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02252887",1,"DB00441,DB00072,DB06366","60750, 3001322, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"873",873,"METASTATIC  BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","ELACESTRANT","UNK","I","Advanced, First&Second line","Dose Limiting Toxicities (DLT)","NCT02338349","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02338349",1,"DB06374","23642301","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"874",874,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","TRASTUZUMAB, PERTUZUMAB, DOCETAXEL, PACLITAXEL, NAB-PACLITAXEL, VINORELBINE, ERIBULIN, CAPECITABINE, GEMCITABINE","UNK, HER2/HER3, UNK, UNK, UNK, UNK, UNK, UNK, UNK","III","Advanced, Second line","Progression-free survival","NCT02514681","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02514681",1,"DB00072,DB06366,DB01248,DB01229,NA,DB00361,DB08871,DB01101,DB00441","3001322, NA, 148124, 36314, 36314, 5311497, 17755248, 60953, 60750","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"875",875,"BREAST CANCER (STAGE I-IIA)","Ki67, TAZ","Positive, Positive","AND","Protein Expression, Protein Expression","ATORVASTATIN","TAZ","II","First Line","Ki-67 reduction below the 15% (marker response).","NCT02416427","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02416427",1,"DB01076","60823","ENSG00000148773, ENSG00000102125","MONDO_0007254","KI67 PROTEIN EXPRESSION POSITIVE AND TAZ PROTEIN EXPRESSION POSITIVE","pass"
"876",876,"METASTATIC BREAST CANCER","absent","NA","NA","NA","ORAXOL PACLITAXEL","UNK","III","NA","Tumor response as determined by response criteria","NCT02594371","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02594371",1,"NA","NA","ENSG00000104313","EFO_1000984","ABSENT NA NA","failed drug,no biomarker"
"877",1,"METASTATIC BREAST CANCER","ERBB2, EGFR, AR","Positive, Positive, Positive","OR, OR","Mutation, Mutation/ Protein Expression & Amplification, Protein Epression","POZIOTINIB","UNK","II","Advanced, Second Line","Progression free survival (PFS)","NCT02544997","HER2-overexpressing breast cancer is excluded from trial, Two or more regimens for locally recurrent or metastatic breast cancer, including an anthracycline and a taxane","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02544997",1,"DB12114","25127713","ENSG00000141736, ENSG00000146648, ENSG00000169083","EFO_1000984","ERBB2 MUTATION POSITIVE OR EGFR MUTATION/ PROTEIN EXPRESSION & AMPLIFICATION POSITIVE OR AR PROTEIN EPRESSION POSITIVE","pass"
"878",2,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","AZD2014, PALBOCICLIB, FULVESTRANT","UNK, CDK, UNK","II","Advanced, Second Line","Parts A and B: Number of adverse events experienced by patients","NCT02599714","must be post-menopausal","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02599714",1,"NA,DB09073,DB00947","25262792, 11478676, 104741","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"879",3,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Positive, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","PALBOCICLIB, TRASTUZUMAB, ENDOCRINE THERAPY","UNK, UNK, UNK","II","Advanced, Second Line","Progression-Free Survival (PFS)as Assessed by the Investigator","NCT02448420","Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant or Tamoxifen, Active Comparator: Arm C2: Treatment based of physician's choice (trastuzumab, chemotherapy, antibody-drug conjugates). Must be Centrally confirmed Luminal intrinsic subtype as per PAM50 analysis (i.e. Luminal A or Luminal B).All patients must have received at least 1(maximum 4) previous lines of systemic treatment for metastatic or locally advanced disease, at least one of which must have included trastuzumab. Previous use of other anti-HER2 treatment, alone or in combination with chemotherapy, is permitted, including lapatinib, neratinib, pertuzumab or T-DM1. Previous use of any chemotherapy or hormone agent is permitted.","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02448420",1,"DB09073,DB00072,NA","11478676, 3001322, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"880",4,"LOCALLY ADVANCED OR TRIPLE NEGATIVE METASTATIC BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","BYL719","PI3Kalpha","II","Advanced, Second Line","Objective response rate","NCT02506556","Patients with TNBC disease (ER<1%, HER2-negative) should have documented progression on at least one line of prior systemic therapy in the metastatic setting or within 12 months of adjuvant therapy completion. There is no limit on previous therapies. There will be no molecular selection of these patients","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02506556",1,"NA","56649450","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"881",5,"METASTATIC BREAST CANCER","absent","NA","NA","NA","VINORELBINE, GEMCITABINE, CISPLATIN","UNK, UNK, UNK","II","Advanced, Second Line","Progression Free Survival","NCT02544243","Patients must have received a previous treatment with anthracyclines and taxanes","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02544243",1,"DB00361,DB00441,DB00515","5311497, 60750, 135804801","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"882",6,"INVASIVE EARLY BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","LETROZOLE, PALBOCICLIB","UNK, UNK","II","First Line","Measurement of the proliferation marker Ki67 (% positive tumor cells), Clinical Complete Response (cCR): Number of patients who have resolution of measurable lesions or no new lesions or other signs of disease progression compared to baseline.","NCT02296801","Patents must be post-menopausal, must be operable, must be suitable for neoadjuvant AI treatment","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02296801",1,"DB01006,DB09073","3902, 11478676","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"883",7,"BREAST CANCER","ERBB2, ESR1, PGR","Positive, Negative, Negative","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","5-FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, TRASTUZUMAB, PERTUZUMAB, CARBOPLATIN","UNK, UNK, UNK, UNK, UNK, UNK, UNK","II","First Line","Pathological complete response according to Chevallier classification","NCT02339532","Drug cohorts based on TOP2A gene amplification, TOP2A not listed anywhere in inclusion critera, different drug combinations based on status","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02339532",1,"DB00544,DB00445,DB00531,DB01248,DB00072,DB06366,DB00958","3385, 65348, 2907, 148124, 3001322, NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"884",8,"METASTATIC BREAST CANCER","absent","NA","NA","NA","ENDOSTATIN, GEMCITABINE, NAVELBINE, PLATINUM, XELODA","UNK, UNK, UNK, UNK, UNK","II","Advanced, First Line","response rate","NCT02489409","Active comparator is Gemcitabine, Navelbine,  Platinum, Xeloda","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02489409",1,"DB06423,DB00441,NA,DB12257,NA","187888, 60750, 5311497, 23939, 60953","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"885",9,"BREAST CANCER","ERBB2, ESR1, PGR","Negative, Postitive, Positive/Negative","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","EPIRUBICIN, CYCLOPHOSPHAMIDE","UNK, UNK","IV","First Line","number of participants with grade 3-4 neutropenia assessed by CTCAE v4.0","NCT02549677","Active comparator is docetaxel and cyclophosphamide, cannot have metastatic breast cancer","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02549677",1,"DB00445,DB00531","65348, 2907","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSTITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"886",10,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","DOCETAXEL, PERTUZUMAB, TRASTUZUMAB","UNK, UNK, UNK","IV","Advanced, First Line","Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant, Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme),  According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03), Number of Participants With Serious Adverse Events Related to Docetaxel, Number of Participants With Serious Adverse Events Related to Pertuzumab, Number of Participants With Serious Adverse Events Related to Trastuzumab, Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug, Overall Number of Participants With Serious Adverse Events by Event Outcome, Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events, Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events, Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events, Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death, Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant, Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03, Number of Participants With Non-Serious Adverse Events Related to Docetaxel, Number of Participants With Non-Serious Adverse Events Related to Pertuzumab, Number of Participants With Non-Serious Adverse Events Related to Trastuzumab, Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab, Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab, Overall Number of Participants With Non-Serious Adverse Events by Event Outcome, Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE), Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events, Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events, Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events, Number of Participants With Congestive Heart Failure, Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time, Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time, Number of Participants With Adverse Events Leading to Treatment Discontinuation","NCT02445586","NA","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02445586",1,"DB01248,DB06366,DB00072","148124, NA, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"887",11,"LOCALLY ADVANCED OR METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, FULVESTRANT, TAMOXIFEN, AROMATASE INHIBITOR","UNK, UNK, Aromatase","II","Advanced, First Line, Second Line","Progression Free Survival Using the RECIST 1.1 Criteria","NCT02630693","Patients take Fulvestrant or Tamoxifen or Aromatase Inhibitor","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02630693",1,"DB09073,DB00947,DB00675,NA","11478676, 104741, 2733526, NA","ENSG00000141736, ENSG00000091831","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"888",12,"INVASIVE TRIPLE NEGATIVE BREAST CANCER (IA-IIIA)","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","IPATASERTIB, PACLITAXEL","UNK, UNK","II","First Line","Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System, Percentage of Participants With pCR in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging System (in Participants Who Have Phosphatase and Tensin Homolog [PTEN]-Low Tumors)","NCT02301988","Comparator is just paclitaxel monotherapy","ALV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02301988",1,"DB11743,DB01229","24788740, 36314","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"889",13,"BREAST CANCER (I-IIIA)","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB","UNK, UNK, UNK, UNK, UNK, UNK","IV","First Line, Second Line","Percentage of Participants Experiencing Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography, Percentage of Participants With Adverse Events","NCT02419742","Patients must have Histologically confirmed early invasive HER2 positive, node positive or high risk node negative breast cancer with no evidence of residual, locally recurrent or metastatic disease and defined as clinical stage I to IIIA that is eligible for adjuvant treatment with trastuzumab","ALV","NA","NA","https://ClinicalTrials.gov/show/NCT02419742",1,"DB00958,DB00531,DB01248,DB00997,DB01229,DB00072","56840877, 2907, 148124, 443939, 36314, 3001322","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"890",14,"BREAST CANCER (STAGE I-III)","ERBB2","Positive","NA","Protein Expression&Amplification/Protein Expression","PACLITAXEL, CARBOPLATIN, ASLAN001","UNK, UNK, HER2/HER1/HER4","I/II","Advanced&Non-advanced, First&Second line","Pathologic complete response rate","NCT02396108","does not give much for clinical state. Only that there should be no concurrent treatment, and no treatment within 28 days of start","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02396108",1,"DB01229,DB00958,NA","36314, 56840877, 42642648","ENSG00000141736","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","pass"
"891",15,"RECURRENT BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","KHK2375, EXEMESTANE","UNK, UNK","I","Advanced, Second line","Number and percentage of subjects with treatment-emergent adverse events including dose-limiting toxicities and serious adverse events","NCT02623751","Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02623751",1,"NA,DB00990","NA, 60198","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","failed drug"
"892",16,"BREAST CANCER","absent","NA","NA","NA","PEGYLATED LIPOSOMAL DOXORUBICIN, DOCETAXEL","UNK, UNK","UNK","First line","pathologic complete response rate","NCT03221881","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT03221881",1,"NA,DB01248","NA, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"893",17,"INVASIVE BREAST CANCER (II-III)","ERBB2, ESR1, PGR","Positive, Positive/Negative, Positive/Negative","AND, AND","Protein Expression&Amplification/Protein Expression, Protein Expression, Protein Expression","DOCETAXEL, TRASTUZUMAB, CARBOPLATIN","UNK, UNK, UNK","II","Advanced&Non-advanced, First line","pathological complete response rate","NCT02510781","just needs hr status","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02510781",1,"DB01248,DB00072,DB00958","148124, 3001322, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"894",18,"METASTATIC  BREAST CANCER","absent","NA","NA","NA","LENVATINIB, LETROZOLE","UNK, UNK","I/II","Advanced, First line","Rates of clinical response","NCT02562118","says HR+ thoroughout trial, but not in inclusion/exculsion criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02562118",1,"DB09078,DB01006","11237762, 3902","ENSG00000104313","EFO_1000984","ABSENT NA NA","no biomarker"
"895",19,"STAGE III-IV TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","ROMIDEPSIN, CISPLATIN, NIVOLUMAB","UNK, UNK, UNK","I/II","Advanced, First&Second line","Phase I: Recommended Phase II Dose of romidepsin in combination with cisplatin, Phase II: Objective response rate of treated subjects according to RECIST v1.1 criteria","NCT02393794","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02393794",1,"DB06176,DB00515,DB09035","5352062, 135804801, NA","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"896",20,"BREAST CANCER (STAGE III-IV)","BRCA1, BRCA2","Positive, Positive","OR","Mutation, Mutation","ROMIDEPSIN, CISPLATIN, NIVOLUMAB","UNK, UNK, UNK","I/II","Advanced, Second line","Phase I: Recommended Phase II Dose of romidepsin in combination with cisplatin, Phase II: Objective response rate of treated subjects according to RECIST v1.1 criteria","NCT02393794","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02393794",1,"DB06176,DB00515,DB09035","5352062, 135804801, NA","ENSG00000012048, ENSG00000139618","MONDO_0007254","BRCA1 MUTATION POSITIVE OR BRCA2 MUTATION POSITIVE","pass"
"897",21,"BREAST CANCER (STAGE IIIA-IIIC)","absent","NA","NA","NA","DOXORUBICIN HYDROCHLORIDE LIPOSOME, CYCLOPHOSPHAMIDE, DOCETAXEL","UNK, UNK, UNK","UNK","Advanced, First&Second line","maximum tolerated dose","NCT03017404","only requires no anti-tumor drugs within 30 dyas. But also says newly diagnosed","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT03017404",1,"NA,DB00531,DB01248","NA, 2907, 148124","ENSG00000104313","MONDO_0007254","ABSENT NA NA","failed drug,no biomarker"
"898",22,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","NIVOLUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, CISPLATIN","UNK, UNK, UNK, UNK","II","Advanced, Second line","Progression free survival","NCT02499367","different arms with different drug combos, some with radiation treatment","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02499367",1,"DB09035,DB00997,DB00531,DB00515","NA, 443939, 2907, 135804801","ENSG00000141736, ENSG00000091831, ENSG00000082175","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"899",23,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, AND/OR","Protein Expression, Protein Expression, Protein Expression","TAMOXIFEN, ANASTROZOLE, FULVESTRANT","UNK, UNK, UNK","II","First line","Ki67 proliferative index","NCT02206984","Postmenopausal","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02206984",1,"DB00675,DB01217,DB00947","2733526, 2187, 104741","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"900",24,"TRIPLE NEGATIVE INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","TAXANE, CARBOPLATIN","UNK, UNK","III","First line","5-year event free survival","NCT02441933","Taxane: either docetaxel or paclitaxel. Surgery prerequirment","TVV","NA","NA","https://clinicaltrials.gov/ct2/show/NCT02441933",1,"NA,DB00958","9548828, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"901",25,"METASTATIC TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR, PDL1","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","Protein Expression, Protein Expression, Protein Expression, Protein Expression","PEMBROLIZUMAB","UNK","II","Advanced, First&Second line","Overall Response Rate (ORR) , Number of Participants Experiencing at Least One Adverse Event (AE), Number of Participants Discontinuing Study Drug Due to Aes","NCT02447003","different. Cohorts had diffferent prior treatment/pdl1 requirements","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02447003",1,"DB09037","NA","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","MONDO_0007254","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","pass"
"902",26,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","PALBOCICLIB, LETROZOLE","CDK4/CDK6, UNK","III","Advanced, First line","Progression-Free Survival (PFS)","NCT02297438","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02297438",1,"DB09073,DB01006","11478676, 3902","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"903",27,"LOCALLY ADVANCED BREAST CANCER","absent","NA","NA","NA","METFORMIN, FLUORURACIL, DOXORUBICIN, CYCLOPHOSPHAMIDE, MELATONIN","UNK, UNK, UNK, UNK, UNK","II","Advanced, First line","Response rate, Pathomorphological response","NCT02506777","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02506777",1,"DB00331,NA,DB00997,DB00531,DB01065","14219, 3385, 443939, 2907, 896","ENSG00000104313","MONDO_0007254","ABSENT NA NA","no biomarker"
"904",28,"METASTATIC BREAST CANCER","ERBB2","Positive","NA","Protein Expression","TRASTUZUMAB, NON-PEGYLATED LIPOSOMAL DOXORUBICIN","UNK, UNK","I","Advanced, Second line","Dose Limiting Toxicities","NCT02562378","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02562378",1,"DB00072,NA","3001322, NA","ENSG00000141736","EFO_1000984","ERBB2 PROTEIN EXPRESSION POSITIVE","pass"
"905",29,"METASTATIC BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","FULVESTRANT","UNK","II","Advanced, First line","PFS","NCT02646735","mentions the requirement to be her2 -, but not in the criteria","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02646735",1,"DB00947","104741","ENSG00000091831, ENSG00000082175","EFO_1000984","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"906",30,"TRIPLE NEGATIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Negative, Negative","AND, AND","Protein Expression, Protein Expression, Protein Expression","EPIRUBICIN, CYCLOPHOSPHAMIDE, TAXANES, CARBOPLATIN","UNK, UNK, UNK, UNK","III","First line","Disease-free survival ","NCT02455141","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02455141",1,"DB00445,DB00531,NA,DB00958","65348, 2907, NA, 56840877","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_0005537","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","pass"
"907",31,"INVASIVE BREAST CANCER","ERBB2, ESR1, PGR","Negative, Positive, Positive","AND, OR","Protein Expression, Protein Expression, Protein Expression","GOSERELIN, TAM, AI","UNK, UNK, UNK","III","First line","ultrasound response rate","NCT02535221","35 years old ＜age≤55 years old, in premenopausal status. I believe AI stands for aromatase inhibitor, but it never states that in the trial","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02535221",1,"DB00014,NA,NA","5311128, 1983, 53697","ENSG00000141736, ENSG00000091831, ENSG00000082175","EFO_1000307","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"908",32,"INVASIVE BREAST CANCER","ESR1, PGR","Positive, Positive","AND/OR","Protein Expression, Protein Expression","ANASTROZOLE, GOSERELIN","UNK, UNK","II","First&Second line","Incidence of bone or joint pains","NCT02440230","premenopausal, spilt pts up by whether they received prior treatment","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02440230",1,"DB01217,DB00014","2187, 5311128","ENSG00000091831, ENSG00000082175","EFO_1000307","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","pass"
"909",33,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GDC-0927","UNK","I","Advanced, Second line","Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927 , Percentage of Participants With Adverse Events (AEs)","NCT02316509","No more than 2 prior chemotherapies in the advanced or metastatic setting","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02316509",1,"DB14934","87055263","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
"910",34,"METASTATIC BREAST CANCER","ERBB2, ESR1","Negative, Positive","AND","Protein Expression, Protein Expression","GDC-0810","UNK","II","Advanced, Second line","Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Intent-to-Treat (ITT) Population, PFS According to RECIST v1.1 in Participants With Estrogen Receptor (ESR)1 Mutations","NCT02569801","NA","TVV","NA","NA","https://ClinicalTrials.gov/show/NCT02569801",1,"DB12253","56941241","ENSG00000141736, ENSG00000091831","EFO_1000984","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","pass"
